Nucleic acids encoding human anti-IL-23 antibodies

ABSTRACT

A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

CROSS REFERENCE TO RELATED APPLICATION

This application is a divisional of U.S. application Ser. No.11/617,503, filed 28 Dec. 2006, now U.S. Pat. No. 7,935,344, issued 3May 2011, which claims the benefit of U.S. Provisional Application Ser.No. 60/754,889, filed 29 Dec. 2005. The entire contents of each of theaforesaid applications are incorporated herein by reference in theirentireties.

FIELD OF THE INVENTION

The present invention relates to antibodies, including specifiedportions or variants, specific for at least one IL-23 protein orfragment thereof, as well as anti-idiotype antibodies, and nucleic acidsencoding anti-IL-23p19 antibodies, complementary nucleic acids, vectors,host cells, and methods of making and using thereof, includingtherapeutic formulations, administration and devices.

BACKGROUND OF THE INVENTION

Interleukin (IL)-12 is a secreted heterodimeric cytokine comprised of 2disulfide-linked glycosylated protein subunits, designated p35 and p40for their approximate molecular weights. IL-12 is produced primarily byantigen-presenting cells and drives cell-mediated immunity by binding toa two-chain receptor complex that is expressed on the surface of T cellsor natural killer (NK) cells. The IL-12 receptor beta-1 (IL-12Rβ1) chainbinds to the p40 subunit of IL-12, providing the primary interactionbetween IL-12 and its receptor. However, it is IL-12p35 ligation of thesecond receptor chain, IL-12Rβ2, that confers intracellular signaling(e.g. STAT4 phosphorylation) and activation of the receptor-bearing cell(Presky et al, 1996). IL-12 signaling concurrent with antigenpresentation is thought to invoke T cell differentiation towards the Thelper 1 (Th1) phenotype, characterized by interferon gamma (IFNγ)production (Trinchieri, 2003). Th1 cells are believed to promoteimmunity to some intracellular pathogens, generate complement-fixingantibody isotypes, and contribute to tumor immunosurveillance. Thus,IL-12 is thought to be a significant component to host defense immunemechanisms.

It was discovered that the p40 protein subunit of IL-12 can alsoassociate with a separate protein subunit, designated p19, to form anovel cytokine, IL-23 (Oppman et al, 2000). IL-23 also signals through atwo-chain receptor complex. Since the p40 subunit is shared betweenIL-12 and IL-23, it follows that the IL-12Rβ1 chain is also sharedbetween IL-12 and IL-23. However, it is the IL-23p19 ligation of thesecond component of the IL-23 receptor complex, IL-23R, that confersIL-23 specific intracellular signaling (e.g., STAT3 phosphorylation) andsubsequent IL-17 production by T cells (Parham et al, 2002; Aggarwal etal. 2003). Recent studies have demonstrated that the biologicalfunctions of IL-23 are distinct from those of IL-12, despite thestructural similarity between the two cytokines (Langrish et al, 2005).

Abnormal regulation of IL-12 and Th1 cell populations has beenassociated with many immune-mediated diseases since neutralization ofIL-12 by antibodies is effective in treating animal models of psoriasis,multiple sclerosis (MS), rheumatoid arthritis, inflammatory boweldisease, insulin-dependent (type 1) diabetes mellitus, and uveitis(Leonard et al, 1995; Hong et al, 1999; Malfait et al, 1998; Davidson etal, 1998). However, since these studies targeted the shared p40 subunit,both IL-12 and IL-23 were neutralized in vivo. Therefore, it was unclearwhether IL-12 or IL-23 was mediating disease, or if both cytokinesneeded to be inhibited to achieve disease suppression. Recent studieshave confirmed through IL-23p19 deficient mice or specific antibodyneutralization of IL-23 that IL-23 inhibition can provide equivalentbenefit as anti-IL-12p40 strategies (Cua et al, 2003, Murphy et al,2003, Benson et al 2004). Therefore, there is increasing evidence forthe specific role of IL-23 in immune-mediated disease. Neutralization ofIL-23 without inhibition of IL-12 pathways could then provide effectivetherapy of immune-mediated disease with limited impact on important hostdefense immune mechanism. This would represent a significant improvementover current therapeutic options.

SUMMARY OF THE INVENTION

The present invention provides isolated mammalian, including, withoutlimitation, human, antibodies that bind to the p19 subunit of IL-23,anti-IL-23p19 antibodies (also referred to as IL-23p19 antibodies),immunoglobulins, fragments, cleavage products and other specifiedportions and variants thereof, as well as anti-IL-23p19 antibodycompositions, IL-23p19 anti-idiotype antibodies, encoding orcomplementary nucleic acids, vectors, host cells, compositions,combinations, formulations, devices, transgenic animals, transgenicplants, and methods of making and using them.

The present invention provides, in one aspect, isolated nucleic acidmolecules comprising, complementary, or hybridizing to, a polynucleotideencoding specific anti-IL-23p19 antibodies or anti-idiotype antibodies,comprising at least one specified sequence, domain, portion or variantthereof. The present invention further provides recombinant vectorscomprising said anti-IL-23p19 antibody nucleic acid molecules, hostcells containing such nucleic acids and/or recombinant vectors, as wellas methods of making and/or using such antibody nucleic acids, vectorsand/or host cells.

The present invention also provides at least one method for expressingat least one anti-IL-23p19 antibody, or IL-23p19 anti-idiotype antibody,in a host cell, comprising culturing a host cell as described hereinunder conditions wherein at least one anti-IL-23p19 antibody isexpressed in detectable and/or recoverable amounts.

The present invention also provides at least one composition comprising(a) an isolated anti-IL-23p19 antibody encoding nucleic acid and/orantibody as described herein; and (b) a suitable and/or pharmaceuticallyacceptable carrier or diluent.

The present invention further provides at least one anti-IL-23p19antibody method or composition, for administering a therapeuticallyeffective amount to modulate or treat at least one IL-23p19 relatedcondition in a cell, tissue, organ, animal or patient and/or, prior to,subsequent to, or during a related condition, as known in the art and/oras described herein.

The present invention also provides at least one composition, deviceand/or method of delivery of a therapeutically or prophylacticallyeffective amount of at least one anti-IL-23p19 antibody, according tothe present invention.

The present invention further provides at least one anti-IL-23p19antibody method or composition, for diagnosing at least one IL-23related condition in a cell, tissue, organ, animal or patient and/or,prior to, subsequent to, or during a related condition, as known in theart and/or as described herein.

The present invention also provides at least one composition, deviceand/or method of delivery for diagnosing of at least one anti-IL-23p19antibody, according to the present invention.

Also provided is a medical device, comprising at least one isolatedmammalian anti-IL-23p19 antibody of the invention, wherein the device issuitable for contacting or administering the at least one anti-IL-23p19antibody, IL-23p19 anti-idiotypic antibody, nucleic acid molecule,compound, protein, and/or composition.

Also provided is an article of manufacture for human pharmaceutical ordiagnostic use, comprising packaging material and a container comprisinga solution or a lyophilized form of at least one isolated anti-IL-23p19antibody of the present invention. The article of manufacture canoptionally have the container as a component of a delivery device orsystem.

The present invention further provides any invention described herein.

DESCRIPTION OF THE FIGURES

FIG. 1A shows that human IL-23p19 antibodies bind specifically tohrIL-23 and not hrIL-12 or hrp40 monomer. An anti-IL-12/IL-23 p40antibody is shown to bind IL-23, IL-12 and the p40 monomer.

FIG. 1B shows that human IL-23p19 antibodies bind to human IL-23, butnot to murine IL-23 or its subunits.

FIG. 2 shows the IL-23 binding to two of the plate-immobilized IL-23p19antibodies of the invention.

FIG. 3A shows that antibodies MOR04083 and MOR04190 block normalIL-23/IL-23R binding.

FIG. 3B shows that antibodies MOR04083 and MOR04190 do not block normalIL-23/IL-12Rβ1 binding.

FIG. 3C shows that antibodies MOR04083, MOR04190, and MOR04217 do notinhibit IL-12 binding to IL-12Rβ1-Fc binding.

FIG. 4 shows that the IL-23p19 antibodies MOR04083 and MOR04190 of theinvention inhibit hrIL-23 mediated STAT 3 phosphorylation.

FIG. 5A shows that the IL-23p19 antibodies MOR04083 and MOR04190 of theinvention inhibit recombinant hrIL-23 mediated IL-17 production.

FIG. 5B shows that the IL-23p19 antibodies MOR04083 and MOR04190 of theinvention inhibit native hrIL-23 mediated IL-17 production.

FIG. 5C shows that the IL-23p19 antibodies MOR04083 and MOR04190 of theinvention inhibit native cynomologous monkey IL-23 mediated IL-17production.

FIG. 6 shows that the IL-23p19 antibodies MOR04083 and MOR04190 of theinvention do not inhibit hrIL-12 mediated IFNγ production.

FIGS. 7A-C show that the IL-23p19 antibodies MOR04083, MOR04190, andMOR04217 of the invention cross-compete with each other for binding tohuIL-23.

FIG. 8 shows that the IL-23p19 antibodies MOR05028, 05038, 05040, 05042,05045, 05049, and 05053 of the invention inhibit recombinant hrIL-23mediated IL-17 production.

FIG. 9 shows that the IL-23p19 antibodies MOR05028, 05038, 05040, 05042,05045, 05049, and 05053 of the invention block normal IL-23/IL-23Rbinding.

FIG. 10 shows that the IL-23p19 antibodies 5040^(Q/EV) and 3759^(EQ/QS)of the invention bind specifically to hrIL-23 and not hrIL-12 or hrp40monomer, comparable to the anti-IL-23p19 murine monoclonal antibody,mAb23A. The anti-IL-12/IL-23p40 antibody mAb12A is shown to bind IL-23,IL-12 and the p40 monomer.

FIG. 11A shows that the IL-23p19 antibodies 5040^(Q/EV) and 3759^(EQ/QS)of the invention block normal IL-23/IL-23R binding.

FIG. 11B shows that the IL-23p19 antibodies 5040^(Q/EV) and 3759^(EQ/QS)of the invention do not block normal IL-23/IL-12Rβ1 binding.

FIG. 11C shows that the IL-23p19 antibodies 5040^(Q/EV) and 3759^(EQ/QS)of the invention do not inhibit IL-12 binding to IL-12Rβ1-Fc binding.

FIG. 12 shows that the IL-23p19 antibodies 5040^(Q/EV) and 3759^(EQ/QS)of the invention do not inhibit IL-12 induced INFγ production fromNK92MI cells.

FIG. 13 shows that the IL-23p19 antibodies 5040^(Q/EV) and 3759^(EQ/QS)of the invention inhibit recombinant hrIL-23 mediated IL-17 production.

FIG. 14 shows that the IL-23p19 antibodies 5040^(Q/EV) and 3759^(EQ/QS)of the invention inhibit native hrIL-23 mediated IL-17 production.

FIG. 15 shows that the IL-23p19 antibodies 5040^(Q/EV) and 3759^(EQ/QS)of the invention inhibit native cynomologous monkey IL-23 mediated IL-17production.

FIG. 16A shows that the IL-23p19 antibodies 5040^(Q/EV) and 3759^(EQ/QS)of the invention and mAb23A compete with the binding to of IL-23 toimmobilized mAb23A.

FIG. 16B shows that the IL-23p19 antibodies 5040^(Q/EV) and 3759^(EQ/QS)of the invention and, to a lesser extent, mAb23A compete with thebinding to of IL-23 to immobilized 5040^(Q/EV) mAb.

FIG. 16C shows that the IL-23p19 antibodies 5040^(Q/EV) and 3759^(EQ/QS)of the invention and mAb23A compete with the binding to of IL-23 toimmobilized 3759^(EQ/QS) mAb.

DESCRIPTION OF THE INVENTION

The present invention provides isolated, recombinant and/or syntheticanti-IL-23p19 antibodies, including, without limitation, mammalian(e.g., human antibodies) and IL-23p19 anti-idiotype antibodies thereto,as well as compositions and encoding nucleic acid molecules comprisingat least one polynucleotide encoding at least one anti-IL-23p19 antibodyor anti-idiotype antibody. The present invention further includes, butis not limited to, methods of making and using such nucleic acids andantibodies and anti-idiotype antibodies, including diagnostic andtherapeutic compositions, methods and devices.

As used herein, an “anti-IL-23p19 antibody,” “IL-23p19 antibody,”“anti-IL-23p19 antibody portion,” or “anti-IL-23p19 antibody fragment”and/or “anti-IL-23p19 antibody variant” and the like include any proteinor peptide containing molecule that comprises at least a portion of animmunoglobulin molecule, such as but not limited to, at least onecomplementarity determining region (CDR) of a heavy or light chain or aligand binding portion thereof, a heavy chain or light chain variableregion, a heavy chain or light chain constant region, a frameworkregion, or any portion thereof, or at least one portion of an IL-23receptor or binding protein, which can be incorporated into an antibodyof the present invention. Such antibody optionally further affects aspecific ligand, such as but not limited to, where such antibodymodulates, decreases, increases, antagonizes, agonizes, mitigates,alleviates, blocks, inhibits, abrogates and/or interferes with at leastone IL-23 activity or binding, or with IL-23 receptor activity orbinding, in vitro, in situ and/or in vivo. As a non-limiting example, asuitable anti-IL-23p19 antibody, specified portion or variant of thepresent invention can bind at least one IL-23 molecule, or specifiedportions, variants or domains thereof. A suitable anti-IL-23p19antibody, specified portion, or variant can also optionally affect atleast one of IL-23p19 activity or function, such as but not limited to,RNA, DNA or protein synthesis, IL-23 release, IL-23 receptor signaling,membrane IL-23 cleavage, IL-23 activity, IL-23 production and/orsynthesis.

The term “antibody” is further intended to encompass antibodies,digestion fragments, specified portions and variants thereof, including,without limitation, antibody mimetics or comprising portions ofantibodies that mimic the structure and/or function of an antibody orspecified fragment or portion thereof, including, without limitation,single chain antibodies, single domain antibodies, and fragmentsthereof. Functional fragments include antigen-binding fragments thatbind to a human IL-23p19. For example, antibody fragments capable ofbinding to IL-23p19 or portions thereof, including, but not limited to,Fab (e.g., by papain digestion), Fab′ (e.g., by pepsin digestion andpartial reduction) and F(ab′)₂ (e.g., by pepsin digestion), facb (e.g.,by plasmin digestion), pFc′ (e.g., by pepsin or plasmin digestion), Fd(e.g., by pepsin digestion, partial reduction and reaggregation), Fv orscFv (e.g., by molecular biology techniques) fragments, are encompassedby the invention (see, e.g., Colligan, Immunology, supra).

Such fragments can be produced by enzymatic cleavage, synthetic orrecombinant techniques, as known in the art and/or as described herein.Antibodies can also be produced in a variety of truncated forms usingantibody genes in which one or more stop codons have been introducedupstream of the natural stop site. For example, a combination geneencoding a F(ab′)₂ heavy chain portion can be designed to include DNAsequences encoding the CH₁ domain and/or hinge region of the heavychain. The various portions of antibodies can be joined togetherchemically by conventional techniques, or can be prepared as acontiguous protein using genetic engineering techniques.

The term “human antibody,” as used herein, is intended to includeantibodies having variable and constant regions derived from or closelymatching human germline immunoglobulin sequences. The human antibodiesof the invention may include amino acid residues not encoded by humangermline immunoglobulin sequences (e.g., mutations introduced by randomor site-specific mutagenesis in vitro or by somatic mutation in vivo).Thus, as used herein, the term “human antibody” refers to an antibody inwhich substantially every part of the protein (e.g., CDR, framework,C_(L), C_(H) domains (e.g., C_(H)1, C_(H)2, C_(H)3), hinge, (V_(L),V_(H))) is substantially similar to a human germline antibody. Humanantibodies have been classified into groupings based on their amino acidsequence similarities, see e.g. http://people.cryst.bbk.ac.uk/˜ubcg07s/.Thus, using a sequence similarity search, an antibody with similarlinear sequence can be chosen as a template to create “humanizedantibodies.”

“Humanization” (also called Reshaping or CDR-grafting) is now awell-established technique for reducing the immunogenicity of monoclonalantibodies (mAbs) from xenogeneic sources (commonly rodent) and forimproving the effector functions (ADCC, complement activation, C1qbinding). The engineered mAb is engineered using the techniques ofmolecular biology, however simple CDR-grafting of the rodentcomplementarity-determining regions (CDRs) into human frameworks oftenresults in loss of binding affinity and/or specificity of the originalmAb. In order to humanize an antibody, the design of the humanizedantibody includes variations such as conservative amino acidsubstitutions in residues of the CDRs, and back substitution of residuesfrom the rodent mAb into the human framework regions (backmutations).The positions can be discerned or identified by sequence comparison forstructural analysis or by analysis of a homology model of the variableregions' 3D structure. The process of affinity maturation has mostrecently used phage libraries to vary the amino acids at chosenpositions. Similarly, many approaches have been used to choose the mostappropriate human frameworks in which to graft the rodent CDRs. As thedatasets of known parameters for antibody structures increases, so doesthe sophistication and refinement of these techniques. Consensus orgermline sequences from a single antibody or fragments of the frameworksequences within each light or heavy chain variable region from severaldifferent human mAbs can be used. Another approach to humanization is tomodify only surface residues of the rodent sequence with the most commonresidues found in human mAbs and has been termed “resurfacing” or“veneering.” Known human Ig sequences are disclosed, e.g., www.ncbi.nlm.nih gov/entrez/query.fcgi; www. ncbi.nih.gov/igblast; www.atcc.org/phage/hdb.html; www. kabatdatabase.com/top.html; www.antibodyresource.com/onlinecomp.html; www. appliedbiosystems.com; www.biodesign.com; antibody.bath.ac.uk; www. unizh.ch; www.cryst.bbk.ac.uk/˜ubcg07s; Kabat et al., Sequences of Proteins ofImmunological Interest, U.S. Dept. Health (1983), each entirelyincorporated herein by reference. Often, the human or humanized antibodyis substantially non-immunogenic in humans.

Similarly, antibodies designated primate (monkey, baboon, chimpanzee,etc.), rodent (mouse, rat, rabbit, guinea pig, hamster, and the like)and other mammals designate such species, sub-genus, genus, sub-family,and family specific antibodies. Further, chimeric antibodies can includeany combination of the above. Such changes or variations optionally andpreferably retain or reduce the immunogenicity in humans or otherspecies relative to non-modified antibodies. Thus, a human antibody isdistinct from a chimeric or humanized antibody.

It is pointed out that a human antibody can be produced by a non-humananimal or prokaryotic or eukaryotic cell that is capable of expressingfunctionally rearranged human immunoglobulin (e.g., heavy chain and/orlight chain) genes. Further, when a human antibody is a single chain orsingle domain antibody, it can comprise a linker peptide that is notfound in native human antibodies. For example, an Fv can comprise alinker peptide, such as two to about eight glycine or other amino acidresidues, which connects the variable region of the heavy chain and thevariable region of the light chain. Such linker peptides are consideredto be of human origin.

Bispecific, heterospecific, heteroconjugate or similar antibodies canalso be used that are monoclonal, preferably, human or humanized,antibodies that have binding specificities for at least two differentantigens. In the present case, one of the binding specificities is forat least one IL-23p19 protein subunit, the other one is for any otherantigen. Methods for making bispecific antibodies are known in the art.Traditionally, the recombinant production of bispecific antibodies isbased on the co-expression of two immunoglobulin heavy chain-light chainpairs, where the two heavy chains have different specificities (Milsteinand Cuello, Nature 305:537 (1983)). Because of the random assortment ofimmunoglobulin heavy and light chains, these hybridomas (quadromas)produce a potential mixture of 10 different antibody molecules, of whichonly one has the correct bispecific structure. The purification of thecorrect molecule is usually done by affinity chromatography steps.Similar procedures are disclosed, e.g., in WO 93/08829, U.S. Pat. Nos.6,210,668, 6,193,967, 6,132,992, 6,106,833, 6,060,285, 6,037,453,6,010,902, 5,989,530, 5,959,084, 5,959,083, 5,932,448, 5,833,985,5,821,333, 5,807,706, 5,643,759, 5,601,819, 5,582,996, 5,496,549,4,676,980, WO 91/00360, WO 92/00373, EP 03089, Traunecker et al., EMBOJ. 10:3655 (1991), Suresh et al., Methods in Enzymology 121:210 (1986),each entirely incorporated herein by reference.

Anti-IL-23p19 antibodies useful in the methods and compositions of thepresent invention can optionally be characterized by high affinitybinding to IL-23p19 and, optionally and preferably, as having lowtoxicity. In particular, an antibody, specified fragment or variant ofthe invention, where the individual components, such as the variableregion, constant region and framework, individually and/or collectively,optionally and preferably possess low immunogenicity, is useful in thepresent invention. The antibodies that can be used in the invention areoptionally characterized by their ability to treat patients for extendedperiods with measurable alleviation of symptoms and low and/oracceptable toxicity. Low or acceptable immunogenicity and/or highaffinity, as well as other suitable properties, can contribute to thetherapeutic results achieved. “Low immunogenicity” is defined herein asthe incidence of titrable levels of antibodies to the anti-IL-23p19antibody in patients treated with anti-IL-23p19 antibody as occurring inless than 25% of patients treated, preferably, in less than 10% ofpatients treated with the recommended dose for the recommended course oftherapy during the treatment period.

The isolated nucleic acids of the present invention can be used forproduction of at least one anti-IL-23p19 antibody or specified variantthereof, which can be used to measure or effect in an cell, tissue,organ or animal (including mammals and humans), to diagnose, monitor,modulate, treat, alleviate, help prevent the incidence of, or reduce thesymptoms of, at least one IL-23 related condition, selected from, butnot limited to, at least one of an immune disorder or disease, acardiovascular disorder or disease, an infectious, malignant, and/orneurologic disorder or disease, or other known or specified IL-23related condition.

Such a method can comprise administering an effective amount of acomposition or a pharmaceutical composition comprising at least oneanti-IL-23p19 antibody to a cell, tissue, organ, animal or patient inneed of such modulation, treatment, alleviation, prevention, orreduction in symptoms, effects or mechanisms. The effective amount cancomprise an amount of about 0.001 to 500 mg/kg per single (e.g., bolus),multiple or continuous administration, or to achieve a serumconcentration of 0.01-5000 μg/ml serum concentration per single,multiple, or continuous administration, or any effective range or valuetherein, as done and determined using known methods, as described hereinor known in the relevant arts.

Antibodies of the Present Invention—Production and Generation

At least one anti-IL-23p19 antibody of the present invention can beoptionally produced by a cell line, a mixed cell line, an immortalizedcell or clonal population of immortalized cells, as well known in theart. See, e.g., Ausubel, et al., ed., Current Protocols in MolecularBiology, John Wiley & Sons, Inc., NY, N.Y. (1987-2001); Sambrook, etal., Molecular Cloning: A Laboratory Manual, 2^(nd) Edition, Cold SpringHarbor, N.Y. (1989); Harlow and Lane, Antibodies, a Laboratory Manual,Cold Spring Harbor, N.Y. (1989); Colligan, et al., eds., CurrentProtocols in Immunology, John Wiley & Sons, Inc., NY (1994-2001);Colligan et al., Current Protocols in Protein Science, John Wiley &Sons, NY, N.Y., (1997-2001).

Antibodies that are specific for human IL-23p19 proteins or fragmentsthereof can be obtained from recombinant human antibody libraries usingan appropriate antigen, such as an isolated IL-23p19 protein and/or aportion thereof (including synthetic molecules, such as syntheticpeptides). Other specific or general antibodies, including, withoutlimitation, mammalian antibodies, can be similarly raised. Preparationof antigens, and Isolation of antibodies from human libraries can beperformed using any suitable technique.

In one approach, a recombinant antibody is obtained by phage displayusing antibody libraries (Hoogenboom H R. Overview of antibodyphage-display technology and its applications. Methods in MolecularBiology. 178:1-37, 2002). In a preferred approach, a recombinant humanFab is isolated from the HuCal Gold™ Library developed by MorphoSys, AG(Kretzschmar, 2002) and subsequently improved in its activity by CDRcassette diversification (Knappik et al., 2000; Krebs et al., 2001).

Recombinant human antibodies recovered from phage display libraries maybe engineered to replace certain residues with specific amino acidscorresponding to consensus or specific human antibody sequences. Thesesequences are identified by comparisons to databases of known humangermline or rearranged antibodies.

Known human Ig sequences are disclosed, e.g., www.ncbi.nlm.nih.gov/entrez/query.fcgi; www. ncbi.nih.gov/igblast; www.atcc.org/phage/hdb.html; www. mrc-cpe.cam.ac.uk/ALIGNMENTS.php; www.kabatdatabase.com/top.html; ftp. ncbi.nih.gov/repository/kabat; www.imgt.cines.fr.8104/; www. biochem.unizh.ch/antibody/index.html; www.sciquest.com; www. abcam.com; www. antibodyresource.com/onlinecomp.html;www. public.iastate.edu/˜pedro/research_tools.html; www.whfreeman.com/immunology/CH05/kuby05.htm; www.hhmi.org/grants/lectures/1996/vlab; www.path.cam.ac.uk/˜mrc7/mikeimages.html;mcb.harvard.edu/BioLinks/Immunology.html; www. immunologylink.com;pathbox. wustl.edu/˜hcenter/index.html; www. appliedbiosystems.com; www.nal.usda.gov/awic/pubs/antibody; www.m.ehime-u.ac.jp/˜yasuhito/Elisa.html; www. biodesign.com; www.cancerresearchuk.org; www. biotech.ufl.edu; www. isac-net.org; baserv.uci.kun.nl/˜jraats/linksl.html; www. recab.uni-hd.de/immuno.bme.nwu.edu;www. mrc-cpe.cam.ac.uk; www. ibt.unam.mx/virV_mice.html; http://www.bioinf.org.uk/abs; antibody.bath.ac.uk; www. unizh.ch; www.cryst.bbk.ac.uk/˜ubcg07s; www. nimr.mrc.ac.uk/CC/ccaewg/ccaewg.html;www. path.cam.ac.uk/˜mrc7/humanisation/TAHHP.html; www.ibt.unam.mx/vir/structure/stat_aim.html; www.biosci.missouri.edu/smithgp/index.html; www. jerini.de; Kabat et al.,Sequences of Proteins of Immunological Interest, U.S. Dept. Health(1983), each entirely incorporated herein by reference.

Such replaced amino acids can be used to reduce immunogenicity orreduce, enhance or modify binding, affinity, on-rate, off-rate, avidity,specificity, half-life, or any other suitable characteristic, as knownin the art. In general, the CDR residues are directly and mostsubstantially involved in influencing antigen binding.

Optionally, human antibodies can be engineered with retention of highaffinity for the antigen and other favorable biological properties. Toachieve this goal, the human antibodies can be optionally prepared by aprocess of analysis of the parental sequences and various conceptualengineered products using three-dimensional models of the parental,engineered, and human sequences. Three-dimensional immunoglobulin modelsare commonly available and are familiar to those skilled in the art.Computer programs are available which illustrate and display probablethree-dimensional conformational structures of selected candidateimmunoglobulin sequences. Inspection of these displays permits analysisof the likely role of the residues in the functioning of the candidateimmunoglobulin sequence, i.e., the analysis of residues that influencethe ability of the candidate immunoglobulin to bind its antigen. In thisway, residues can be selected and combined from the parent and referencehuman sequences so that the desired antibody characteristic, such asaffinity for the target antigen(s), is achieved. Alternatively, or inaddition to, the above procedures, engineering can be accomplishedempirically by CDR cassette diversification and selection for thedesired activity, such as described for the MorphoSys HuCAL system(Knappik et al., 2000; Krebs et al., 2001).

In addition, the IL-23p19 antibody of the present invention may comprisea human germline light chain framework. In particular embodiments, thelight chain germline sequence is selected from human VK sequencesincluding, but not limited to, A1, A10, A11, A14, A17, A18, A19, A2,A20, A23, A26, A27, A3, A30, A5, A7, B2, B3, L1, L10, L11, L12, L14,L15, L16, L18, L19, L2, L20, L22, L23, L24, L25, L4/18a, L5, L6, L8, L9,O1, O11, O12, O14, O18, O2, O4, and O8. In certain embodiments, thislight chain human germline framework is selected from V1-11, V1-13,V1-16, V1-17, V1-18, V1-19, V1-2, V1-20, V1-22, V1-3, V1-4, V1-5, V1-7,V1-9, V2-1, V2-11, V2-13, V2-14, V2-15, V2-17, V2-19, V2-6, V2-7, V2-8,V3-2, V3-3, V3-4, V4-1, V4-2, V4-3, V4-4, V4-6, V5-1, V5-2, V5-4, andV5-6. See PCT WO 2005/005604 for a description of the different germlinesequences.

In other embodiments, the IL-23 antibody of the present invention maycomprise a human germline heavy chain framework. In particularembodiments, this heavy chain human germline framework is selected fromVH1-18, VH1-2, VH1-24, VH1-3, VH1-45, VH1-46, VH1-58, VH1-69, VH1-8,VH2-26, VH2-5, VH2-70, VH3-11, VH3-13, VH3-15, VH3-16, VH3-20, VH3-21,VH3-23, VH3-30, VH3-33, VH3-35, VH3-38, VH3-43, VH3-48, VH3-49, VH3-53,VH3-64, VH3-66, VH3-7, VH3-72, VH3-73, VH3-74, VH3-9, VH4-28, VH4-31,VH4-34, VH4-39, VH4-4, VH4-59, VH4-61, VH5-51, VH6-1, and VH7-81. SeePCT WO 2005/005604 for a description of the different germlinesequences.

In particular embodiments, the light chain variable region and/or heavychain variable region comprises a framework region or at least a portionof a framework region (e.g., containing 2 or 3 subregions, such as FR2and FR3). In certain embodiments, at least FRL1, FRL2, FRL3, or FRL4 isfully human. In other embodiments, at least FRH1, FRH2, FRH3, or FRH4 isfully human. In some embodiments, at least FRL1, FRL2, FRL3, or FRL4 isa germline sequence (e.g., human germline) or comprises human consensussequences for the particular framework (readily available at the sourcesof known human Ig sequences described above). In other embodiments, atleast FRH1, FRH2, FRH3, or FRH4 is a germline sequence (e.g., humangermline) or comprises human consensus sequences for the particularframework. In preferred embodiments, the framework region is a humanframework region.

Engineering of antibodies of the present invention can be performedusing any known method, such as but not limited to those described in,Winter (Jones et al., Nature 321:522 (1986); Riechmann et al., Nature332:323 (1988); Verhoeyen et al., Science 239:1534 (1988)), Sims et al.,J. Immunol. 151: 2296 (1993); Chothia and Lesk, J. Mol. Biol. 196:901(1987), Carter et al., Proc. Natl. Acad. Sci. U.S.A. 89:4285 (1992);Presta et al., J. Immunol. 151:2623 (1993), U.S. Pat. Nos. 5,723,323,5,976,862, 5,824,514, 5,817,483, 5,814,476, 5,763,192, 5,723,323,5,766,886, 5,714,352, 6,204,023, 6,180,370, 5,693,762, 5,530,101,5,585,089, 5,225,539; 4,816,567, PCT/: US98/16280, US96/18978,US91/09630, US91/05939, US94/01234, GB89/01334, GB91/01134, GB92/01755;WO90/14443, WO90/14424, WO90/14430, EP 229246, each entirelyincorporated herein by reference, included references cited therein.

In certain embodiments, the antibody comprises an altered (e.g.,mutated) Fc region. For example, in some embodiments, the Fc region hasbeen altered to reduce or enhance the effector functions of theantibody. In some embodiments, the Fc region is an isotype selected fromIgM, IgA, IgG, IgE, or other isotype.

Alternatively or additionally, it may be useful to combine amino acidmodifications with one or more further amino acid modifications thatalter C1q binding and/or the complement dependent cytotoxicity (CDC)function of the Fc region of an IL-23p19 binding molecule. The bindingpolypeptide of particular interest may be one that binds to C1q anddisplays complement dependent cytotoxicity. Polypeptides withpre-existing C1q binding activity, optionally further having the abilityto mediate CDC may be modified such that one or both of these activitiesare enhanced. Amino acid modifications that alter C1q and/or modify itscomplement dependent cytotoxicity function are described, for example,in WO/0042072, which is hereby incorporated by reference.

As disclosed above, one can design an Fc region of the IL-23p19 antibodyof the present invention with altered effector function, e.g., bymodifying C1q binding and/or FcγR binding and thereby changing CDCactivity and/or ADCC activity. “Effector functions” are responsible foractivating or diminishing a biological activity (e.g., in a subject).Examples of effector functions include, but are not limited to: C1qbinding; complement dependent cytotoxicity (CDC); Fc receptor binding;antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; downregulation of cell surface receptors (e.g., B cell receptor; BCR), etc.Such effector functions may require the Fc region to be combined with abinding domain (e.g., an antibody variable domain) and can be assessedusing various assays (e.g., Fc binding assays, ADCC assays, CDC assays,etc.).

For example, one can generate a variant Fc region of the IL-23p19antibody with improved C1q binding and improved FcγRIII binding (e.g.,having both improved ADCC activity and improved CDC activity).Alternatively, if it is desired that effector function be reduced orablated, a variant Fc region can be engineered with reduced CDC activityand/or reduced ADCC activity. In other embodiments, only one of theseactivities may be increased, and, optionally, also the other activityreduced (e.g., to generate an Fc region variant with improved ADCCactivity, but reduced CDC activity and vice versa).

Fc mutations can also be introduced and engineered to alter theirinteraction with the neonatal Fc receptor (FcRn) and improve theirpharmacokinetic properties. A collection of human Fc variants withimproved binding to the FcRn have been described (Shields et al.,(2001). High resolution mapping of the binding site on human IgG1 forFcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants withimproved binding to the FcγR, (J. Biol. Chem. 276:6591-6604).

Another type of amino acid substitution serves to alter theglycosylation pattern of the Fc region of the IL-23p19 antibody.Glycosylation of an Fc region is typically either N-linked or O-linked.N-linked refers to the attachment of the carbohydrate moiety to the sidechain of an asparagine residue. O-linked glycosylation refers to theattachment of one of the sugars N-aceylgalactosamine, galactose, orxylose to a hydroxyamino acid, most commonly serine or threonine,although 5-hydroxyproline or 5-hydroxylysine may also be used. Therecognition sequences for enzymatic attachment of the carbohydratemoiety to the asparagine side chain peptide sequences areasparagine-X-serine and asparagine-X-threonine, where X is any aminoacid except proline. Thus, the presence of either of these peptidesequences in a polypeptide creates a potential glycosylation site.

The glycosylation pattern may be altered, for example, by deleting oneor more glycosylation site(s) found in the polypeptide, and/or addingone or more glycosylation site(s) that are not present in thepolypeptide. Addition of glycosylation sites to the Fc region of anIL-23p19 antibody is conveniently accomplished by altering the aminoacid sequence such that it contains one or more of the above-describedtripeptide sequences (for N-linked glycosylation sites). An exemplaryglycosylation variant has an amino acid substitution of residue Asn 297of the heavy chain. The alteration may also be made by the addition of,or substitution by, one or more serine or threonine residues to thesequence of the original polypeptide (for O-linked glycosylation sites).Additionally, a change of Asn 297 to Ala can remove one of theglycosylation sites.

In certain embodiments, the IL-23p19 antibody of the present inventionis expressed in cells that express beta(1,4)-N-acetylglucosaminyltransferase III (GnT III), such that GnT IIIadds GlcNAc to the IL-23p19 antibody. Methods for producing antibodiesin such a fashion are provided in WO/9954342, WO/03011878, patentpublication 20030003097A1, and Umana et al., Nature Biotechnology,17:176-180, February 1999.

Screening antibodies for specific binding to similar proteins orfragments can be conveniently achieved using peptide display libraries.This method involves the screening of large collections of peptides forindividual members having the desired function or structure. Antibodyscreening of peptide display libraries is well known in the art. Thedisplayed peptide sequences can be from 3 to 5000 or more amino acids inlength, frequently from 5-100 amino acids long, and often from about 8to 25 amino acids long. In addition to direct chemical synthetic methodsfor generating peptide libraries, several recombinant DNA methods havebeen described. One type involves the display of a peptide sequence onthe surface of a bacteriophage or cell. Each bacteriophage or cellcontains the nucleotide sequence encoding the particular displayedpeptide sequence. Such methods are described in PCT Patent PublicationNos. 91/17271, 91/18980, 91/19818, and 93/08278.

Other systems for generating libraries of peptides have aspects of bothin vitro chemical synthesis and recombinant methods. See, PCT PatentPublication Nos. 92/05258, 92/14843, and 96/19256. See also, U.S. Pat.Nos. 5,658,754; and 5,643,768. Peptide display libraries, vector, andscreening kits are commercially available from such suppliers asInvitrogen (Carlsbad, Calif.), and Cambridge Antibody Technologies(Cambridgeshire, UK). See, e.g., U.S. Pat. Nos. 4,704,692, 4,939,666,4,946,778, 5,260,203, 5,455,030, 5,518,889, 5,534,621, 5,656,730,5,763,733, 5,767,260, 5,856,456, assigned to Enzon; 5,223,409,5,403,484, 5,571,698, 5,837,500, assigned to Dyax, 5,427,908, 5,580,717,assigned to Affymax; 5,885,793, assigned to Cambridge AntibodyTechnologies; 5,750,373, assigned to Genentech, 5,618,920, 5,595,898,5,576,195, 5,698,435, 5,693,493, 5,698,417, assigned to Xoma, Colligan,supra; Ausubel, supra; or Sambrook, supra.

Antibodies of the present invention can also be prepared using at leastone anti-IL-23p19 antibody encoding nucleic acid to provide transgenicanimals or mammals, such as goats, cows, horses, sheep, rabbits and thelike, that produce such antibodies in their milk. Such animals can beprovided using known methods. See, e.g., but not limited to, U.S. Pat.Nos. 5,827,690; 5,849,992; 4,873,316; 5,849,992; 5,994,616; 5,565,362;5,304,489, and the like, each of which is entirely incorporated hereinby reference.

Antibodies of the present invention can additionally be prepared usingat least one anti-IL-23p19 antibody encoding nucleic acid to providetransgenic plants and cultured plant cells (e.g., but not limited to,tobacco and maize) that produce such antibodies, specified portions orvariants in the plant parts or in cells cultured therefrom. As anon-limiting example, transgenic tobacco leaves expressing recombinantproteins have been successfully used to provide large amounts ofrecombinant proteins, e.g., using an inducible promoter. See, e.g.,Cramer et al., Curr. Top. Microbol. Immunol. 240:95-118 (1999) andreferences cited therein. Also, transgenic maize have been used toexpress mammalian proteins at commercial production levels, withbiological activities equivalent to those produced in other recombinantsystems or purified from natural sources. See, e.g., Hood et al., Adv.Exp. Med. Biol. 464:127-147 (1999) and references cited therein.Antibodies have also been produced in large amounts from transgenicplant seeds including antibody fragments, such as single chainantibodies (scFv's), including tobacco seeds and potato tubers. See,e.g., Conrad et al., Plant Mol. Biol. 38:101-109 (1998) and referencescited therein. Thus, antibodies of the present invention can also beproduced using transgenic plants, according to known methods. See also,e.g., Fischer et al., Biotechnol. Appl. Biochem. 30:99-108 (October,1999), Ma et al., Trends Biotechnol. 13:522-7 (1995); Ma et al., PlantPhysiol. 109:341-6 (1995); Whitelam et al., Biochem. Soc. Trans.22:940-944 (1994); and references cited therein.

The antibodies of the invention can bind human IL-23p19 with a widerange of affinities (K_(D)). In a preferred embodiment, at least one mAbof the present invention can optionally bind human IL-23p19 with highaffinity. For example, a human or other mAb can bind human IL-23p19 witha K_(D) equal to or less than about 10⁻⁷ M, such as but not limited to,0.1-9.9 (or any range or value therein) X 10⁻⁷, 10⁻⁸, 10⁻⁹, 10⁻¹⁰,10⁻¹¹, 10⁻¹², 10⁻¹³, 10⁻¹⁴, 10⁻¹⁵ or any range or value therein, asdetermined by surface plasmon resonance or the Kinexa method, aspracticed by those of skill in the art. In one embodiment, theantibodies of the invention bind human IL-23p19 with a K_(D) betweenabout 4 and about 4400 pM.

The affinity or avidity of an antibody for an antigen can be determinedexperimentally using any suitable method. (See, for example, Berzofsky,et al., “Antibody-Antigen Interactions,” In Fundamental Immunology,Paul, W. E., Ed., Raven Press: New York, N.Y. (1984); Kuby, JanisImmunology, W. H. Freeman and Company: New York, N.Y. (1992); andmethods described herein). The measured affinity of a particularantibody-antigen interaction can vary if measured under differentconditions (e.g., salt concentration, pH). Thus, measurements ofaffinity and other antigen-binding parameters (e.g., K_(D), K_(on),K_(off)) are preferably made with standardized solutions of antibody andantigen, and a standardized buffer, such as the buffer described herein.

Competitive assays can be performed with the antibody of the presentinvention in order to determine what proteins, antibodies, and otherantagonists compete for binding to IL-23p19 with the antibody of thepresent invention and/or share the epitope region. These assays asreadily known to those of ordinary skill in the art evaluate competitionbetween antagonists or ligands for a limited number of binding sites ona protein, e.g., p19. The protein and/or antibody is immobilized orinsolubilized before or after the competition and the sample bound tothe p19 subunit is separated from the unbound sample, for example, bydecanting (where the protein/antibody was preinsolubilized) or bycentrifuging (where the protein/antibody was precipitated after thecompetitive reaction). Also, the competitive binding may be determinedby whether function is altered by the binding or lack of binding of theantibody to the protein, e.g., whether the antibody molecule inhibits orpotentiates the enzymatic activity of, for example, a label. ELISA andother functional assays may be used, as well known in the art.

Certain embodiments of the anti-IL-23p19 antibodies of the inventionhave the sequences shown in the Sequence Tables below. For example, ananti-IL-23p19 antibody of the invention has one of the light chain CDR1sequences of SEQ ID NOS:46-51; one of the light chain CDR2 sequences ofSEQ ID NOS:52-57; one of the light chain CDR3 sequences of SEQ IDNOS:58-79; one of the heavy chain CDR1 sequences SEQ ID NOS:1-6; one ofthe heavy chain CDR2 sequences SEQ ID NOS:7-39 and 146; and/or one ofthe heavy chain CDR3 sequences SEQ ID NOS:40-45.

Nucleic Acid Molecules

Using the information provided herein, for example, the nucleotidesequences encoding at least 70-100% of the contiguous amino acids of atleast one of the light chain variable regions of the antibodies of theinvention (e.g., SEQ ID NOS:136-138 and 142-144) and at least one of theheavy chain variable regions of the antibodies of the invention (e.g.,SEQ ID NOS:133-135 and 139-141), specified fragments, variants orconsensus sequences thereof, or a deposited vector comprising at leastone of these sequences, a nucleic acid molecule of the present inventionencoding at least one anti-IL-23p19 antibody can be obtained usingmethods described herein or as known in the art.

Nucleic acid molecules of the present invention can be in the form ofRNA, such as mRNA, hnRNA, tRNA or any other form, or in the form of DNA,including, but not limited to, cDNA and genomic DNA obtained by cloningor produced synthetically, or any combinations thereof. The DNA can betriple-stranded, double-stranded or single-stranded, or any combinationthereof. Any portion of at least one strand of the DNA or RNA can be thecoding strand, also known as the sense strand, or it can be thenon-coding strand, also referred to as the anti-sense strand.

Isolated nucleic acid molecules of the present invention can includenucleic acid molecules comprising an open reading frame (ORF),optionally, with one or more introns, e.g., but not limited to, at leastone specified portion of at least one CDR, such as CDR1, CDR2 and/orCDR3 of at least light chain (SEQ ID NOS: 46-51, 52-57, or 58-79) or atleast one heavy chain (SEQ ID NOS: 1-6, 7-39, or 40-45); nucleic acidmolecules comprising the coding sequence for an anti-IL-23p19 antibodyor variable region (e.g., light chain variable regions of SEQ ID NOS:82-85, 93-98, 100, 102, 113-116, and 128-132 and heavy chain variableregions of SEQ ID NOS: 80, 81, 86-92, 99, 101, 103-112, 117-127, and147); and nucleic acid molecules which comprise a nucleotide sequencesubstantially different from those described above but which, due to thedegeneracy of the genetic code, still encode at least one anti-IL-23p19antibody as described herein and/or as known in the art. Of course, thegenetic code is well known in the art. Thus, it would be routine for oneskilled in the art to generate such degenerate nucleic acid variantsthat code for specific anti-IL-23p19 antibodies of the presentinvention. See, e.g., Ausubel, et al., supra, and such nucleic acidvariants are included in the present invention.

As indicated herein, nucleic acid molecules of the present inventionwhich comprise a nucleic acid encoding an anti-IL-23p19 antibody caninclude, but are not limited to, those encoding the amino acid sequenceof an antibody fragment, by itself; the coding sequence for the entireantibody or a portion thereof; the coding sequence for an antibody,fragment or portion, as well as additional sequences, such as the codingsequence of at least one signal leader or fusion peptide, with orwithout the aforementioned additional coding sequences, such as at leastone intron, together with additional, non-coding sequences, includingbut not limited to, non-coding 5′ and 3′ sequences, such as thetranscribed, non-translated sequences that play a role in transcription,mRNA processing, including splicing and polyadenylation signals (forexample, ribosome binding and stability of mRNA); an additional codingsequence that codes for additional amino acids, such as those thatprovide additional functionalities. Thus, the sequence encoding anantibody can be fused to a marker sequence, such as a sequence encodinga peptide that facilitates purification of the fused antibody comprisingan antibody fragment or portion.

Polynucleotides Selectively Hybridizing to a Polynucleotide as DescribedHerein

The present invention provides isolated nucleic acids that hybridizeunder selective hybridization conditions to a polynucleotide disclosedherein. Thus, the polynucleotides of this embodiment can be used forisolating, detecting, and/or quantifying nucleic acids comprising suchpolynucleotides. For example, polynucleotides of the present inventioncan be used to identify, isolate, or amplify partial or full-lengthclones in a deposited library. In some embodiments, the polynucleotidesare genomic or cDNA sequences isolated, or otherwise complementary to, acDNA from a human or mammalian nucleic acid library.

Preferably, the cDNA library comprises at least 80% full-lengthsequences, preferably, at least 85% or 90% full-length sequences, and,more preferably, at least 95% full-length sequences. The cDNA librariescan be normalized to increase the representation of rare sequences. Lowor moderate stringency hybridization conditions are typically, but notexclusively, employed with sequences having a reduced sequence identityrelative to complementary sequences. Moderate and high stringencyconditions can optionally be employed for sequences of greater identity.Low stringency conditions allow selective hybridization of sequenceshaving about 70% sequence identity and can be employed to identifyorthologous or paralogous sequences.

Optionally, polynucleotides of this invention will encode at least aportion of an antibody encoded by the polynucleotides described herein.The polynucleotides of this invention embrace nucleic acid sequencesthat can be employed for selective hybridization to a polynucleotideencoding an antibody of the present invention. See, e.g., Ausubel,supra; Colligan, supra, each entirely incorporated herein by reference.

Construction of Nucleic Acids

The isolated nucleic acids of the present invention can be made using(a) recombinant methods, (b) synthetic techniques, (c) purificationtechniques, and/or (d) combinations thereof, as well-known in the art.

The nucleic acids can conveniently comprise sequences in addition to apolynucleotide of the present invention. For example, a multi-cloningsite comprising one or more endonuclease restriction sites can beinserted into the nucleic acid to aid in isolation of thepolynucleotide. Also, translatable sequences can be inserted to aid inthe isolation of the translated polynucleotide of the present invention.For example, a hexa-histidine marker sequence provides a convenientmeans to purify the proteins of the present invention. The nucleic acidof the present invention, excluding the coding sequence, is optionally avector, adapter, or linker for cloning and/or expression of apolynucleotide of the present invention.

Additional sequences can be added to such cloning and/or expressionsequences to optimize their function in cloning and/or expression, toaid in isolation of the polynucleotide, or to improve the introductionof the polynucleotide into a cell. Use of cloning vectors, expressionvectors, adapters, and linkers is well known in the art. (See, e.g.,Ausubel, supra; or Sambrook, supra)

Recombinant Methods for Constructing Nucleic Acids

The isolated nucleic acid compositions of this invention, such as RNA,cDNA, genomic DNA, or any combination thereof, can be obtained frombiological sources using any number of cloning methodologies known tothose of skill in the art. In some embodiments, oligonucleotide probesthat selectively hybridize, under stringent conditions, to thepolynucleotides of the present invention are used to identify thedesired sequence in a cDNA or genomic DNA library. The isolation of RNA,and construction of cDNA and genomic libraries, are well known to thoseof ordinary skill in the art. (See, e.g., Ausubel, supra; or Sambrook,supra)

Nucleic Acid Screening and Isolation Methods

A cDNA or genomic library can be screened using a probe based upon thesequence of a polynucleotide of the present invention, such as thosedisclosed herein. Probes can be used to hybridize with genomic DNA orcDNA sequences to isolate homologous genes in the same or differentorganisms. Those of skill in the art will appreciate that variousdegrees of stringency of hybridization can be employed in the assay; andeither the hybridization or the wash medium can be stringent. As theconditions for hybridization become more stringent, there must be agreater degree of complementarity between the probe and the target forduplex formation to occur. The degree of stringency can be controlled byone or more of temperature, ionic strength, pH and the presence of apartially denaturing solvent, such as formamide. For example, thestringency of hybridization is conveniently varied by changing thepolarity of the reactant solution through, for example, manipulation ofthe concentration of formamide within the range of 0% to 50%. The degreeof complementarity (sequence identity) required for detectable bindingwill vary in accordance with the stringency of the hybridization mediumand/or wash medium. The degree of complementarity will optimally be100%, or 70-100%, or any range or value therein. However, it should beunderstood that minor sequence variations in the probes and primers canbe compensated for by reducing the stringency of the hybridizationand/or wash medium.

Methods of amplification of RNA or DNA are well known in the art and canbe used according to the present invention without undueexperimentation, based on the teaching and guidance presented herein.

Known methods of DNA or RNA amplification include, but are not limitedto, polymerase chain reaction (PCR) and related amplification processes(see, e.g., U.S. Pat. Nos. 4,683,195, 4,683,202, 4,800,159, 4,965,188,to Mullis, et al.; 4,795,699 and 4,921,794 to Tabor, et al; 5,142,033 toInnis; 5,122,464 to Wilson, et al.; 5,091,310 to Innis; 5,066,584 toGyllensten, et al; 4,889,818 to Gelfand, et al; 4,994,370 to Silver, etal; 4,766,067 to Biswas; 4,656,134 to Ringold) and RNA mediatedamplification that uses anti-sense RNA to the target sequence as atemplate for double-stranded DNA synthesis (U.S. Pat. No. 5,130,238 toMalek, et al, with the tradename NASBA), the entire contents of whichreferences are incorporated herein by reference. (See, e.g., Ausubel,supra; or Sambrook, supra.)

For instance, polymerase chain reaction (PCR) technology can be used toamplify the sequences of polynucleotides of the present invention andrelated genes directly from genomic DNA or cDNA libraries. PCR and otherin vitro amplification methods can also be useful, for example, to clonenucleic acid sequences that code for proteins to be expressed, to makenucleic acids to use as probes for detecting the presence of the desiredmRNA in samples, for nucleic acid sequencing, or for other purposes.Examples of techniques sufficient to direct persons of skill through invitro amplification methods are found in Berger, supra, Sambrook, supra,and Ausubel, supra, as well as Mullis, et al., U.S. Pat. No. 4,683,202(1987); and Innis, et al., PCR Protocols A Guide to Methods andApplications, Eds., Academic Press Inc., San Diego, Calif. (1990).Commercially available kits for genomic PCR amplification are known inthe art. See, e.g., Advantage-GC Genomic PCR Kit (Clontech).Additionally, e.g., the T4 gene 32 protein (Boehringer Mannheim) can beused to improve yield of long PCR products.

Synthetic Methods for Constructing Nucleic Acids

The isolated nucleic acids of the present invention can also be preparedby direct chemical synthesis by known methods (see, e.g., Ausubel, etal., supra). Chemical synthesis generally produces a single-strandedoligonucleotide, which can be converted into double-stranded DNA byhybridization with a complementary sequence, or by polymerization with aDNA polymerase using the single strand as a template. One of skill inthe art will recognize that while chemical synthesis of DNA can belimited to sequences of about 100 or more bases, longer sequences can beobtained by the ligation of shorter sequences.

Recombinant Expression Cassettes

The present invention further provides recombinant expression cassettescomprising a nucleic acid of the present invention. A nucleic acidsequence of the present invention, for example, a cDNA or a genomicsequence encoding an antibody of the present invention, can be used toconstruct a recombinant expression cassette that can be introduced intoat least one desired host cell. A recombinant expression cassette willtypically comprise a polynucleotide of the present invention operablylinked to transcriptional initiation regulatory sequences that willdirect the transcription of the polynucleotide in the intended hostcell. Both heterologous and non-heterologous (i.e., endogenous)promoters can be employed to direct expression of the nucleic acids ofthe present invention.

In some embodiments, isolated nucleic acids that serve as promoter,enhancer, or other elements can be introduced in the appropriateposition (upstream, downstream or in the intron) of a non-heterologousform of a polynucleotide of the present invention so as to up or downregulate expression of a polynucleotide of the present invention. Forexample, endogenous promoters can be altered in vivo or in vitro bymutation, deletion and/or substitution.

Vectors and Host Cells

The present invention also relates to vectors that include isolatednucleic acid molecules of the present invention, host cells that aregenetically engineered with the recombinant vectors, and the productionof at least one anti-IL-23p19 antibody by recombinant techniques, as iswell known in the art. See, e.g., Sambrook, et al., supra; Ausubel, etal., supra, each entirely incorporated herein by reference.

The polynucleotides can optionally be joined to a vector containing aselectable marker for propagation in a host. Generally, a plasmid vectoris introduced in a precipitate, such as a calcium phosphate precipitate,or in a complex with a charged lipid. If the vector is a virus, it canbe packaged in vitro using an appropriate packaging cell line and thentransduced into host cells.

The DNA insert should be operatively linked to an appropriate promoter.The expression constructs will further contain sites for transcriptioninitiation, termination and, in the transcribed region, a ribosomebinding site for translation. The coding portion of the maturetranscripts expressed by the constructs will preferably include atranslation initiating at the beginning and a termination codon (e.g.,UAA, UGA or UAG) appropriately positioned at the end of the mRNA to betranslated, with UAA and UAG preferred for mammalian or eukaryotic cellexpression.

Expression vectors will preferably but optionally include at least oneselectable marker. Such markers include, e.g., but are not limited to,methotrexate (MTX), dihydrofolate reductase (DHFR, U.S. Pat. Nos.4,399,216; 4,634,665; 4,656,134; 4,956,288; 5,149,636; 5,179,017,ampicillin, neomycin (G418), mycophenolic acid, or glutamine synthetase(GS, U.S. Pat. Nos. 5,122,464; 5,770,359; 5,827,739) resistance foreukaryotic cell culture, and tetracycline or ampicillin resistance genesfor culturing in E. coli and other bacteria or prokaryotics (the abovepatents are entirely incorporated hereby by reference). Appropriateculture mediums and conditions for the above-described host cells areknown in the art. Suitable vectors will be readily apparent to theskilled artisan. Introduction of a vector construct into a host cell canbe effected by calcium phosphate transfection, DEAE-dextran mediatedtransfection, cationic lipid-mediated transfection, electroporation,transduction, infection or other known methods. Such methods aredescribed in the art, such as Sambrook, supra, Chapters 1-4 and 16-18;Ausubel, supra, Chapters 1, 9, 13, 15, 16.

At least one antibody of the present invention can be expressed in amodified form, such as a fusion protein, and can include not onlysecretion signals, but also additional heterologous functional regions.For instance, a region of additional amino acids, particularly chargedamino acids, can be added to the N-terminus of an antibody to improvestability and persistence in the host cell, during purification, orduring subsequent handling and storage. Also, peptide moieties can beadded to an antibody of the present invention to facilitatepurification. Such regions can be removed prior to final preparation ofan antibody or at least one fragment thereof. Such methods are describedin many standard laboratory manuals, such as Sambrook, supra, Chapters17.29-17.42 and 18.1-18.74; Ausubel, supra, Chapters 16, 17 and 18.

Those of ordinary skill in the art are knowledgeable in the numerousexpression systems available for expression of a nucleic acid encoding aprotein of the present invention. Alternatively, nucleic acids of thepresent invention can be expressed in a host cell by turning on (bymanipulation) in a host cell that contains endogenous DNA encoding anantibody of the present invention. Such methods are well known in theart, e.g., as described in U.S. Pat. Nos. 5,580,734, 5,641,670,5,733,746, and 5,733,761, entirely incorporated herein by reference.

Illustrative of cell cultures useful for the production of theantibodies, specified portions or variants thereof, are mammalian cells.Mammalian cell systems often will be in the form of monolayers of cellsalthough mammalian cell suspensions or bioreactors can also be used. Anumber of suitable host cell lines capable of expressing intactglycosylated proteins have been developed in the art, and include theCOS-1 (e.g., ATCC CRL 1650), COS-7 (e.g., ATCC CRL-1651), HEK293, BHK21(e.g., ATCC CRL-10), CHO (e.g., ATCC CRL 1610) and BSC-1 (e.g., ATCCCRL-26) cell lines, Cos-7 cells, CHO cells, hep G2 cells, P3X63Ag8.653,SP2/0-Ag14, 293 cells, HeLa cells and the like, which are readilyavailable from, for example, American Type Culture Collection, Manassas,Va (www.atcc.org). Preferred host cells include cells of lymphoidorigin, such as myeloma and lymphoma cells. Particularly preferred hostcells are P3X63Ag8.653 cells (ATCC Accession Number CRL-1580) andSP2/0-Ag14 cells (ATCC Accession Number CRL-1851). In a particularlypreferred embodiment, the recombinant cell is a P3X63Ab8.653 or aSP2/0-Ag14 cell.

Expression vectors for these cells can include one or more of thefollowing expression control sequences, such as, but not limited to, anorigin of replication; a promoter (e.g., late or early SV40 promoters,the CMV promoter (U.S. Pat. Nos. 5,168,062; 5,385,839), an HSV tkpromoter, a pgk (phosphoglycerate kinase) promoter, an EF-1 alphapromoter (U.S. Pat. No. 5,266,491), at least one human immunoglobulinpromoter; an enhancer, and/or processing information sites, such asribosome binding sites, RNA splice sites, polyadenylation sites (e.g.,an SV40 large T Ag poly A addition site), and transcriptional terminatorsequences. See, e.g., Ausubel et al., supra; Sambrook, et al., supra.Other cells useful for production of nucleic acids or proteins of thepresent invention are known and/or available, for instance, from theAmerican Type Culture Collection Catalogue of Cell Lines and Hybridomas(www.atcc.org) or other known or commercial sources.

When eukaryotic host cells are employed, polyadenlyation ortranscription terminator sequences are typically incorporated into thevector. An example of a terminator sequence is the polyadenlyationsequence from the bovine growth hormone gene. Sequences for accuratesplicing of the transcript can also be included. An example of asplicing sequence is the VP1 intron from SV40 (Sprague, et al., J.Virol. 45:773-781 (1983)). Additionally, gene sequences to controlreplication in the host cell can be incorporated into the vector, asknown in the art.

Purification of an Antibody

An anti-IL-23p19 antibody can be recovered and purified from recombinantcell cultures by well-known methods including, but not limited to,protein A purification, ammonium sulfate or ethanol precipitation, acidextraction, anion or cation exchange chromatography, phosphocellulosechromatography, hydrophobic interaction chromatography, affinitychromatography, hydroxylapatite chromatography and lectinchromatography. High performance liquid chromatography (“HPLC”) can alsobe employed for purification. See, e.g., Colligan, Current Protocols inImmunology, or Current Protocols in Protein Science, John Wiley & Sons,NY, N.Y., (1997-2001), e.g., Chapters 1, 4, 6, 8, 9, 10, each entirelyincorporated herein by reference.

Antibodies of the present invention include naturally purified products,products of chemical synthetic procedures, and products produced byrecombinant techniques from a eukaryotic host, including, for example,yeast, higher plant, insect and mammalian cells. Depending upon the hostemployed in a recombinant production procedure, the antibody of thepresent invention can be glycosylated or can be non-glycosylated, withglycosylated preferred. Such methods are described in many standardlaboratory manuals, such as Sambrook, supra, Sections 17.37-17.42;Ausubel, supra, Chapters 10, 12, 13, 16, 18 and 20, Colligan, ProteinScience, supra, Chapters 12-14, all entirely incorporated herein byreference.

Anti-IL-23p19 Antibodies

An anti-IL-23p19 antibody according to the present invention includesany protein or peptide containing molecule that comprises at least aportion of an immunoglobulin molecule, such as but not limited to, atleast one ligand binding portion (LBP), such as but not limited to, acomplementarity determining region (CDR) of a heavy or light chain or aligand binding portion thereof, a heavy chain or light chain variableregion, a framework region (e.g., FR1, FR2, FR3, FR4 or fragmentthereof, further optionally comprising at least one substitution,insertion or deletion), a heavy chain or light chain constant region,(e.g., comprising at least one CH1, hinge1, hinge2, hinge3, hinge4, CH2,or CH3 or fragment thereof, further optionally comprising at least onesubstitution, insertion or deletion), or any portion thereof, that canbe incorporated into an antibody of the present invention. An antibodyof the invention can include or be derived from any mammal, such as butnot limited to, a human, a mouse, a rabbit, a rat, a rodent, a primate,or any combination thereof, and the like.

The isolated antibodies of the present invention comprise the antibodyamino acid sequences disclosed herein encoded by any suitablepolynucleotide, or any isolated or prepared antibody. Preferably, thehuman antibody or antigen-binding fragment binds human IL-23p19 and,thereby, partially or substantially neutralizes at least one biologicalactivity of the protein. An antibody, or specified portion or variantthereof, that partially or preferably substantially neutralizes at leastone biological activity of at least one IL-23 protein or fragment canbind the protein or fragment and thereby inhibit activities mediatedthrough the binding of IL-23 to the IL-23 receptor or through otherIL-23-dependent or mediated mechanisms. As used herein, the term“neutralizing antibody” refers to an antibody that can inhibit anIL-23-dependent activity by about 20-120%, preferably by at least about10, 20, 30, 40, 50, 55, 60, 65, 70, 75, 80, 85, 90, 91, 92, 93, 94, 95,96, 97, 98, 99, 100% or more depending on the assay. The capacity of ananti-IL-23p19 antibody to inhibit an IL-23-dependent activity ispreferably assessed by at least one suitable IL-23 protein or receptorassay, as described herein and/or as known in the art. A human antibodyof the invention can be of any class (IgG, IgA, IgM, IgE, IgD, etc.) orisotype and can comprise a kappa or lambda light chain. In oneembodiment, the human antibody comprises an IgG heavy chain or definedfragment, for example, at least one of isotypes, IgG1, IgG2, IgG3 orIgG4 (e.g., γ1, γ2, γ3, or γ4). Antibodies of this type can be preparedby employing a transgenic mouse or other trangenic non-human mammalcomprising at least one human light chain (e.g., IgG, IgA, and IgM)transgenes as described herein and/or as known in the art. In anotherembodiment, the anti-human IL-23p19 antibody comprises an IgG1 heavychain and an IgG1 light chain.

At least one antibody of the invention binds at least one specifiedepitope specific to at least one IL-23p19 protein, subunit, fragment,portion or any combination thereof. The at least one epitope cancomprise at least one antibody binding region that comprises at leastone portion of the protein, which epitope is preferably comprised of atleast one extracellular, soluble, hydrophillic, external or cytoplasmicportion of the protein. The at least one specified epitope can compriseany combination of at least one amino acid sequence of at least 1-3amino acids to the entire specified portion of contiguous amino acids ofamino acid residues 93-105 of SEQ ID NO:145 (that contains the initial19 amino acid signal sequence for the p19 protein subunit) (or aminoacid residues 74-86 of the p19 sequence without inclusion of the signalsequence), for example, amino acid residues 93, 93-94, 93-95, 93-96,97-99, 100-102 of SEQ ID NO:145, etc. that include any portions orcombinations of these sequences.

Generally, the antibody or antigen-binding fragment of the presentinvention will comprise an antigen-binding region that comprises atleast one complementarity determining region (CDR1, CDR2 and CDR3) orvariant of at least one heavy chain variable region and at least onecomplementarity determining region (CDR1, CDR2 and CDR3) or variant ofat least one light chain variable region. Optionally, the CDR sequencesmay be derived from human germline sequences or closely match thegermline sequences. For example, the CDRs from a synthetic libraryderived from the original mouse CDRs can be used. As a non-limitingexample, the antibody or antigen-binding portion or variant can compriseat least one of the heavy chain CDR3, e.g., selected from SEQ ID NOS:1-6, 7-39 and 146, or 40-45, and/or a light chain CDR3, e.g., selectedfrom SEQ ID NOS: SEQ ID NOS: 46-51, 52-57, or 58-79. In a particularembodiment, the antibody or antigen-binding fragment can have anantigen-binding region that comprises at least a portion of at least oneheavy chain CDR (i.e., CDR1, CDR2 and/or CDR3) (e.g., those disclosedherein). In another particular embodiment, the antibody orantigen-binding portion or variant can have an antigen-binding regionthat comprises at least a portion of at least one light chain CDR (i.e.,CDR1, CDR2 and/or CDR3) (e.g., those disclosed herein).

In a preferred embodiment, the three heavy chain CDRs and the threelight chain CDRs of the antibody or antigen-binding fragment can beprepared by chemically joining together the various portions (e.g.,CDRs, framework) of the antibody using conventional techniques, bypreparing and expressing a (i.e., one or more) nucleic acid moleculethat encodes the antibody using conventional techniques of recombinantDNA technology or by using any other suitable method.

The anti-IL-23p19 antibody can comprise at least one of a heavy or lightchain variable region having a defined amino acid sequence. For example,in a preferred embodiment, the anti-IL-23p19 antibody comprises at leastone of at least one heavy chain variable region optionally selected fromSEQ ID NOS: 80, 81, 86-92, 99, 101, 103-112, 117-127, and 147 and/or atleast one light chain variable region optionally selected from SEQ IDNOS: 82-85, 93-98, 100, 102, 113-116, and 128-132. Antibodies that bindto human IL-23p19 and that comprise a defined heavy or light chainvariable region can be prepared using suitable methods. The antibody,specified portion or variant can be expressed using the encoding nucleicacid or portion thereof in a suitable host cell.

Amino Acid Codes

The amino acids that make up anti-IL-23p19 antibodies of the presentinvention are often abbreviated. The amino acid designations can beindicated by designating the amino acid by its single letter code, itsthree letter code, name, or three nucleotide codon(s) as is wellunderstood in the art (see Alberts, B., et al., Molecular Biology of TheCell, Third Ed., Garland Publishing, Inc., New York, 1994). Ananti-IL-23p19 antibody of the present invention can include one or moreamino acid substitutions, deletions or additions, either from naturalmutations or human manipulation, as specified herein. Amino acids in ananti-IL-23p19 antibody of the present invention that are essential forfunction can be identified by methods known in the art, such assite-directed mutagenesis or alanine-scanning mutagenesis (e.g.,Ausubel, supra, Chapters 8, 15; Cunningham and Wells, Science244:1081-1085 (1989)). The latter procedure introduces single alaninemutations at every residue in the molecule. The resulting mutantmolecules are then tested for biological activity, such as, but notlimited to, at least one IL-23 neutralizing activity. Sites that arecritical for antibody binding can also be identified by structuralanalysis, such as crystallization, nuclear magnetic resonance orphotoaffinity labeling (Smith, et al., J. Mol. Biol. 224:899-904 (1992)and de Vos, et al., Science 255:306-312 (1992)).

Anti-IL-23p19 antibodies of the present invention can include, but arenot limited to, at least one portion, sequence or combination selectedfrom 5 to all of the contiguous amino acids of the variable regionsequences of SEQ ID NOS: 82-85, 93-98, 100, 102, 113-116, and 128-132and SEQ ID NOS: 80, 81, 86-92, 99, 101, 103-112, 117-127, and 147.

Non-limiting variants that can enhance or maintain at least one of thelisted activities include, but are not limited to, any of the abovepolypeptides, further comprising at least one mutation corresponding toat least one substitution in the residues varied among the disclosedvariant amino acid sequences.

An anti-IL-23p19 antibody can further optionally comprise a polypeptidewith an amino acid sequence that varies from the sequences disclosedherein (e.g., one or more conservative substitutions from the sequencesprovided herein). Also, more specifically, the present inventioncomprises variants of the amino acid sequence of a light chain variableregion of SEQ ID NOS: 82-85, 93-98, 100, 102, 113-116, and 128-132 orthe amino acid sequence of a heavy chain variable region of SEQ ID NOS:80, 81, 86-92, 99, 101, 103-112, 117-127, and 147.

As those of skill will appreciate, the present invention includes atleast one biologically active antibody of the present invention.Biologically active antibodies have a specific activity at least 20%,30%, or 40%, and, preferably, at least 50%, 60%, or 70%, and, mostpreferably, at least 80%, 90%, or 95%-1000% or more of that of thenative (non-synthetic), endogenous or related and known antibody.Methods of assaying and quantifying measures of enzymatic activity andsubstrate specificity are well known to those of skill in the art.

In another aspect, the invention relates to human antibodies andantigen-binding fragments, as described herein, which are modified bythe covalent attachment of an organic moiety. Such modification canproduce an antibody or antigen-binding fragment with improvedpharmacokinetic properties (e.g., increased in vivo serum half-life).The organic moiety can be a linear or branched hydrophilic polymericgroup, fatty acid group, or fatty acid ester group. In particularembodiments, the hydrophilic polymeric group can have a molecular weightof about 800 to about 120,000 Daltons and can be a polyalkane glycol(e.g., polyethylene glycol (PEG), polypropylene glycol (PPG)),carbohydrate polymer, amino acid polymer or polyvinyl pyrolidone, andthe fatty acid or fatty acid ester group can comprise from about eightto about forty carbon atoms.

The modified antibodies and antigen-binding fragments of the inventioncan comprise one or more organic moieties that are covalently bonded,directly or indirectly, to the antibody. Each organic moiety that isbonded to an antibody or antigen-binding fragment of the invention canindependently be a hydrophilic polymeric group, a fatty acid group or afatty acid ester group. As used herein, the term “fatty acid”encompasses mono-carboxylic acids and di-carboxylic acids. A“hydrophilic polymeric group,” as the term is used herein, refers to anorganic polymer that is more soluble in water than in octane. Forexample, polylysine is more soluble in water than in octane. Thus, anantibody modified by the covalent attachment of polylysine isencompassed by the invention. Hydrophilic polymers suitable formodifying antibodies of the invention can be linear or branched andinclude, for example, polyalkane glycols (e.g., PEG,monomethoxy-polyethylene glycol (mPEG), PPG and the like), carbohydrates(e.g., dextran, cellulose, oligosaccharides, polysaccharides and thelike), polymers of hydrophilic amino acids (e.g., polylysine,polyarginine, polyaspartate and the like), polyalkane oxides (e.g.,polyethylene oxide, polypropylene oxide and the like) and polyvinylpyrolidone. Preferably, the hydrophilic polymer that modifies theantibody of the invention has a molecular weight of about 800 to about150,000 Daltons as a separate molecular entity. For example, PEG₅₀₀₀ andPEG_(20,000), wherein the subscript is the average molecular weight ofthe polymer in Daltons, can be used. The hydrophilic polymeric group canbe substituted with one to about six alkyl, fatty acid or fatty acidester groups. Hydrophilic polymers that are substituted with a fattyacid or fatty acid ester group can be prepared by employing suitablemethods. For example, a polymer comprising an amine group can be coupledto a carboxylate of the fatty acid or fatty acid ester, and an activatedcarboxylate (e.g., activated with N,N-carbonyl diimidazole) on a fattyacid or fatty acid ester can be coupled to a hydroxyl group on apolymer.

Fatty acids and fatty acid esters suitable for modifying antibodies ofthe invention can be saturated or can contain one or more units ofunsaturation. Fatty acids that are suitable for modifying antibodies ofthe invention include, for example, n-dodecanoate (C₁₂, laurate),n-tetradecanoate (C₁₄, myristate), n-octadecanoate (C₁₈, stearate),n-eicosanoate (C₂₀, arachidate), n-docosanoate (C₂₂, behenate),n-triacontanoate (C₃₀), n-tetracontanoate (C₄₀), cis-Δ9-octadecanoate(C₁₈, oleate), all cis-Δ5,8,11,14-eicosatetraenoate (C₂₀, arachidonate),octanedioic acid, tetradecanedioic acid, octadecanedioic acid,docosanedioic acid, and the like. Suitable fatty acid esters includemono-esters of dicarboxylic acids that comprise a linear or branchedlower alkyl group. The lower alkyl group can comprise from one to abouttwelve, preferably, one to about six, carbon atoms.

The modified human antibodies and antigen-binding fragments can beprepared using suitable methods, such as by reaction with one or moremodifying agents. A “modifying agent” as the term is used herein, refersto a suitable organic group (e.g., hydrophilic polymer, a fatty acid, afatty acid ester) that comprises an activating group. An “activatinggroup” is a chemical moiety or functional group that can, underappropriate conditions, react with a second chemical group therebyforming a covalent bond between the modifying agent and the secondchemical group. For example, amine-reactive activating groups includeelectrophilic groups, such as tosylate, mesylate, halo (chloro, bromo,fluoro, iodo), N-hydroxysuccinimidyl esters (NHS), and the like.Activating groups that can react with thiols include, for example,maleimide, iodoacetyl, acrylolyl, pyridyl disulfides,5-thiol-2-nitrobenzoic acid thiol (TNB-thiol), and the like. An aldehydefunctional group can be coupled to amine- or hydrazide-containingmolecules, and an azide group can react with a trivalent phosphorousgroup to form phosphoramidate or phosphorimide linkages. Suitablemethods to introduce activating groups into molecules are known in theart (see for example, Hermanson, G. T., Bioconjugate Techniques,Academic Press: San Diego, Calif. (1996)). An activating group can bebonded directly to the organic group (e.g., hydrophilic polymer, fattyacid, fatty acid ester), or through a linker moiety, for example, adivalent C₁-C₁₂ group wherein one or more carbon atoms can be replacedby a heteroatom, such as oxygen, nitrogen or sulfur. Suitable linkermoieties include, for example, tetraethylene glycol, —(CH₂)₃—,—NH—(CH₂)₆—NH—, —(CH₂)₂—NH— and —CH₂—O—CH₂—CH₂—O—CH₂—CH₂—O—CH—NH—.Modifying agents that comprise a linker moiety can be produced, forexample, by reacting a mono-Boc-alkyldiamine (e.g.,mono-Boc-ethylenediamine, mono-Boc-diaminohexane) with a fatty acid inthe presence of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) toform an amide bond between the free amine and the fatty acidcarboxylate. The Boc protecting group can be removed from the product bytreatment with trifluoroacetic acid (TFA) to expose a primary amine thatcan be coupled to another carboxylate, as described, or can be reactedwith maleic anhydride and the resulting product cyclized to produce anactivated maleimido derivative of the fatty acid. (See, for example,Thompson, et al., WO 92/16221, the entire teachings of which areincorporated herein by reference.)

The modified antibodies of the invention can be produced by reacting ahuman antibody or antigen-binding fragment with a modifying agent. Forexample, the organic moieties can be bonded to the antibody in anon-site specific manner by employing an amine-reactive modifying agent,for example, an NHS ester of PEG. Modified human antibodies orantigen-binding fragments can also be prepared by reducing disulfidebonds (e.g., intra-chain disulfide bonds) of an antibody orantigen-binding fragment. The reduced antibody or antigen-bindingfragment can then be reacted with a thiol-reactive modifying agent toproduce the modified antibody of the invention. Modified humanantibodies and antigen-binding fragments comprising an organic moietythat is bonded to specific sites of an antibody of the present inventioncan be prepared using suitable methods, such as reverse proteolysis(Fisch et al., Bioconjugate Chem., 3:147-153 (1992); Werlen et al.,Bioconjugate Chem., 5:411-417 (1994); Kumaran et al., Protein Sci.6(10):2233-2241 (1997); Itoh et al., Bioorg. Chem., 24(1): 59-68 (1996);Capellas et al., Biotechnol. Bioeng., 56(4):456-463 (1997)), and themethods described in Hermanson, G. T., Bioconjugate Techniques, AcademicPress: San Diego, Calif. (1996).

Anti-Idiotype Antibodies to Anti-IL-23p19 Antibody Compositions

In addition to monoclonal anti-IL-23p19 antibodies, the presentinvention is also directed to an anti-idiotypic (anti-Id) antibodyspecific for such antibodies of the invention. An anti-Id antibody is anantibody which recognizes unique determinants generally associated withthe antigen-binding region of another antibody. The anti-Id can beprepared by immunizing an animal of the same species and genetic type(e.g., mouse strain) as the source of the Id antibody with the antibodyor a CDR containing region thereof. The immunized animal will recognizeand respond to the idiotypic determinants of the immunizing antibody andproduce an anti-Id antibody. The anti-Id antibody may also be used as an“immunogen” to induce an immune response in yet another animal,producing a so-called anti-anti-Id antibody.

The present invention also provides at least one anti-IL-23p19 antibodycomposition comprising at least one, at least two, at least three, atleast four, at least five, at least six or more anti-IL-23p19 antibodiesthereof, as described herein and/or as known in the art that areprovided in a non-naturally occurring composition, mixture or form. Suchcompositions comprise non-naturally occurring compositions comprising atleast one or two full length, C- and/or N-terminally deleted variants,domains, fragments, or specified variants, of the anti-IL-23p19 antibodyamino acid sequence selected from the group consisting of 70-100% of thecontiguous amino acids of SEQ ID NOS:1-132, 146, and 147, or specifiedfragments, domains or variants thereof. Preferred anti-IL-23p19 antibodycompositions include at least one or two full length, fragments, domainsor variants of at least one CDR or LBP containing portions of theanti-IL-23p19 antibody sequence described herein, for example, 70-100%of SEQ ID NOS:1-132, 146, and 147, or specified fragments, domains orvariants thereof. Further preferred compositions comprise, for example,40-99% of at least one of 70-100% of SEQ ID NOS:1-132, 146, and 147, orspecified fragments, domains or variants thereof. Such compositionpercentages are by weight, volume, concentration, molarity, or molalityas liquid or dry solutions, mixtures, suspension, emulsions, particles,powder, or colloids, as known in the art or as described herein.

Antibody Compositions Comprising Further Therapeutically ActiveIngredients

The antibody compositions of the invention can optionally furthercomprise an effective amount of at least one compound or proteinselected from at least one of an anti-infective drug, a cardiovascular(CV) system drug, a central nervous system (CNS) drug, an autonomicnervous system (ANS) drug, a respiratory tract drug, a gastrointestinal(GI) tract drug, a hormonal drug, a drug for fluid or electrolytebalance, a hematologic drug, an antineoplastic, an immunomodulationdrug, an ophthalmic, otic or nasal drug, a topical drug, a nutritionaldrug or the like. Such drugs are well known in the art, includingformulations, indications, dosing and administration for each presentedherein (see, e.g., Nursing 2001 Handbook of Drugs, 21^(st) edition,Springhouse Corp., Springhouse, Pa., 2001; Health Professional's DrugGuide 2001, ed., Shannon, Wilson, Stang, Prentice-Hall, Inc, UpperSaddle River, N.J.; Pharmcotherapy Handbook, Wells et al., ed., Appleton& Lange, Stamford, Conn., each entirely incorporated herein byreference).

The anti-infective drug can be at least one selected from amebicides orat least one of antiprotozoals, anthelmintics, antifungals,antimalarials, antituberculotics or at least one antileprotics,aminoglycosides, penicillins, cephalosporins, tetracyclines,sulfonamides, fluoroquinolones, antivirals, macrolide anti-infectives,and miscellaneous anti-infectives. The CV drug can be at least oneselected from inotropics, antiarrhythmics, antianginals,antihypertensives, antilipemics, and miscellaneous cardiovascular drugs.The CNS drug can be at least one selected from normarcotic analgesics orat least one selected from antipyretics, nonsteroidal anti-inflammatorydrugs, narcotic or at least one opiod analgesics, sedative-hypnotics,anticonvulsants, antidepressants, antianxiety drugs, antipsychotics,central nervous system stimulants, antiparkinsonians, and miscellaneouscentral nervous system drugs. The ANS drug can be at least one selectedfrom cholinergics (parasympathomimetics), anticholinergics, adrenergics(sympathomimetics), adrenergic blockers (sympatholytics), skeletalmuscle relaxants, and neuromuscular blockers. The respiratory tract drugcan be at least one selected from antihistamines, bronchodilators,expectorants or at least one antitussive, and miscellaneous respiratorydrugs. The GI tract drug can be at least one selected from antacids orat least one adsorbent or at least one antiflatulent, digestive enzymeor at least one gallstone solubilizer, antidiarrheals, laxatives,antiemetics, and antiulcer drugs. The hormonal drug can be at least oneselected from corticosteroids, androgens or at least one anabolicsteroid, estrogen or at least one progestin, gonadotropin, antidiabeticdrug or at least one glucagon, thyroid hormone, thyroid hormoneantagonist, pituitary hormone, and parathyroid-like drug. The drug forfluid and electrolyte balance can be at least one selected fromdiuretics, electrolytes or at least one replacement solution, acidifieror at least one alkalinizer. The hematologic drug can be at least oneselected from hematinics, anticoagulants, blood derivatives, andthrombolytic enzymes. The antineoplastics can be at least one selectedfrom alkylating drugs, antimetabolites, antibiotic antineoplastics,antineoplastics that alter hormone balance, and miscellaneousantineoplastics. The immunomodulation drug can be at least one selectedfrom immunosuppressants, vaccines or at least one toxoid, antitoxin orat least one antivenin, immune serum, and biological response modifier.The ophthalmic, otic, and nasal drugs can be at least one selected fromophthalmic anti-infectives, ophthalmic anti-inflammatories, miotics,mydriatics, ophthalmic vasoconstrictors, miscellaneous ophthalmics,otics, and nasal drugs. The topical drug can be at least one selectedfrom local anti-infectives, scabicides or at least one pediculicide ortopical corticosteroid. The nutritional drug can be at least oneselected from vitamins, minerals, or calorics. See, e.g., contents ofNursing 2001 Drug Handbook, supra.

The at least one amebicide or antiprotozoal can be at least one selectedfrom atovaquone, chloroquine hydrochloride, chloroquine phosphate,metronidazole, metronidazole hydrochloride, and pentamidine isethionate.The at least one anthelmintic can be at least one selected frommebendazole, pyrantel pamoate, and thiabendazole. The at least oneantifungal can be at least one selected from amphotericin B,amphotericin B cholesteryl sulfate complex, amphotericin B lipidcomplex, amphotericin B liposomal, fluconazole, flucytosine,griseofulvin microsize, griseofulvin ultramicrosize, itraconazole,ketoconazole, nystatin, and terbinafine hydrochloride. The at least oneantimalarial can be at least one selected from chloroquinehydrochloride, chloroquine phosphate, doxycycline, hydroxychloroquinesulfate, mefloquine hydrochloride, primaquine phosphate, pyrimethamine,and pyrimethamine with sulfadoxine. The at least one antituberculotic orantileprotic can be at least one selected from clofazimine, cycloserine,dapsone, ethambutol hydrochloride, isoniazid, pyrazinamide, rifabutin,rifampin, rifapentine, and streptomycin sulfate. The at least oneaminoglycoside can be at least one selected from amikacin sulfate,gentamicin sulfate, neomycin sulfate, streptomycin sulfate, andtobramycin sulfate. The at least one penicillin can be at least oneselected from amoxicillin/clavulanate potassium, amoxicillin trihydrate,ampicillin, ampicillin sodium, ampicillin trihydrate, ampicillinsodium/sulbactam sodium, cloxacillin sodium, dicloxacillin sodium,mezlocillin sodium, nafcillin sodium, oxacillin sodium, penicillin Gbenzathine, penicillin G potassium, penicillin G procaine, penicillin Gsodium, penicillin V potassium, piperacillin sodium, piperacillinsodium/tazobactam sodium, ticarcillin disodium, and ticarcillindisodium/clavulanate potassium. The at least one cephalosporin can be atleast one selected from cefaclor, cefadroxil, cefazolin sodium,cefdinir, cefepime hydrochloride, cefixime, cefinetazole sodium,cefonicid sodium, cefoperazone sodium, cefotaxime sodium, cefotetandisodium, cefoxitin sodium, cefpodoxime proxetil, cefprozil,ceftazidime, ceftibuten, ceftizoxime sodium, ceftriaxone sodium,cefuroxime axetil, cefuroxime sodium, cephalexin hydrochloride,cephalexin monohydrate, cephradine, and loracarbef. The at least onetetracycline can be at least one selected from demeclocyclinehydrochloride, doxycycline calcium, doxycycline hyclate, doxycyclinehydrochloride, doxycycline monohydrate, minocycline hydrochloride, andtetracycline hydrochloride. The at least one sulfonamide can be at leastone selected from co-trimoxazole, sulfadiazine, sulfamethoxazole,sulfisoxazole, and sulfisoxazole acetyl. The at least onefluoroquinolone can be at least one selected from alatrofloxacinmesylate, ciprofloxacin, enoxacin, levofloxacin, lomefloxacinhydrochloride, nalidixic acid, norfloxacin, ofloxacin, sparfloxacin, andtrovafloxacin mesylate. The at least one fluoroquinolone can be at leastone selected from alatrofloxacin mesylate, ciprofloxacin, enoxacin,levofloxacin, lomefloxacin hydrochloride, nalidixic acid, norfloxacin,ofloxacin, sparfloxacin, and trovafloxacin mesylate. The at least oneantiviral can be at least one selected from abacavir sulfate, acyclovirsodium, amantadine hydrochloride, amprenavir, cidofovir, delavirdinemesylate, didanosine, efavirenz, famciclovir, fomivirsen sodium,foscarnet sodium, ganciclovir, indinavir sulfate, lamivudine,lamivudine/zidovudine, nelfinavir mesylate, nevirapine, oseltamivirphosphate, ribavirin, rimantadine hydrochloride, ritonavir, saquinavir,saquinavir mesylate, stavudine, valacyclovir hydrochloride, zalcitabine,zanamivir, and zidovudine. The at least one macroline anti-infective canbe at least one selected from azithromycin, clarithromycin,dirithromycin, erythromycin base, erythromycin estolate, erythromycinethylsuccinate, erythromycin lactobionate, and erythromycin stearate.The at least one miscellaneous anti-infective can be at least oneselected from aztreonam, bacitracin, chloramphenicol sodium sucinate,clindamycin hydrochloride, clindamycin palmitate hydrochloride,clindamycin phosphate, imipenem and cilastatin sodium, meropenem,nitrofurantoin macrocrystals, nitrofurantoin microcrystals,quinupristin/dalfopristin, spectinomycin hydrochloride, trimethoprim,and vancomycin hydrochloride. (See, e.g., pp. 24-214 of Nursing 2001Drug Handbook.)

The at least one inotropic can be at least one selected from aminonelactate, digoxin, and milrinone lactate. The at least one antiarrhythmiccan be at least one selected from adenosine, amiodarone hydrochloride,atropine sulfate, bretylium tosylate, diltiazem hydrochloride,disopyramide, disopyramide phosphate, esmolol hydrochloride, flecamideacetate, ibutilide fumarate, lidocaine hydrochloride, mexiletinehydrochloride, moricizine hydrochloride, phenyloin, phenyloin sodium,procainamide hydrochloride, propafenone hydrochloride, propranololhydrochloride, quinidine bisulfate, quinidine gluconate, quinidinepolygalacturonate, quinidine sulfate, sotalol, tocamide hydrochloride,and verapamil hydrochloride. The at least one antianginal can be atleast one selected from amlodipidine besylate, amyl nitrite, bepridilhydrochloride, diltiazem hydrochloride, isosorbide dinitrate, isosorbidemononitrate, nadolol, nicardipine hydrochloride, nifedipine,nitroglycerin, propranolol hydrochloride, verapamil, and verapamilhydrochloride. The at least one antihypertensive can be at least oneselected from acebutolol hydrochloride, amlodipine besylate, atenolol,benazepril hydrochloride, betaxolol hydrochloride, bisoprolol fumarate,candesartan cilexetil, captopril, carteolol hydrochloride, carvedilol,clonidine, clonidine hydrochloride, diazoxide, diltiazem hydrochloride,doxazosin mesylate, enalaprilat, enalapril maleate, eprosartan mesylate,felodipine, fenoldopam mesylate, fosinopril sodium, guanabenz acetate,guanadrel sulfate, guanfacine hydrochloride, hydralazine hydrochloride,irbesartan, isradipine, labetalol hydrchloride, lisinopril, losartanpotassium, methyldopa, methyldopate hydrochloride, metoprolol succinate,metoprolol tartrate, minoxidil, moexipril hydrochloride, nadolol,nicardipine hydrochloride, nifedipine, nisoldipine, nitroprussidesodium, penbutolol sulfate, perindopril erbumine, phentolamine mesylate,pindolol, prazosin hydrochloride, propranolol hydrochloride, quinaprilhydrochloride, ramipril, telmisartan, terazosin hydrochloride, timololmaleate, trandolapril, valsartan, and verapamil hydrochloride. The atleast one antilipemic can be at least one selected from atorvastatincalcium, cerivastatin sodium, cholestyramine, colestipol hydrochloride,fenofibrate (micronized), fluvastatin sodium, gemfibrozil, lovastatin,niacin, pravastatin sodium, and simvastatin. The at least onemiscellaneous CV drug can be at least one selected from abciximab,alprostadil, arbutamine hydrochloride, cilostazol, clopidogrelbisulfate, dipyridamole, eptifibatide, midodrine hydrochloride,pentoxifylline, ticlopidine hydrochloride, and tirofiban hydrochloride.(See, e.g., pp. 215-336 of Nursing 2001 Drug Handbook.)

The at least one normarcotic analgesic or antipyretic can be at leastone selected from acetaminophen, aspirin, choline magnesiumtrisalicylate, diflunisal, and magnesium salicylate. The at least onenonsteroidal anti-inflammatory drug can be at least one selected fromcelecoxib, diclofenac potassium, diclofenac sodium, etodolac, fenoprofencalcium, flurbiprofen, ibuprofen, indomethacin, indomethacin sodiumtrihydrate, ketoprofen, ketorolac tromethamine, nabumetone, naproxen,naproxen sodium, oxaprozin, piroxicam, rofecoxib, and sulindac. The atleast one narcotic or opiod analgesic can be at least one selected fromalfentanil hydrochloride, buprenorphine hydrochloride, butorphanoltartrate, codeine phosphate, codeine sulfate, fentanyl citrate, fentanyltransdermal system, fentanyl transmucosal, hydromorphone hydrochloride,meperidine hydrochloride, methadone hydrochloride, morphinehydrochloride, morphine sulfate, morphine tartrate, nalbuphinehydrochloride, oxycodone hydrochloride, oxycodone pectinate, oxymorphonehydrochloride, pentazocine hydrochloride, pentazocine hydrochloride andnaloxone hydrochloride, pentazocine lactate, propoxyphene hydrochloride,propoxyphene napsylate, remifentanil hydrochloride, sufentanil citrate,and tramadol hydrochloride. The at least one sedative-hypnotic can be atleast one selected from chloral hydrate, estazolam, flurazepamhydrochloride, pentobarbital, pentobarbital sodium, phenobarbitalsodium, secobarbital sodium, temazepam, triazolam, zaleplon, andzolpidem tartrate. The at least one anticonvulsant can be at least oneselected from acetazolamide sodium, carbamazepine, clonazepam,clorazepate dipotassium, diazepam, divalproex sodium, ethosuximde,fosphenyloin sodium, gabapentin, lamotrigine, magnesium sulfate,phenobarbital, phenobarbital sodium, phenyloin, phenyloin sodium,phenyloin sodium (extended), primidone, tiagabine hydrochloride,topiramate, valproate sodium, and valproic acid. The at least oneantidepressant can be at least one selected from amitriptylinehydrochloride, amitriptyline pamoate, amoxapine, bupropionhydrochloride, citalopram hydrobromide, clomipramine hydrochloride,desipramine hydrochloride, doxepin hydrochloride, fluoxetinehydrochloride, imipramine hydrochloride, imipramine pamoate,mirtazapine, nefazodone hydrochloride, nortriptyline hydrochloride,paroxetine hydrochloride, phenelzine sulfate, sertraline hydrochloride,tranylcypromine sulfate, trimipramine maleate, and venlafaxinehydrochloride. The at least one antianxiety drug can be at least oneselected from alprazolam, buspirone hydrochloride, chlordiazepoxide,chlordiazepoxide hydrochloride, clorazepate dipotassium, diazepam,doxepin hydrochloride, hydroxyzine embonate, hydroxyzine hydrochloride,hydroxyzine pamoate, lorazepam, mephrobamate, midazolam hydrochloride,and oxazepam. The at least one antipsychotic drug can be at least oneselected from chlorpromazine hydrochloride, clozapine, fluphenazinedecanoate, fluephenazine enanthate, fluphenazine hydrochloride,haloperidol, haloperidol decanoate, haloperidol lactate, loxapinehydrochloride, loxapine succinate, mesoridazine besylate, molindonehydrochloride, olanzapine, perphenazine, pimozide, prochlorperazine,quetiapine fumarate, risperidone, thioridazine hydrochloride,thiothixene, thiothixene hydrochloride, and trifluoperazinehydrochloride. The at least one central nervous system stimulant can beat least one selected from amphetamine sulfate, caffeine,dextroamphetamine sulfate, doxapram hydrochloride, methamphetaminehydrochloride, methylphenidate hydrochloride, modafinil, pemoline, andphentermine hydrochloride. The at least one antiparkinsonian can be atleast one selected from amantadine hydrochloride, benztropine mesylate,biperiden hydrochloride, biperiden lactate, bromocriptine mesylate,carbidopa-levodopa, entacapone, levodopa, pergolide mesylate,pramipexole dihydrochloride, ropinirole hydrochloride, selegilinehydrochloride, tolcapone, and trihexyphenidyl hydrochloride. The atleast one miscellaneous central nervous system drug can be at least oneselected from bupropion hydrochloride, donepezil hydrochloride,droperidol, fluvoxamine maleate, lithium carbonate, lithium citrate,naratriptan hydrochloride, nicotine polacrilex, nicotine transdermalsystem, propofol, rizatriptan benzoate, sibutramine hydrochloridemonohydrate, sumatriptan succinate, tacrine hydrochloride, andzolmitriptan. (See, e.g., pp. 337-530 of Nursing 2001 Drug Handbook.)

The at least one cholinergic (e.g., parasymathomimetic) can be at leastone selected from bethanechol chloride, edrophonium chloride,neostigmine bromide, neostigmine methylsulfate, physostigminesalicylate, and pyridostigmine bromide. The at least one anticholinergiccan be at least one selected from atropine sulfate, dicyclominehydrochloride, glycopyrrolate, hyoscyamine, hyoscyamine sulfate,propantheline bromide, scopolamine, scopolamine butylbromide, andscopolamine hydrobromide. The at least one adrenergic (sympathomimetics)can be at least one selected from dobutamine hydrochloride, dopaminehydrochloride, metaraminol bitartrate, norepinephrine bitartrate,phenylephrine hydrochloride, pseudoephedrine hydrochloride, andpseudoephedrine sulfate. The at least one adrenergic blocker(sympatholytic) can be at least one selected from dihydroergotaminemesylate, ergotamine tartrate, methysergide maleate, and propranololhydrochloride. The at least one skeletal muscle relaxant can be at leastone selected from baclofen, carisoprodol, chlorzoxazone, cyclobenzaprinehydrochloride, dantrolene sodium, methocarbamol, and tizanidinehydrochloride. The at least one neuromuscular blocker can be at leastone selected from atracurium besylate, cisatracurium besylate,doxacurium chloride, mivacurium chloride, pancuronium bromide,pipecuronium bromide, rapacuronium bromide, rocuronium bromide,succinylcholine chloride, tubocurarine chloride, and vecuronium bromide.(See, e.g., pp. 531-84 of Nursing 2001 Drug Handbook.)

The at least one antihistamine can be at least one selected frombrompheniramine maleate, cetirizine hydrochloride, chlorpheniraminemaleate, clemastine fumarate, cyproheptadine hydrochloride,diphenhydramine hydrochloride, fexofenadine hydrochloride, loratadine,promethazine hydrochloride, promethazine theoclate, and triprolidinehydrochloride. The at least one bronchodilator can be at least oneselected from albuterol, albuterol sulfate, aminophylline, atropinesulfate, ephedrine sulfate, epinephrine, epinephrine bitartrate,epinephrine hydrochloride, ipratropium bromide, isoproterenol,isoproterenol hydrochloride, isoproterenol sulfate, levalbuterolhydrochloride, metaproterenol sulfate, oxtriphylline, pirbuterolacetate, salmeterol xinafoate, terbutaline sulfate, and theophylline.The at least one expectorant or antitussive can be at least one selectedfrom benzonatate, codeine phosphate, codeine sulfate, dextramethorphanhydrobromide, diphenhydramine hydrochloride, guaifenesin, andhydromorphone hydrochloride. The at least one miscellaneous respiratorydrug can be at least one selected from acetylcysteine, beclomethasonedipropionate, beractant, budesonide, calfactant, cromolyn sodium,dornase alfa, epoprostenol sodium, flunisolide, fluticasone propionate,montelukast sodium, nedocromil sodium, palivizumab, triamcinoloneacetonide, zafirlukast, and zileuton. (See, e.g., pp. 585-642 of Nursing2001 Drug Handbook.)

The at least one antacid, adsorbent, or antiflatulent can be at leastone selected from aluminum carbonate, aluminum hydroxide, calciumcarbonate, magaldrate, magnesium hydroxide, magnesium oxide,simethicone, and sodium bicarbonate. The at least one digestive enzymeor gallstone solubilizer can be at least one selected from pancreatin,pancrelipase, and ursodiol. The at least one antidiarrheal can be atleast one selected from attapulgite, bismuth subsalicylate, calciumpolycarbophil, diphenoxylate hydrochloride and atropine sulfate,loperamide, octreotide acetate, opium tincture, and opium tincure(camphorated). The at least one laxative can be at least one selectedfrom bisocodyl, calcium polycarbophil, cascara sagrada, cascara sagradaaromatic fluidextract, cascara sagrada fluidextract, castor oil,docusate calcium, docusate sodium, glycerin, lactulose, magnesiumcitrate, magnesium hydroxide, magnesium sulfate, methylcellulose,mineral oil, polyethylene glycol or electrolyte solution, psyllium,senna, and sodium phosphates. The at least one antiemetic can be atleast one selected from chlorpromazine hydrochloride, dimenhydrinate,dolasetron mesylate, dronabinol, granisetron hydrochloride, meclizinehydrochloride, metocloproamide hydrochloride, ondansetron hydrochloride,perphenazine, prochlorperazine, prochlorperazine edisylate,prochlorperazine maleate, promethazine hydrochloride, scopolamine,thiethylperazine maleate, and trimethobenzamide hydrochloride. The atleast one antiulcer drug can be at least one selected from cimetidine,cimetidine hydrochloride, famotidine, lansoprazole, misoprostol,nizatidine, omeprazole, rabeprozole sodium, rantidine bismuth citrate,ranitidine hydrochloride, and sucralfate. (See, e.g., pp. 643-95 ofNursing 2001 Drug Handbook.)

The at least one corticosteroid can be at least one selected frombetamethasone, betamethasone acetate or betamethasone sodium phosphate,betamethasone sodium phosphate, cortisone acetate, dexamethasone,dexamethasone acetate, dexamethasone sodium phosphate, fludrocortisoneacetate, hydrocortisone, hydrocortisone acetate, hydrocortisonecypionate, hydrocortisone sodium phosphate, hydrocortisone sodiumsuccinate, methylprednisolone, methylprednisolone acetate,methylprednisolone sodium succinate, prednisolone, prednisolone acetate,prednisolone sodium phosphate, prednisolone tebutate, prednisone,triamcinolone, triamcinolone acetonide, and triamcinolone diacetate. Theat least one androgen or anabolic steroid can be at least one selectedfrom danazol, fluoxymesterone, methyltestosterone, nandrolone decanoate,nandrolone phenpropionate, testosterone, testosterone cypionate,testosterone enanthate, testosterone propionate, and testosteronetransdermal system. The at least one estrogen or progestin can be atleast one selected from esterified estrogens, estradiol, estradiolcypionate, estradiol/norethindrone acetate transdermal system, estradiolvalerate, estrogens (conjugated), estropipate, ethinyl estradiol,ethinyl estradiol and desogestrel, ethinyl estradiol and ethynodioldiacetate, ethinyl estradiol and desogestrel, ethinyl estradiol andethynodiol diacetate, ethinyl estradiol and levonorgestrel, ethinylestradiol and norethindrone, ethinyl estradiol and norethindroneacetate, ethinyl estradiol and norgestimate, ethinyl estradiol andnorgestrel, ethinyl estradiol and norethindrone and acetate and ferrousfumarate, levonorgestrel, medroxyprogesterone acetate, mestranol andnorethindron, norethindrone, norethindrone acetate, norgestrel, andprogesterone. The at least one gonadroptropin can be at least oneselected from ganirelix acetate, gonadoreline acetate, histrelinacetate, and menotropins. The at least one antidiabetic or glucaon canbe at least one selected from acarbose, chlorpropamide, glimepiride,glipizide, glucagon, glyburide, insulins, metformin hydrochloride,miglitol, pioglitazone hydrochloride, repaglinide, rosiglitazonemaleate, and troglitazone. The at least one thyroid hormone can be atleast one selected from levothyroxine sodium, liothyronine sodium,liotrix, and thyroid. The at least one thyroid hormone antagonist can beat least one selected from methimazole, potassium iodide, potassiumiodide (saturated solution), propylthiouracil, radioactive iodine(sodium iodide ¹³¹I), and strong iodine solution. The at least onepituitary hormone can be at least one selected from corticotropin,cosyntropin, desmophressin acetate, leuprolide acetate, repositorycorticotropin, somatrem, somatropin, and vasopressin. The at least oneparathyroid-like drug can be at least one selected from calcifediol,calcitonin (human), calcitonin (salmon), calcitriol, dihydrotachysterol,and etidronate disodium. (See, e.g., pp. 696-796 of Nursing 2001 DrugHandbook.)

The at least one diuretic can be at least one selected fromacetazolamide, acetazolamide sodium, amiloride hydrochloride,bumetanide, chlorthalidone, ethacrynate sodium, ethacrynic acid,furosemide, hydrochlorothiazide, indapamide, mannitol, metolazone,spironolactone, torsemide, triamterene, and urea. The at least oneelectrolyte or replacement solution can be at least one selected fromcalcium acetate, calcium carbonate, calcium chloride, calcium citrate,calcium glubionate, calcium gluceptate, calcium gluconate, calciumlactate, calcium phosphate (dibasic), calcium phosphate (tribasic),dextran (high-molecular-weight), dextran (low-molecular-weight),hetastarch, magnesium chloride, magnesium sulfate, potassium acetate,potassium bicarbonate, potassium chloride, potassium gluconate, Ringer'sinjection, Ringer's injection (lactated), and sodium chloride. The atleast one acidifier or alkalinizer can be at least one selected fromsodium bicarbonate, sodium lactate, and tromethamine. (See, e.g., pp.797-833 of Nursing 2001 Drug Handbook.)

The at least one hematinic can be at least one selected from ferrousfumarate, ferrous gluconate, ferrous sulfate, ferrous sulfate (dried),iron dextran, iron sorbitol, polysaccharide-iron complex, and sodiumferric gluconate complex. The at least one anticoagulant can be at leastone selected from ardeparin sodium, dalteparin sodium, danaparoidsodium, enoxaparin sodium, heparin calcium, heparin sodium, and warfarinsodium. The at least one blood derivative can be at least one selectedfrom albumin 5%, albumin 25%, antihemophilic factor, anti-inhibitorcoagulant complex, antithrombin III (human), factor IX (human), factorIX complex, and plasma protein fractions. The at least one thrombolyticenzyme can be at least one selected from alteplase, anistreplase,reteplase (recombinant), streptokinase, and urokinase. (See, e.g., pp.834-66 of Nursing 2001 Drug Handbook.)

The at least one alkylating drug can be at least one selected frombusulfan, carboplatin, carmustine, chlorambucil, cisplatin,cyclophosphamide, ifosfamide, lomustine, mechlorethamine hydrochloride,melphalan, melphalan hydrochloride, streptozocin, temozolomide, andthiotepa. The at least one antimetabolite can be at least one selectedfrom capecitabine, cladribine, cytarabine, floxuridine, fludarabinephosphate, fluorouracil, hydroxyurea, mercaptopurine, methotrexate,methotrexate sodium, and thioguanine. The at least one antibioticantineoplastic can be at least one selected from bleomycin sulfate,dactinomycin, daunorubicin citrate liposomal, daunorubicinhydrochloride, doxorubicin hydrochloride, doxorubicin hydrochlorideliposomal, epirubicin hydrochloride, idarubicin hydrochloride,mitomycin, pentostatin, plicamycin, and valrubicin. The at least oneantineoplastic that alters hormone balance can be at least one selectedfrom anastrozole, bicalutamide, estramustine phosphate sodium,exemestane, flutamide, goserelin acetate, letrozole, leuprolide acetate,megestrol acetate, nilutamide, tamoxifen citrate, testolactone, andtoremifene citrate. The at least one miscellaneous antineoplastic can beat least one selected from asparaginase, bacillus Calmette-Guerin (BCG)(live intravesical), dacarbazine, docetaxel, etoposide, etoposidephosphate, gemcitabine hydrochloride, irinotecan hydrochloride,mitotane, mitoxantrone hydrochloride, paclitaxel, pegaspargase, porfimersodium, procarbazine hydrochloride, rituximab, teniposide, topotecanhydrochloride, trastuzumab, tretinoin, vinblastine sulfate, vincristinesulfate, and vinorelbine tartrate. (See, e.g., pp. 867-963 of Nursing2001 Drug Handbook.)

The at least one immunosuppressant can be at least one selected fromazathioprine, basiliximab, cyclosporine, daclizumab, lymphocyte immuneglobulin, muromonab-CD3, mycophenolate mofetil, mycophenolate mofetilhydrochloride, sirolimus, and tacrolimus. The at least one vaccine ortoxoid can be at least one selected from BCG vaccine, cholera vaccine,diphtheria and tetanus toxoids (adsorbed), diphtheria and tetanustoxoids and acellular pertussis vaccine adsorbed, diphtheria and tetanustoxoids and whole-cell pertussis vaccine, Haemophilus b conjugatevaccines, hepatitis A vaccine (inactivated), hepatisis B vaccine(recombinant), influenza virus vaccine 1999-2000 trivalent types A & B(purified surface antigen), influenza virus vaccine 1999-2000 trivalenttypes A & B (subvirion or purified subvirion), influenza virus vaccine1999-2000 trivalent types A & B (whole virion), Japanese encephalitisvirus vaccine (inactivated), Lyme disease vaccine (recombinant OspA),measles and mumps and rubella virus vaccine (live), measles and mumpsand rubella virus vaccine (live attenuated), measles virus vaccine (liveattenuated), meningococcal polysaccharide vaccine, mumps virus vaccine(live), plague vaccine, pneumococcal vaccine (polyvalent), poliovirusvaccine (inactivated), poliovirus vaccine (live, oral, trivalent),rabies vaccine (adsorbed), rabies vaccine (human diploid cell), rubellaand mumps virus vaccine (live), rubella virus vaccine (live,attenuated), tetanus toxoid (adsorbed), tetanus toxoid (fluid), typhoidvaccine (oral), typhoid vaccine (parenteral), typhoid Vi polysaccharidevaccine, varicella virus vaccine, and yellow fever vaccine. The at leastone antitoxin or antivenin can be at least one selected from black widowspider antivenin, Crotalidae antivenom (polyvalent), diphtheriaantitoxin (equine), amd Micrurus fulvius antivenin. The at least oneimmune serum can be at least one selected from cytomegalovirus immuneglobulin (intraveneous), hepatitis B immune globulin (human), immuneglobulin intramuscular, immune globulin intravenous, rabies immuneglobulin (human), respiratory syncytial virus immune globulinintravenous (human), Rh₀(D) immune globulin (human), Rh₀(D) immuneglobulin intravenous (human), tetanus immune globulin (human), andvaricella-zoster immune globulin. The at least one biological responsemodifier can be at least one selected from aldesleukin, epoetin alfa,filgrastim, glatiramer acetate for injection, interferon alfacon-1,interferon alfa-2a (recombinant), interferon alfa-2b (recombinant),interferon beta-1a, interferon beta-1b (recombinant), interferongamma-1b, levamisole hydrochloride, oprelvekin, and sargramostim. (See,e.g., pp. 964-1040 of Nursing 2001 Drug Handbook.)

The at least one ophthalmic anti-infective can be selected formbacitracin, chloramphenicol, ciprofloxacin hydrochloride, erythromycin,gentamicin sulfate, ofloxacin 0.3%, polymyxin B sulfate, sulfacetamidesodium 10%, sulfacetamide sodium 15%, sulfacetamide sodium 30%,tobramycin, and vidarabine. The at least one ophthalmicanti-inflammatory can be at least one selected from dexamethasone,dexamethasone sodium phosphate, diclofenac sodium 0.1%, fluorometholone,flurbiprofen sodium, ketorolac tromethamine, prednisolone acetate(suspension) and prednisolone sodium phosphate (solution). The at leastone miotic can be at least one selected from acetylocholine chloride,carbachol (intraocular), carbachol (topical), echothiophate iodide,pilocarpine, pilocarpine hydrochloride, and pilocarpine nitrate. The atleast one mydriatic can be at least one selected from atropine sulfate,cyclopentolate hydrochloride, epinephrine hydrochloride, epinephrylborate, homatropine hydrobromide, phenylephrine hydrochloride,scopolamine hydrobromide, and tropicamide. The at least one ophthalmicvasoconstrictor can be at least one selected from naphazolinehydrochloride, oxymetazoline hydrochloride, and tetrahydrozolinehydrochloride. The at least one miscellaneous ophthalmic can be at leastone selected from apraclonidine hydrochloride, betaxolol hydrochloride,brimonidine tartrate, carteolol hydrochloride, dipivefrin hydrochloride,dorzolamide hydrochloride, emedastine difumarate, fluorescein sodium,ketotifen fumarate, latanoprost, levobunolol hydrochloride, metipranololhydrochloride, sodium chloride (hypertonic), and timolol maleate. The atleast one otic can be at least one selected from boric acid, carbamideperoxide, chloramphenicol, and triethanolamine polypeptideoleate-condensate. The at least one nasal drug can be at least oneselected from beclomethasone dipropionate, budesonide, ephedrinesulfate, epinephrine hydrochloride, flunisolide, fluticasone propionate,naphazoline hydrochloride, oxymetazoline hydrochloride, phenylephrinehydrochloride, tetrahydrozoline hydrochloride, triamcinolone acetonide,and xylometazoline hydrochloride. (See, e.g., pp. 1041-97 of Nursing2001 Drug Handbook.)

The at least one local anti-infective can be at least one selected fromacyclovir, amphotericin B, azelaic acid cream, bacitracin, butoconazolenitrate, clindamycin phosphate, clotrimazole, econazole nitrate,erythromycin, gentamicin sulfate, ketoconazole, mafenide acetate,metronidazole (topical), miconazole nitrate, mupirocin, naftifinehydrochloride, neomycin sulfate, nitrofurazone, nystatin, silversulfadiazine, terbinafine hydrochloride, terconazole, tetracyclinehydrochloride, tioconazole, and tolnaftate. The at least one scabicideor pediculicide can be at least one selected from crotamiton, lindane,permethrin, and pyrethrins. The at least one topical corticosteroid canbe at least one selected from betamethasone dipropionate, betamethasonevalerate, clobetasol propionate, desonide, desoximetasone,dexamethasone, dexamethasone sodium phosphate, diflorasone diacetate,fluocinolone acetonide, fluocinonide, flurandrenolide, fluticasonepropionate, halcionide, hydrocortisone, hydrocortisone acetate,hydrocortisone butyrate, hydrocorisone valerate, mometasone furoate, andtriamcinolone acetonide. (See, e.g., pp. 1098-1136 of Nursing 2001 DrugHandbook.)

The at least one vitamin or mineral can be at least one selected fromvitamin A, vitamin B complex, cyanocobalamin, folic acid,hydroxocobalamin, leucovorin calcium, niacin, niacinamide, pyridoxinehydrochloride, riboflavin, thiamine hydrochloride, vitamin C, vitamin D,cholecalciferol, ergocalciferol, vitamin D analogue, doxercalciferol,paricalcitol, vitamin E, vitamin K analogue, phytonadione, sodiumfluoride, sodium fluoride (topical), trace elements, chromium, copper,iodine, manganese, selenium, and zinc. The at least one caloric can beat least one selected from amino acid infusions (crystalline), aminoacid infusions in dextrose, amino acid infusions with electrolytes,amino acid infusions with electrolytes in dextrose, amino acid infusionsfor hepatic failure, amino acid infusions for high metabolic stress,amino acid infusions for renal failure, dextrose, fat emulsions, andmedium-chain triglycerides. (See, e.g., pp. 1137-63 of Nursing 2001 DrugHandbook.)

Anti-IL-23p19 antibody compositions of the present invention can furthercomprise at least one of any suitable and effective amount of acomposition or pharmaceutical composition comprising at least oneanti-IL-23p19 antibody contacted or administered to a cell, tissue,organ, animal or patient in need of such modulation, treatment ortherapy, optionally further comprising at least one selected from atleast one TNF antagonist (e.g., but not limited to a TNF chemical orprotein antagonist, TNF monoclonal or polyclonal antibody or fragment, asoluble TNF receptor (e.g., p55, p70 or p85) or fragment, fusionpolypeptides thereof, or a small molecule TNF antagonist, e.g., TNFbinding protein I or II (TBP-1 or TBP-II), nerelimonmab, infliximab,etanercept, CDP-571, CDP-870, afelimomab, lenercept, and the like), anantirheumatic (e.g., methotrexate, auranofin, aurothioglucose,azathioprine, etanercept, gold sodium thiomalate, hydroxychloroquinesulfate, leflunomide, sulfasalzine), a muscle relaxant, a narcotic, anon-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic,a sedative, a local anethetic, a neuromuscular blocker, an antimicrobial(e.g., aminoglycoside, an antifungal, an antiparasitic, an antiviral, acarbapenem, cephalosporin, a fluororquinolone, a macrolide, apenicillin, a sulfonamide, a tetracycline, another antimicrobial), anantipsoriatic, a corticosteriod, an anabolic steroid, a diabetes relatedagent, a mineral, a nutritional, a thyroid agent, a vitamin, a calciumrelated hormone, an antidiarrheal, an antitussive, an antiemetic, anantiulcer, a laxative, an anticoagulant, an erythropoietin (e.g.,epoetin alpha), a filgrastim (e.g., G-CSF, Neupogen), a sargramostim(GM-CSF, Leukine), an immunization, an immunoglobulin, animmunosuppressive (e.g., basiliximab, cyclosporine, daclizumab), agrowth hormone, a hormone replacement drug, an estrogen receptormodulator, a mydriatic, a cycloplegic, an alkylating agent, anantimetabolite, a mitotic inhibitor, a radiopharmaceutical, anantidepressant, antimanic agent, an antipsychotic, an anxiolytic, ahypnotic, a sympathomimetic, a stimulant, donepezil, tacrine, an asthmamedication, a beta agonist, an inhaled steroid, a leukotriene inhibitor,a methylxanthine, a cromolyn, an epinephrine or analog, dornase alpha(Pulmozyme), a cytokine or a cytokine antagonist. Non-limiting examplesof such cytokines include, but are not limted to, any of IL-1 to IL-28(e.g., IL-1, IL-2, etc.). Suitable dosages are well known in the art.See, e.g., Wells et al., eds., Pharmacotherapy Handbook, 2^(nd) Edition,Appleton and Lange, Stamford, Conn. (2000); PDR Pharmacopoeia, TarasconPocket Pharmacopoeia 2000, Deluxe Edition, Tarascon Publishing, LomaLinda, Calif. (2000), each of which references are entirely incorporatedherein by reference.

Such anti-cancer or anti-infectives can also include toxin moleculesthat are associated, bound, co-formulated or co-administered with atleast one antibody of the present invention. The toxin can optionallyact to selectively kill the pathologic cell or tissue. The pathologiccell can be a cancer or other cell. Such toxins can be, but are notlimited to, purified or recombinant toxin or toxin fragment comprisingat least one functional cytotoxic domain of toxin, e.g., selected fromat least one of ricin, diphtheria toxin, a venom toxin, or a bacterialtoxin. The term toxin also includes both endotoxins and exotoxinsproduced by any naturally occurring, mutant or recombinant bacteria orviruses which may cause any pathological condition in humans and othermammals, including toxin shock, which can result in death. Such toxinsmay include, but are not limited to, enterotoxigenic E. coli heat-labileenterotoxin (LT), heat-stable enterotoxin (ST), Shigella cytotoxin,Aeromonas enterotoxins, toxic shock syndrome toxin-1 (TSST-1),Staphylococcal enterotoxin A (SEA), B (SEB), or C (SEC), Streptococcalenterotoxins and the like. Such bacteria include, but are not limitedto, strains of a species of enterotoxigenic E. coli (ETEC),enterohemorrhagic E. coli (e.g., strains of serotype 0157:H7),Staphylococcus species (e.g., Staphylococcus aureus, Staphylococcuspyogenes), Shigella species (e.g., Shigella dysenteriae, Shigellaflexneri, Shigella boydii, and Shigella sonnei), Salmonella species(e.g., Salmonella typhi, Salmonella cholera-suis, Salmonellaenteritidis), Clostridium species (e.g., Clostridium perfringens,Clostridium dificile, Clostridium botulinum), Camphlobacter species(e.g., Camphlobacter jejuni, Camphlobacter fetus), Heliobacter species,(e.g., Heliobacter pylori), Aeromonas species (e.g., Aeromonas sobria,Aeromonas hydrophile, Aeromonas caviae), Pleisomonas shigelloides,Yersina enterocolitica, Vibrios species (e.g., Vibrios cholerae, Vibriosparahemolyticus), Klebsiella species, Pseudomonas aeruginosa, andStreptococci. See, e.g., Stein, ed., INTERNAL MEDICINE, 3rd ed., pp1-13, Little, Brown and Co., Boston, (1990); Evans et al., eds.,Bacterial Infections of Humans: Epidemiology and Control, 2d. Ed., pp239-254, Plenum Medical Book Co., New York (1991); Mandell et al,Principles and Practice of Infectious Diseases, 3d. Ed., ChurchillLivingstone, New York (1990); Berkow et al, eds., The Merck Manual, 16thedition, Merck and Co., Rahway, N.J., 1992; Wood et al, FEMSMicrobiology Immunology, 76:121-134 (1991); Marrack et al, Science,248:705-711 (1990), the contents of which references are incorporatedentirely herein by reference.

Anti-IL-23p19 antibody compounds, compositions or combinations of thepresent invention can further comprise at least one of any suitableauxiliary, such as, but not limited to, diluent, binder, stabilizer,buffers, salts, lipophilic solvents, preservative, adjuvant or the like.Pharmaceutically acceptable auxiliaries are preferred. Non-limitingexamples of, and methods of preparing such sterile solutions are wellknown in the art, such as, but limited to, Gennaro, Ed., Remington'sPharmaceutical Sciences, 18^(th) Edition, Mack Publishing Co. (Easton,Pa.) 1990. Pharmaceutically acceptable carriers can be routinelyselected that are suitable for the mode of administration, solubilityand/or stability of the anti-IL-23p19 antibody, fragment or variantcomposition as well known in the art or as described herein.

Pharmaceutical excipients and additives useful in the presentcomposition include, but are not limited to, proteins, peptides, aminoacids, lipids, and carbohydrates (e.g., sugars, includingmonosaccharides, di-, tri-, tetra-, and oligosaccharides; derivatizedsugars, such as alditols, aldonic acids, esterified sugars and the like;and polysaccharides or sugar polymers), which can be present singly orin combination, comprising alone or in combination 1-99.99% by weight orvolume. Exemplary protein excipients include serum albumin, such ashuman serum albumin (HSA), recombinant human albumin (rHA), gelatin,casein, and the like. Representative amino acid/antibody components,which can also function in a buffering capacity, include alanine,glycine, arginine, betaine, histidine, glutamic acid, aspartic acid,cysteine, lysine, leucine, isoleucine, valine, methionine,phenylalanine, aspartame, and the like. One preferred amino acid isglycine.

Carbohydrate excipients suitable for use in the invention include, forexample, monosaccharides, such as fructose, maltose, galactose, glucose,D-mannose, sorbose, and the like; disaccharides, such as lactose,sucrose, trehalose, cellobiose, and the like; polysaccharides, such asraffinose, melezitose, maltodextrins, dextrans, starches, and the like;and alditols, such as mannitol, xylitol, maltitol, lactitol, xylitolsorbitol (glucitol), myoinositol and the like. Preferred carbohydrateexcipients for use in the present invention are mannitol, trehalose, andraffinose.

Anti-IL-23p19 antibody compositions can also include a buffer or apH-adjusting agent; typically, the buffer is a salt prepared from anorganic acid or base. Representative buffers include organic acid salts,such as salts of citric acid, ascorbic acid, gluconic acid, carbonicacid, tartaric acid, succinic acid, acetic acid, or phthalic acid; Tris,tromethamine hydrochloride, or phosphate buffers. Preferred buffers foruse in the present compositions are organic acid salts, such as citrate.

Additionally, anti-IL-23p19 antibody compositions of the invention caninclude polymeric excipients/additives, such as polyvinylpyrrolidones,ficolls (a polymeric sugar), dextrates (e.g., cyclodextrins, such as2-hydroxypropyl-β-cyclodextrin), polyethylene glycols, flavoring agents,antimicrobial agents, sweeteners, antioxidants, antistatic agents,surfactants (e.g., polysorbates, such as “TWEEN 20” and “TWEEN 80”),lipids (e.g., phospholipids, fatty acids), steroids (e.g., cholesterol),and chelating agents (e.g., EDTA).

These and additional known pharmaceutical excipients and/or additivessuitable for use in the anti-IL-23p19 antibody, portion or variantcompositions according to the invention are known in the art, e.g., aslisted in “Remington: The Science & Practice of Pharmacy”, 19^(th) ed.,Williams & Williams, (1995), and in the “Physician's Desk Reference”,52^(nd) ed., Medical Economics, Montvale, N.J. (1998), the disclosuresof which are entirely incorporated herein by reference. Preferredcarrier or excipient materials are carbohydrates (e.g., saccharides andalditols) and buffers (e.g., citrate) or polymeric agents. An exemplarycarrier molecule is the mucopolysaccharide, hyaluronic acid, which maybe useful for intraarticular delivery.

Formulations

As noted above, the invention provides for stable formulations, whichpreferably comprise a phosphate buffer with saline or a chosen salt, aswell as preserved solutions and formulations containing a preservativeas well as multi-use preserved formulations suitable for pharmaceuticalor veterinary use, comprising at least one anti-IL-23p19 antibody in apharmaceutically acceptable formulation. Preserved formulations containat least one known preservative or optionally selected from the groupconsisting of at least one phenol, m-cresol, p-cresol, o-cresol,chlorocresol, benzyl alcohol, phenylmercuric nitrite, phenoxyethanol,formaldehyde, chlorobutanol, magnesium chloride (e.g., hexahydrate),alkylparaben (methyl, ethyl, propyl, butyl and the like), benzalkoniumchloride, benzethonium chloride, sodium dehydroacetate and thimerosal,polymers, or mixtures thereof in an aqueous diluent. Any suitableconcentration or mixture can be used as known in the art, such as about0.0015%, or any range, value, or fraction therein. Non-limiting examplesinclude, no preservative, about 0.1-2% m-cresol (e.g., 0.2, 0.3. 0.4,0.5, 0.9, 1.0%), about 0.1-3% benzyl alcohol (e.g., 0.5, 0.9, 1.1, 1.5,1.9, 2.0, 2.5%), about 0.001-0.5% thimerosal (e.g., 0.005, 0.01), about0.001-2.0% phenol (e.g., 0.05, 0.25, 0.28, 0.5, 0.9, 1.0%), 0.0005-1.0%alkylparaben(s) (e.g., 0.00075, 0.0009, 0.001, 0.002, 0.005, 0.0075,0.009, 0.01, 0.02, 0.05, 0.075, 0.09, 0.1, 0.2, 0.3, 0.5, 0.75, 0.9,1.0%), and the like.

As noted above, the invention provides an article of manufacture,comprising packaging material and at least one vial comprising asolution of at least one anti-IL-23p19 antibody with the prescribedbuffers and/or preservatives, optionally in an aqueous diluent, whereinsaid packaging material comprises a label that indicates that suchsolution can be held over a period of 1, 2, 3, 4, 5, 6, 9, 12, 18, 20,24, 30, 36, 40, 48, 54, 60, 66, 72 hours or greater. The inventionfurther comprises an article of manufacture, comprising packagingmaterial, a first vial comprising lyophilized at least one anti-IL-23p19antibody, and a second vial comprising an aqueous diluent of prescribedbuffer or preservative, wherein said packaging material comprises alabel that instructs a patient to reconstitute the at least oneanti-IL-23p19 antibody in the aqueous diluent to form a solution thatcan be held over a period of twenty-four hours or greater.

The at least one anti-IL-23p19 antibody used in accordance with thepresent invention can be produced by recombinant means, including frommammalian cell or transgenic preparations, or can be purified from otherbiological sources, as described herein or as known in the art.

The range of at least one anti-IL-23p19 antibody in the product of thepresent invention includes amounts yielding upon reconstitution, if in awet/dry system, concentrations from about 1.0 μg/ml to about 1000 mg/ml,although lower and higher concentrations are operable and are dependenton the intended delivery vehicle, e.g., solution formulations willdiffer from transdermal patch, pulmonary, transmucosal, or osmotic ormicro pump methods.

Preferably, the aqueous diluent optionally further comprises apharmaceutically acceptable preservative. Preferred preservativesinclude those selected from the group consisting of phenol, m-cresol,p-cresol, o-cresol, chlorocresol, benzyl alcohol, alkylparaben (methyl,ethyl, propyl, butyl and the like), benzalkonium chloride, benzethoniumchloride, sodium dehydroacetate and thimerosal, or mixtures thereof. Theconcentration of preservative used in the formulation is a concentrationsufficient to yield an anti-microbial effect. Such concentrations aredependent on the preservative selected and are readily determined by theskilled artisan.

Other excipients, e.g., isotonicity agents, buffers, antioxidants, andpreservative enhancers, can be optionally and preferably added to thediluent. An isotonicity agent, such as glycerin, is commonly used atknown concentrations. A physiologically tolerated buffer is preferablyadded to provide improved pH control. The formulations can cover a widerange of pHs, such as from about pH 4 to about pH 10, and preferredranges from about pH 5 to about pH 9, and a most preferred range ofabout 6.0 to about 8.0. Preferably, the formulations of the presentinvention have a pH between about 6.8 and about 7.8. Preferred buffersinclude phosphate buffers, most preferably, sodium phosphate,particularly, phosphate buffered saline (PBS).

Other additives, such as a pharmaceutically acceptable solubilizers likeTween 20 (polyoxyethylene (20) sorbitan monolaurate), Tween 40(polyoxyethylene (20) sorbitan monopalmitate), Tween 80 (polyoxyethylene(20) sorbitan monooleate), Pluronic F68 (polyoxyethylenepolyoxypropylene block copolymers), and PEG (polyethylene glycol) ornon-ionic surfactants, such as polysorbate 20 or 80 or poloxamer 184 or188, Pluronic® polyls, other block co-polymers, and chelators, such asEDTA and EGTA, can optionally be added to the formulations orcompositions to reduce aggregation. These additives are particularlyuseful if a pump or plastic container is used to administer theformulation. The presence of pharmaceutically acceptable surfactantmitigates the propensity for the protein to aggregate.

The formulations of the present invention can be prepared by a processwhich comprises mixing at least one anti-IL-23p19 antibody and apreservative selected from the group consisting of phenol, m-cresol,p-cresol, o-cresol, chlorocresol, benzyl alcohol, alkylparaben, (methyl,ethyl, propyl, butyl and the like), benzalkonium chloride, benzethoniumchloride, sodium dehydroacetate and thimerosal or mixtures thereof in anaqueous diluent. Mixing the at least one anti-IL-23p19 antibody andpreservative in an aqueous diluent is carried out using conventionaldissolution and mixing procedures. To prepare a suitable formulation,for example, a measured amount of at least one anti-IL-23p19 antibody inbuffered solution is combined with the desired preservative in abuffered solution in quantities sufficient to provide the protein andpreservative at the desired concentrations. Variations of this processwould be recognized by one of ordinary skill in the art. For example,the order the components are added, whether additional additives areused, the temperature and pH at which the formulation is prepared, areall factors that can be optimized for the concentration and means ofadministration used.

The claimed formulations can be provided to patients as clear solutionsor as dual vials comprising a vial of lyophilized at least oneanti-IL-23p19 antibody that is reconstituted with a second vialcontaining water, a preservative and/or excipients, preferably, aphosphate buffer and/or saline and a chosen salt, in an aqueous diluent.Either a single solution vial or dual vial requiring reconstitution canbe reused multiple times and can suffice for a single or multiple cyclesof patient treatment and thus can provide a more convenient treatmentregimen than currently available.

The present claimed articles of manufacture are useful foradministration over a period ranging from immediate to twenty-four hoursor greater. Accordingly, the presently claimed articles of manufactureoffer significant advantages to the patient. Formulations of theinvention can optionally be safely stored at temperatures of from about2° C. to about 40° C. and retain the biological activity of the proteinfor extended periods of time, thus allowing a package label indicatingthat the solution can be held and/or used over a period of 6, 12, 18,24, 36, 48, 72, or 96 hours or greater. If preserved diluent is used,such label can include use up to 1-12 months, one-half, one and a half,and/or two years.

The solutions of at least one anti-IL-23p19 antibody of the inventioncan be prepared by a process that comprises mixing at least one antibodyin an aqueous diluent. Mixing is carried out using conventionaldissolution and mixing procedures. To prepare a suitable diluent, forexample, a measured amount of at least one antibody in water or bufferis combined in quantities sufficient to provide the protein and,optionally, a preservative or buffer at the desired concentrations.Variations of this process would be recognized by one of ordinary skillin the art. For example, the order the components are added, whetheradditional additives are used, the temperature and pH at which theformulation is prepared, are all factors that can be optimized for theconcentration and means of administration used.

The claimed products can be provided to patients as clear solutions oras dual vials comprising a vial of lyophilized at least oneanti-IL-23p19 antibody that is reconstituted with a second vialcontaining the aqueous diluent. Either a single solution vial or dualvial requiring reconstitution can be reused multiple times and cansuffice for a single or multiple cycles of patient treatment and thusprovides a more convenient treatment regimen than currently available.

The claimed products can be provided indirectly to patients by providingto pharmacies, clinics, or other such institutions and facilities, clearsolutions or dual vials comprising a vial of lyophilized at least oneanti-IL-23p19 antibody that is reconstituted with a second vialcontaining the aqueous diluent. The clear solution in this case can beup to one liter or even larger in size, providing a large reservoir fromwhich smaller portions of the at least one antibody solution can beretrieved one or multiple times for transfer into smaller vials andprovided by the pharmacy or clinic to their customers and/or patients.

Recognized devices comprising single vial systems include pen-injectordevices for delivery of a solution, such as BD Pens, BD Autojector®,Humaject®, NovoPen®, B-D®Pen, AutoPen®, and OptiPen®, GenotropinPen®,Genotronorm Pen®, Humatro Pen®, Reco-Pen® Roferon Pen® Biojector®,Iject®, J-tip Needle-Free Injector®, Intraject®, Medi-Ject®, e.g., asmade or developed by Becton Dickensen (Franklin Lakes, N.J.,www.bectondickenson.com), Disetronic (Burgdorf, Switzerland,www.disetronic.com; Bioject, Portland, Oreg. (www.bioject.com); NationalMedical Products, Weston Medical (Peterborough, UK,www.weston-medical.com), Medi-Ject Corp (Minneapolis, MN, www.mediject.com), and similary suitable devices. Recognized devicescomprising a dual vial system include those pen-injector systems forreconstituting a lyophilized drug in a cartridge for delivery of thereconstituted solution, such as the HumatroPen®. Examples of otherdevices suitable include pre-filled syringes, auto-injectors, needlefree injectors and needle free IV infusion sets.

The products presently claimed include packaging material. The packagingmaterial provides, in addition to the information required by theregulatory agencies, the conditions under which the product can be used.The packaging material of the present invention provides instructions tothe patient to reconstitute the at least one anti-IL-23p19 antibody inthe aqueous diluent to form a solution and to use the solution over aperiod of 2-24 hours or greater for the two vial, wet/dry, product. Forthe single vial, solution product, the label indicates that suchsolution can be used over a period of 2-24 hours or greater. Thepresently claimed products are useful for human pharmaceutical productuse.

The formulations of the present invention can be prepared by a processthat comprises mixing at least one anti-IL-23p19 antibody and a selectedbuffer, preferably, a phosphate buffer containing saline or a chosensalt. Mixing the at least one anti-IL-23p19 antibody and buffer in anaqueous diluent is carried out using conventional dissolution and mixingprocedures. To prepare a suitable formulation, for example, a measuredamount of at least one antibody in water or buffer is combined with thedesired buffering agent in water in quantities sufficient to provide theprotein and buffer at the desired concentrations. Variations of thisprocess would be recognized by one of ordinary skill in the art. Forexample, the order the components are added, whether additionaladditives are used, the temperature and pH at which the formulation isprepared, are all factors that can be optimized for the concentrationand means of administration used.

The claimed stable or preserved formulations can be provided to patientsas clear solutions or as dual vials comprising a vial of lyophilized atleast one anti-IL-23p19 antibody that is reconstituted with a secondvial containing a preservative or buffer and excipients in an aqueousdiluent. Either a single solution vial or dual vial requiringreconstitution can be reused multiple times and can suffice for a singleor multiple cycles of patient treatment and thus provides a moreconvenient treatment regimen than currently available.

Other formulations or methods of stabilizing the anti-IL-23p19 antibodymay result in other than a clear solution of lyophilized powdercomprising the antibody. Among non-clear solutions are formulationscomprising particulate suspensions, said particulates being acomposition containing the anti-IL-23p19 antibody in a structure ofvariable dimension and known variously as a microsphere, microparticle,nanoparticle, nanosphere, or liposome. Such relatively homogenous,essentially spherical, particulate formulations containing an activeagent can be formed by contacting an aqueous phase containing the activeagent and a polymer and a nonaqueous phase followed by evaporation ofthe nonaqueous phase to cause the coalescence of particles from theaqueous phase as taught in U.S. Pat. No. 4,589,330. Porousmicroparticles can be prepared using a first phase containing activeagent and a polymer dispersed in a continuous solvent and removing saidsolvent from the suspension by freeze-drying ordilution-extraction-precipitation as taught in U.S. Pat. No. 4,818,542.Preferred polymers for such preparations are natural or syntheticcopolymers or polymers selected from the group consisting of gleatinagar, starch, arabinogalactan, albumin, collagen, polyglycolic acid,polylactic aced, glycolide-L(−) lactide poly(episilon-caprolactone,poly(epsilon-caprolactone-CO-lactic acid),poly(epsilon-caprolactone-CO-glycolic acid), poly(β-hydroxybutyricacid), polyethylene oxide, polyethylene, poly(alkyl-2-cyanoacrylate),poly(hydroxyethyl methacrylate), polyamides, poly(amino acids),poly(2-hydroxyethyl DL-aspartamide), poly(ester urea),poly(L-phenylalanine/ethylene glycol/1,6-diisocyanatohexane)andpoly(methyl methacrylate). Particularly preferred polymers arepolyesters, such as polyglycolic acid, polylactic aced, glycolide-L(−)lactide poly(episilon-caprolactone, poly(epsilon-caprolactone-CO-lacticacid), and poly(epsilon-caprolactone-CO-glycolic acid. Solvents usefulfor dissolving the polymer and/or the active include: water,hexafluoroisopropanol, methylenechloride, tetrahydrofuran, hexane,benzene, or hexafluoroacetone sesquihydrate. The process of dispersingthe active containing phase with a second phase may include pressureforcing said first phase through an orifice in a nozzle to affectdroplet formation.

Dry powder formulations may result from processes other thanlyophilization, such as by spray drying or solvent extraction byevaporation or by precipitation of a crystalline composition followed byone or more steps to remove aqueous or nonaqueous solvent. Preparationof a spray-dried antibody preparation is taught in U.S. Pat. No.6,019,968. The antibody-based dry powder compositions may be produced byspray drying solutions or slurries of the antibody and, optionally,excipients, in a solvent under conditions to provide a respirable drypowder. Solvents may include polar compounds, such as water and ethanol,which may be readily dried. Antibody stability may be enhanced byperforming the spray drying procedures in the absence of oxygen, such asunder a nitrogen blanket or by using nitrogen as the drying gas. Anotherrelatively dry formulation is a dispersion of a plurality of perforatedmicrostructures dispersed in a suspension medium that typicallycomprises a hydrofluoroalkane propellant as taught in WO 9916419. Thestabilized dispersions may be administered to the lung of a patientusing a metered dose inhaler. Equipment useful in the commercialmanufacture of spray dried medicaments are manufactured by Buchi Ltd. orNiro Corp.

At least one anti-IL-23p19 antibody in either the stable or preservedformulations or solutions described herein, can be administered to apatient in accordance with the present invention via a variety ofdelivery methods including SC or IM injection; transdermal, pulmonary,transmucosal, implant, osmotic pump, cartridge, micro pump, or othermeans appreciated by the skilled artisan, as well-known in the art.

Therapeutic Applications

The present invention also provides a method for modulating or treatingat least one IL-23 related disease, in a cell, tissue, organ, animal, orpatient, as known in the art or as described herein, using at least oneIL-23p19 antibody of the present invention, e.g., administering orcontacting the cell, tissue, organ, animal, or patient with atherapeutic effective amount of IL-23p19 antibody. The present inventionalso provides a method for modulating or treating at least one IL-23related disease, in a cell, tissue, organ, animal, or patient including,but not limited to, at least one of obesity, an immune related disease,a cardiovascular disease, an infectious disease, a malignant disease ora neurologic disease.

The present invention also provides a method for modulating or treatingat least one IL-23 related immune related disease, in a cell, tissue,organ, animal, or patient including, but not limited to, at least one ofrheumatoid arthritis, juvenile rheumatoid arthritis, systemic onsetjuvenile rheumatoid arthritis, psoriatic arthritis, ankylosingspondilitis, gastric ulcer, seronegative arthropathies, osteoarthritis,osteolysis, aseptic loosening of orthopedic implants, inflammatory boweldisease, ulcerative colitis, systemic lupus erythematosus,antiphospholipid syndrome, iridocyclitis/uveitis/optic neuritis,idiopathic pulmonary fibrosis, systemic vasculitis/wegener'sgranulomatosis, sarcoidosis, orchitis/vasectomy reversal procedures,allergic/atopic diseases, asthma, allergic rhinitis, eczema, allergiccontact dermatitis, allergic conjunctivitis, hypersensitivitypneumonitis, transplants, organ transplant rejection, graft-versus-hostdisease, systemic inflammatory response syndrome, sepsis syndrome, grampositive sepsis, gram negative sepsis, culture negative sepsis, fungalsepsis, neutropenic fever, urosepsis, meningococcemia,trauma/hemorrhage, burns, ionizing radiation exposure, acutepancreatitis, adult respiratory distress syndrome, rheumatoid arthritis,alcohol-induced hepatitis, chronic inflammatory pathologies,sarcoidosis, Crohn's pathology, sickle cell anemia, diabetes, nephrosis,atopic diseases, hypersensitity reactions, allergic rhinitis, hay fever,perennial rhinitis, conjunctivitis, endometriosis, asthma, urticaria,systemic anaphalaxis, dermatitis, pernicious anemia, hemolyticdisesease, thrombocytopenia, graft rejection of any organ or tissue,kidney translplant rejection, heart transplant rejection, livertransplant rejection, pancreas transplant rejection, lung transplantrejection, bone marrow transplant (BMT) rejection, skin allograftrejection, cartilage transplant rejection, bone graft rejection, smallbowel transplant rejection, fetal thymus implant rejection, parathyroidtransplant rejection, xenograft rejection of any organ or tissue,allograft rejection, anti-receptor hypersensitivity reactions, Gravesdisease, Raynaud's disease, type B insulin-resistant diabetes, asthma,myasthenia gravis, antibody-meditated cytotoxicity, type IIIhypersensitivity reactions, POEMS syndrome (polyneuropathy,organomegaly, endocrinopathy, monoclonal gammopathy, and skin changessyndrome), polyneuropathy, organomegaly, endocrinopathy, monoclonalgammopathy, skin changes syndrome, antiphospholipid syndrome, pemphigus,scleroderma, mixed connective tissue disease, idiopathic Addison'sdisease, diabetes mellitus, chronic active hepatitis, primary billiarycirrhosis, vitiligo, vasculitis, post-MI cardiotomy syndrome, type IVhypersensitivity, contact dermatitis, hypersensitivity pneumonitis,allograft rejection, granulomas due to intracellular organisms, drugsensitivity, metabolic/idiopathic, Wilson's disease, hemachromatosis,alpha-1-antitrypsin deficiency, diabetic retinopathy, hashimoto'sthyroiditis, osteoporosis, hypothalamic-pituitary-adrenal axisevaluation, primary biliary cirrhosis, thyroiditis, encephalomyelitis,cachexia, cystic fibrosis, neonatal chronic lung disease, chronicobstructive pulmonary disease (COPD), familial hematophagocyticlymphohistiocytosis, dermatologic conditions, psoriasis, alopecia,nephrotic syndrome, nephritis, glomerular nephritis, acute renalfailure, hemodialysis, uremia, toxicity, preeclampsia, okt3 therapy,anti-cd3 therapy, cytokine therapy, chemotherapy, radiation therapy(e.g., including but not limited to, asthenia, anemia, cachexia, and thelike), chronic salicylate intoxication, and the like. See, e.g., theMerck Manual, 12th-17th Editions, Merck & Company, Rahway, N.J. (1972,1977, 1982, 1987, 1992, 1999), Pharmacotherapy Handbook, Wells et al.,eds., Second Edition, Appleton and Lange, Stamford, Conn. (1998, 2000),each entirely incorporated by reference.

The present invention also provides a method for modulating or treatingat least one cardiovascular disease in a cell, tissue, organ, animal, orpatient, including, but not limited to, at least one of cardiac stunsyndrome, myocardial infarction, congestive heart failure, stroke,ischemic stroke, hemorrhage, acute coronary syndrome, arteriosclerosis,atherosclerosis, restenosis, diabetic ateriosclerotic disease,hypertension, arterial hypertension, renovascular hypertension, syncope,shock, syphilis of the cardiovascular system, heart failure, corpulmonale, primary pulmonary hypertension, cardiac arrhythmias, atrialectopic beats, atrial flutter, atrial fibrillation (sustained orparoxysmal), post perfusion syndrome, cardiopulmonary bypassinflammation response, chaotic or multifocal atrial tachycardia, regularnarrow QRS tachycardia, specific arrythmias, ventricular fibrillation, His bundle arrythmias, atrioventricular block, bundle branch block,myocardial ischemic disorders, coronary artery disease, angina pectoris,myocardial infarction, cardiomyopathy, dilated congestivecardiomyopathy, restrictive cardiomyopathy, valvular heart diseases,endocarditis, pericardial disease, cardiac tumors, aordic and peripheralaneuryisms, aortic dissection, inflammation of the aorta, occlusion ofthe abdominal aorta and its branches, peripheral vascular disorders,occlusive arterial disorders, peripheral atherlosclerotic disease,thromboangitis obliterans, functional peripheral arterial disorders,Raynaud's phenomenon and disease, acrocyanosis, erythromelalgia, venousdiseases, venous thrombosis, varicose veins, arteriovenous fistula,lymphederma, lipedema, unstable angina, reperfusion injury, post pumpsyndrome, ischemia-reperfusion injury, and the like. Such a method canoptionally comprise administering an effective amount of a compositionor pharmaceutical composition comprising at least one anti-IL-23p19antibody to a cell, tissue, organ, animal or patient in need of suchmodulation, treatment or therapy.

The present invention also provides a method for modulating or treatingat least one IL-23 related infectious disease in a cell, tissue, organ,animal or patient, including, but not limited to, at least one of: acuteor chronic bacterial infection, acute and chronic parasitic orinfectious processes, including bacterial, viral and fungal infections,HIV infection/HIV neuropathy, meningitis, hepatitis (e.g., A, B or C, orthe like), septic arthritis, peritonitis, pneumonia, epiglottitis, E.coli 0157:h7, hemolytic uremic syndrome/thrombolytic thrombocytopenicpurpura, malaria, dengue hemorrhagic fever, leishmaniasis, leprosy,toxic shock syndrome, streptococcal myositis, gas gangrene,mycobacterium tuberculosis, mycobacterium avium intracellulare,pneumocystis carinii pneumonia, pelvic inflammatory disease,orchitis/epidydimitis, legionella, lyme disease, influenza a,epstein-barr virus, viral-associated hemaphagocytic syndrome, viralencephalitis/aseptic meningitis, and the like.

The present invention also provides a method for modulating or treatingat least one IL-23 related malignant disease in a cell, tissue, organ,animal or patient, including, but not limited to, at least one of:leukemia, acute leukemia, acute lymphoblastic leukemia (ALL), acutelymphocytic leukemia, B-cell, T-cell or FAB ALL, acute myeloid leukemia(AML), acute myelogenous leukemia, chromic myelocytic leukemia (CML),chronic lymphocytic leukemia (CLL), hairy cell leukemia, myelodyplasticsyndrome (MDS), a lymphoma, Hodgkin's disease, a malignant lymphoma,non-hodgkin's lymphoma, Burkitt's lymphoma, multiple myeloma, Kaposi'ssarcoma, colorectal carcinoma, pancreatic carcinoma, nasopharyngealcarcinoma, malignant histiocytosis, paraneoplasticsyndrome/hypercalcemia of malignancy, solid tumors, bladder cancer,breast cancer, colorectal cancer, endometiral cancer, head cancer, neckcancer, hereditary nonpolyposis cancer, Hodgkin's lymphoma, livercancer, lung cancer, non-small cell lung cancer, ovarian cancer,pancreatic cancer, prostate cancer, renal cell carcinoma, testicularcancer, adenocarcinomas, sarcomas, malignant melanoma, hemangioma,metastatic disease, cancer related bone resorption, cancer related bonepain, and the like.

The present invention also provides a method for modulating or treatingat least one IL-23 related neurologic disease in a cell, tissue, organ,animal or patient, including, but not limited to, at least one of:neurodegenerative diseases, multiple sclerosis, migraine headache, AIDSdementia complex, demyelinating diseases, such as multiple sclerosis andacute transverse myelitis; extrapyramidal and cerebellar disorders, suchas lesions of the corticospinal system; disorders of the basal ganglia;hyperkinetic movement disorders, such as Huntington's Chorea and senilechorea; drug-induced movement disorders, such as those induced by drugswhich block CNS dopamine receptors; hypokinetic movement disorders, suchas Parkinson's disease; Progressive supranucleo Palsy; structurallesions of the cerebellum; spinocerebellar degenerations, such as spinalataxia, Friedreich's ataxia, cerebellar cortical degenerations, multiplesystems degenerations (Mencel, Dejerine-Thomas, Shi-Drager, andMachado-Joseph); systemic disorders (Refsum's disease,abetalipoprotemia, ataxia, telangiectasia, and mitochondrialmulti-system disorder); demyelinating core disorders, such as multiplesclerosis, acute transverse myelitis; and disorders of the motor unit,such as neurogenic muscular atrophies (anterior horn cell degeneration,such as amyotrophic lateral sclerosis, infantile spinal muscular atrophyand juvenile spinal muscular atrophy); Alzheimer's disease; Down'sSyndrome in middle age; Diffuse Lewy body disease; Senile Dementia ofLewy body type; Wernicke-Korsakoff syndrome; chronic alcoholism;Creutzfeldt-Jakob disease; Subacute sclerosing panencephalitis,Hallerrorden-Spatz disease; Dementia pugilistica; neurotraumatic injury(e.g., spinal cord injury, brain injury, concussion, repetitiveconcussion); pain; inflammatory pain; autism; depression; stroke;cognitive disorders; epilepsy; and the like. Such a method canoptionally comprise administering an effective amount of a compositionor pharmaceutical composition comprising at least one TNF antibody orspecified portion or variant to a cell, tissue, organ, animal or patientin need of such modulation, treatment or therapy. See, e.g., the MerckManual, 16^(th) Edition, Merck & Company, Rahway, N.J. (1992).

The present invention also provides a method for modulating or treatingat least one IL-23 related wound, trauma or tissue injury or relatedchronic condition, in a cell, tissue, organ, animal or patient,including, but not limited to, at least one of: bodily injury or atrauma associated with oral surgery including periodontal surgery, toothextraction(s), endodontic treatment, insertion of tooth implants,application and use of tooth prosthesis; or wherein the wound isselected from the group consisting of aseptic wounds, contused wounds,incised wounds, lacerated wounds, non-penetrating wounds, open wounds,penetrating wounds, perforating wounds, puncture wounds, septic wounds,infarctions and subcutaneous wounds; or wherein the wound is selectedfrom the group consisting of ischemic ulcers, pressure sores, fistulae,severe bites, thermal burns and donor site wounds; or wherein the woundis anaphthous wound, a traumatic wound or a herpes associated wound.

Wounds and/or ulcers are normally found protruding from the skin or on amucosal surface or as a result of an infarction in an organ (“stroke”).A wound may be a result of a soft tissue defect or a lesion or of anunderlying condition. In the present context, the term “skin” relates tothe outermost surface of the body of an animal, including a human, andembraces intact or almost intact skin as well as an injured skinsurface. The term “mucosa” relates to undamaged or damaged mucosa of ananimal, such as a human, and may be the oral, buccal, aural, nasal,lung, eye, gastrointestinal, vaginal, or rectal mucosa.

In the present context the term “wound” denotes a bodily injury withdisruption of the normal integrity of tissue structures. The term isalso intended to encompass the terms “sore,” “lesion,” “necrosis,” and“ulcer.” Normally, the term “sore” is a popular term for almost anylesion of the skin or mucous membranes and the term “ulcer” is a localdefect, or excavation, of the surface of an organ or tissue, which isproduced by the sloughing of necrotic tissue. Lesion generally relatesto any tissue defect. Necrosis is related to dead tissue resulting frominfection, injury, inflammation or infarctions.

The term “wound” used in the present context denotes any wound (seebelow for a classification of wounds) and at any particular stage in thehealing process, including the stage before any healing has initiated oreven before a specific wound like a surgical incision is made(prophylactic treatment). Examples of wounds which can be preventedand/or treated in accordance with the present invention are, e.g.,aseptic wounds, contused wounds, incised wounds, lacerated wounds,non-penetrating wounds (i.e., wounds in which there is no disruption ofthe skin but there is injury to underlying structures), open wounds,penetrating wounds, perforating wounds, puncture wounds, septic wounds,subcutaneous wounds, etc. Examples of sores are bed sores, canker sores,chrome sores, cold sores, pressure sores, etc. Examples of ulcers are,e.g., a peptic ulcer, duodenal ulcer, gastric ulcer, gouty ulcer,diabetic ulcer, hypertensive ischemic ulcer, stasis ulcer, ulcus cruris(venous ulcer), sublingual ulcer, submucous ulcer, symptomatic ulcer,trophic ulcer, tropical ulcer, and veneral ulcer, e.g., caused bygonorrhoea (including urethritis, endocervicitis and proctitis).Conditions related to wounds or sores which may be successfully treatedaccording to the invention are burns, anthrax, tetanus, gas gangrene,scarlatina, erysipelas, sycosis barbae, folliculitis, impetigocontagiosa, or impetigo bullosa, etc. There is often a certain overlapbetween the use of the terms “wound” and “ulcer” and “wound” and “sore”and, furthermore, the terms are often used at random. Therefore, asmentioned above, in the present context the term “wound” encompasses theterms “ulcer,” “lesion,” “sore” and “infarction,” and the terms areindiscriminately used unless otherwise indicated.

The kinds of wounds to be treated according to the invention includealso (i) general wounds, such as, e.g., surgical, traumatic, infectious,ischemic, thermal, chemical and bullous wounds; (ii) wounds specific forthe oral cavity, such as, e.g., post-extraction wounds, endodonticwounds especially in connection with treatment of cysts and abscesses,ulcers and lesions of bacterial, viral or autoimmunological origin,mechanical, chemical, thermal, infectious and lichenoid wounds; herpesulcers, stomatitis aphthosa, acute necrotising ulcerative gingivitis andburning mouth syndrome are specific examples; and (iii) wounds on theskin, such as, e.g., neoplasm, burns (e.g. chemical, thermal), lesions(bacterial, viral, autoimmunological), bites and surgical incisions.Another way of classifying wounds is as (i) small tissue loss due tosurgical incisions, minor abrasions and minor bites, or as (ii)significant tissue loss. The latter group includes ischemic ulcers,pressure sores, fistulae, lacerations, severe bites, thermal burns anddonor site wounds (in soft and hard tissues) and infarctions.

Other wounds that are of importance in connection with the presentinvention are wounds like ischemic ulcers, pressure sores, fistulae,severe bites, thermal burns and donor site wounds. Ischemic ulcers andpressure sores are wounds which normally only heal very slowly andespecially in such cases, an improved and more rapid healing process isof course of great importance for the patient. Furthermore, the costsinvolved in the treatment of patients suffering from such wounds aremarkedly reduced when the healing is improved and takes place morerapidly.

Donor site wounds are wounds which, e.g., occur in connection withremoval of hard tissue from one part of the body to another part of thebody, e.g., in connection with transplantation. The wounds resultingfrom such operations are very painful and an improved healing istherefore most valuable. The term “skin” is used in a very broad senseembracing the epidermal layer of the skin and—in those cases where theskin surface is more or less injured—also the dermal layer of the skin.Apart from the stratum corneum, the epidermal layer of the skin is theouter (epithelial) layer and the deeper connective tissue layer of theskin is called the dermis.

The present invention also provides a method for modulating or treatingpsoriasis, psoriatic arthritis, Crohn's disease, multiple sclerosis, andoptic neuritis, among the other diseases listed above as IL-23 related,in a cell, tissue, organ, animal, or patient including, but not limitedto, at least one of immune related disease, cardiovascular disease,infectious, malignant and/or neurologic disease. Such a method canoptionally comprise administering an effective amount of at least onecomposition or pharmaceutical composition comprising at least oneanti-IL-23p19 antibody to a cell, tissue, organ, animal or patient inneed of such modulation, treatment or therapy.

Any method of the present invention can comprise administering aneffective amount of a composition or pharmaceutical compositioncomprising at least one anti-IL-23p19 antibody to a cell, tissue, organ,animal or patient in need of such modulation, treatment or therapy. Sucha method can optionally further comprise co-administration orcombination therapy for treating such diseases or disorders, wherein theadministering of said at least one anti-IL-23p19 antibody, specifiedportion or variant thereof, further comprises administering, beforeconcurrently, and/or after, at least one selected from at least one TNFantagonist (e.g., but not limited to, a TNF chemical or proteinantagonist, TNF monoclonal or polyclonal antibody or fragment, a solubleTNF receptor (e.g., p55, p70 or p85) or fragment, fusion polypeptidesthereof, or a small molecule TNF antagonist, e.g., TNF binding protein Ior II (TBP-1 or TBP-II), nerelimonmab, infliximab, etanercept (Enbrel™),adalimulab (Humira™), CDP-571, CDP-870, afelimomab, lenercept, and thelike), an antirheumatic (e.g., methotrexate, auranofin, aurothioglucose,azathioprine, gold sodium thiomalate, hydroxychloroquine sulfate,leflunomide, sulfasalzine), a muscle relaxant, a narcotic, a non-steroidanti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative,a local anesthetic, a neuromuscular blocker, an antimicrobial (e.g.,aminoglycoside, an antifungal, an antiparasitic, an antiviral, acarbapenem, cephalosporin, a fluororquinolone, a macrolide, apenicillin, a sulfonamide, a tetracycline, another antimicrobial), anantipsoriatic, a corticosteriod, an anabolic steroid, a diabetes relatedagent, a mineral, a nutritional, a thyroid agent, a vitamin, a calciumrelated hormone, an antidiarrheal, an antitussive, an antiemetic, anantiulcer, a laxative, an anticoagulant, an erythropoietin (e.g.,epoetin alpha), a filgrastim (e.g., G-CSF, Neupogen), a sargramostim(GM-CSF, Leukine), an immunization, an immunoglobulin, animmunosuppressive (e.g., basiliximab, cyclosporine, daclizumab), agrowth hormone, a hormone replacement drug, an estrogen receptormodulator, a mydriatic, a cycloplegic, an alkylating agent, anantimetabolite, a mitotic inhibitor, a radiopharmaceutical, anantidepressant, antimanic agent, an antipsychotic, an anxiolytic, ahypnotic, a sympathomimetic, a stimulant, donepezil, tacrine, an asthmamedication, a beta agonist, an inhaled steroid, a leukotriene inhibitor,a methylxanthine, a cromolyn, an epinephrine or analog, dornase alpha(Pulmozyme), a cytokine or a cytokine antagonist. Suitable dosages arewell known in the art. See, e.g., Wells et al., eds., PharmacotherapyHandbook, 2^(nd) Edition, Appleton and Lange, Stamford, Conn. (2000);PDR Pharmacopoeia, Tarascon Pocket Pharmacopoeia 2000, Deluxe Edition,Tarascon Publishing, Loma Linda, CA (2000); Nursing 2001 Handbook ofDrugs, 21^(st) edition, Springhouse Corp., Springhouse, Pa., 2001;Health Professional's Drug Guide 2001, ed., Shannon, Wilson, Stang,Prentice-Hall, Inc, Upper Saddle River, N.J. each of which referencesare entirely incorporated herein by reference.

TNF antagonists suitable for compositions, combination therapy,co-administration, devices and/or methods of the present invention(further comprising at least one antibody, specified portion and variantthereof, of the present invention), include, but are not limited to,anti-TNF antibodies (e.g., at least one TNF antagonist as definedabove), antigen-binding fragments thereof, and receptor molecules whichbind specifically to TNF; compounds which prevent and/or inhibit TNFsynthesis, TNF release or its action on target cells, such asthalidomide, tenidap, phosphodiesterase inhibitors (e.g, pentoxifyllineand rolipram), A2b adenosine receptor agonists and A2b adenosinereceptor enhancers; compounds which prevent and/or inhibit TNF receptorsignalling, such as mitogen activated protein (MAP) kinase inhibitors;compounds which block and/or inhibit membrane TNF cleavage, such asmetalloproteinase inhibitors; compounds which block and/or inhibit TNFactivity, such as angiotensin converting enzyme (ACE) inhibitors (e.g.,captopril); and compounds which block and/or inhibit TNF productionand/or synthesis, such as MAP kinase inhibitors.

As used herein, a “tumor necrosis factor antibody,” “TNF antibody,”“TNFα antibody,” or fragment and the like decreases, blocks, inhibits,abrogates or interferes with TNFα activity in vitro, in situ and/or,preferably, in vivo. For example, a suitable TNF human antibody of thepresent invention can bind TNFα and includes anti-TNF antibodies,antigen-binding fragments thereof, and specified mutants or domainsthereof that bind specifically to TNFα. A suitable TNF antibody orfragment can also decrease block, abrogate, interfere, prevent and/orinhibit TNF RNA, DNA or protein synthesis, TNF release, TNF receptorsignaling, membrane TNF cleavage, TNF activity, TNF production and/orsynthesis.

An example of a TNF antibody or antagonist is the chimeric antibody cA2.Additional examples of monoclonal anti-TNF antibodies that can be usedin the present invention are described in the art (see, e.g., U.S. Pat.No. 5,231,024; Möller, A. et al., Cytokine 2(3):162-169 (1990); U.S.application Ser. No. 07/943,852 (filed Sep. 11, 1992); Rathjen et al.,International Publication No. WO 91/02078 (published Feb. 21, 1991);Rubin et al., EPO Patent Publication No. 0 218 868 (published Apr. 22,1987); Yone et al., EPO Patent Publication No. 0 288 088 (Oct. 26,1988); Liang, et al., Biochem. Biophys. Res. Comm. 137:847-854 (1986);Meager, et al., Hybridoma 6:305-311 (1987); Fendly et al., Hybridoma6:359-369 (1987); Bringman, et al., Hybridoma 6:489-507 (1987); andHirai, et al., J. Immunol. Meth. 96:57-62 (1987).

TNF Receptor Molecules

Preferred TNF receptor molecules useful in the present invention arethose that bind TNFα with high affinity (see, e.g., Feldmann et al.,International Publication No. WO 92/07076 (published Apr. 30, 1992);Schall et al., Cell 61:361-370 (1990); and Loetscher et al., Cell61:351-359 (1990), which references are entirely incorporated herein byreference) and optionally possess low immunogenicity. In particular, the55 kDa (p55 TNF-R) and the 75 kDa (p75 TNF-R) TNF cell surface receptorsare useful in the present invention. Truncated forms of these receptors,comprising the extracellular domains (ECD) of the receptors orfunctional portions thereof (see, e.g., Corcoran et al., Eur. J.Biochem. 223:831-840 (1994)), are also useful in the present invention.Truncated forms of the TNF receptors, comprising the ECD, have beendetected in urine and serum as 30 kDa and 40 kDa TNFα inhibitory bindingproteins (Engelmann, H. et al., J. Biol. Chem. 265:1531-1536 (1990)).TNF receptor multimeric molecules and TNF immunoreceptor fusionmolecules, and derivatives and fragments or portions thereof, areadditional examples of TNF receptor molecules which are useful in themethods and compositions of the present invention.

TNF receptor multimeric molecules useful in the present inventioncomprise all or a functional portion of the ECD of two or more TNFreceptors linked via one or more polypeptide linkers or other nonpeptidelinkers, such as polyethylene glycol (PEG). An example of such a TNFimmunoreceptor fusion molecule is TNF receptor/IgG fusion protein. TNFimmunoreceptor fusion molecules and methods for their production havebeen described in the art (Lesslauer et al., Eur. J. Immunol.21:2883-2886 (1991); Ashkenazi et al., Proc. Natl. Acad. Sci. USA88:10535-10539 (1991); Peppel et al., J. Exp. Med. 174:1483-1489 (1991);Kolls et al., Proc. Natl. Acad. Sci. USA 91:215-219 (1994); Butler etal., Cytokine 6(6):616-623 (1994); Baker et al., Eur. J. Immunol.24:2040-2048 (1994); Beutler et al., U.S. Pat. No. 5,447,851; and U.S.application Ser. No. 08/442,133 (filed May 16, 1995), each of whichreferences are entirely incorporated herein by reference). Methods forproducing immunoreceptor fusion molecules can also be found in Capon etal., U.S. Pat. No. 5,116,964; Capon et al., U.S. Pat. No. 5,225,538; andCapon et al., Nature 337:525-531 (1989), which references are entirelyincorporated herein by reference.

Cytokines include any known cytokine See, e.g., CopewithCytokines.com.Cytokine antagonists include, but are not limited to, any antibody,fragment or mimetic, any soluble receptor, fragment or mimetic, anysmall molecule antagonist, or any combination thereof.

Therapeutic Treatments

Any method of the present invention can comprise a method for treatingan IL-23 mediated disorder, comprising administering an effective amountof a composition or pharmaceutical composition comprising at least oneanti-IL-23p19 antibody to a cell, tissue, organ, animal or patient inneed of such modulation, treatment or therapy. Such a method canoptionally further comprise co-administration or combination therapy fortreating such diseases or disorders, wherein the administering of saidat least one anti-IL-23p19 antibody, specified portion or variantthereof, further comprises administering before, concurrently, and/orafter, at least one selected from an anti-infective drug, acardiovascular (CV) system drug, a central nervous system (CNS) drug, anautonomic nervous system (ANS) drug, a respiratory tract drug, agastrointestinal (GI) tract drug, a hormonal drug, a drug for fluid orelectrolyte balance, a hematologic drug, an antineoplastic, animmunomodulation drug, an ophthalmic, otic or nasal drug, a topicaldrug, a nutritional drug or the like, at least one TNF antagonist (e.g.,but not limited to a TNF antibody or fragment, a soluble TNF receptor orfragment, fusion proteins thereof, or a small molecule TNF antagonist),an antirheumatic (e.g., methotrexate, auranofin, aurothioglucose,azathioprine, etanercept, gold sodium thiomalate, hydroxychloroquinesulfate, leflunomide, sulfasalzine), a muscle relaxant, a narcotic, anon-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic,a sedative, a local anesthetic, a neuromuscular blocker, anantimicrobial (e.g., aminoglycoside, an antifungal, an antiparasitic, anantiviral, a carbapenem, cephalosporin, a fluororquinolone, a macrolide,a penicillin, a sulfonamide, a tetracycline, another antimicrobial), anantipsoriatic, a corticosteriod, an anabolic steroid, a diabetes relatedagent, a mineral, a nutritional, a thyroid agent, a vitamin, a calciumrelated hormone, an antidiarrheal, an antitussive, an antiemetic, anantiulcer, a laxative, an anticoagulant, an erythropoietin (e.g.,epoetin alpha), a filgrastim (e.g., G-CSF, Neupogen), a sargramostim(GM-CSF, Leukine), an immunization, an immunoglobulin, animmunosuppressive (e.g., basiliximab, cyclosporine, daclizumab), agrowth hormone, a hormone replacement drug, an estrogen receptormodulator, a mydriatic, a cycloplegic, an alkylating agent, anantimetabolite, a mitotic inhibitor, a radiopharmaceutical, anantidepressant, antimanic agent, an antipsychotic, an anxiolytic, ahypnotic, a sympathomimetic, a stimulant, donepezil, tacrine, an asthmamedication, a beta agonist, an inhaled steroid, a leukotriene inhibitor,a methylxanthine, a cromolyn, an epinephrine or analog, dornase alpha(Pulmozyme), a cytokine or a cytokine antagonist. Such drugs are wellknown in the art, including formulations, indications, dosing andadministration for each presented herein (see., e.g., Nursing 2001Handbook of Drugs, 21^(st) edition, Springhouse Corp., Springhouse, Pa.,2001; Health Professional's Drug Guide 2001, ed., Shannon, Wilson,Stang, Prentice-Hall, Inc, Upper Saddle River, N.J.; PharmcotherapyHandbook, Wells et al., ed., Appleton & Lange, Stamford, Conn., eachentirely incorporated herein by reference).

Typically, treatment of pathologic conditions is effected byadministering an effective amount or dosage of at least oneanti-IL-23p19 antibody composition that total, on average, a range fromat least about 0.01 to 500 milligrams of at least one anti-IL-23p19antibody per kilogram of patient per dose, and, preferably, from atleast about 0.1 to 100 milligrams antibody/kilogram of patient persingle or multiple administration, depending upon the specific activityof the active agent contained in the composition. Alternatively, theeffective serum concentration can comprise 0.1-5000 μg/ml serumconcentration per single or multiple administration. Suitable dosagesare known to medical practitioners and will, of course, depend upon theparticular disease state, specific activity of the composition beingadministered, and the particular patient undergoing treatment. In someinstances, to achieve the desired therapeutic amount, it can benecessary to provide for repeated administration, i.e., repeatedindividual administrations of a particular monitored or metered dose,where the individual administrations are repeated until the desireddaily dose or effect is achieved.

Preferred doses can optionally include about 0.1-99 and/or 100-500mg/kg/administration, or any range, value or fraction thereof, or toachieve a serum concentration of about 0.1-5000 μg/ml serumconcentration per single or multiple administration, or any range, valueor fraction thereof. A preferred dosage range for the anti-IL-23p19antibody of the present invention is from about 1 mg/kg, up to about 3,about 6 or about 12 mg/kg of body weight of the patient.

Alternatively, the dosage administered can vary depending upon knownfactors, such as the pharmacodynamic characteristics of the particularagent, and its mode and route of administration; age, health, and weightof the recipient; nature and extent of symptoms, kind of concurrenttreatment, frequency of treatment, and the effect desired. Usually adosage of active ingredient can be about 0.1 to 100 milligrams perkilogram of body weight. Ordinarily 0.1 to 50, and, preferably, 0.1 to10 milligrams per kilogram per administration or in sustained releaseform is effective to obtain desired results.

As a non-limiting example, treatment of humans or animals can beprovided as a one-time or periodic dosage of at least one antibody ofthe present invention about 0.1 to 100 mg/kg or any range, value orfraction thereof per day, on at least one of day 1-40, or, alternativelyor additionally, at least one of week 1-52, or, alternatively oradditionally, at least one of 1-20 years, or any combination thereof,using single, infusion or repeated doses.

Dosage forms (composition) suitable for internal administrationgenerally contain from about 0.001 milligram to about 500 milligrams ofactive ingredient per unit or container. In these pharmaceuticalcompositions the active ingredient will ordinarily be present in anamount of about 0.5-99.999% by weight based on the total weight of thecomposition.

For parenteral administration, the antibody can be formulated as asolution, suspension, emulsion, particle, powder, or lyophilized powderin association, or separately provided, with a pharmaceuticallyacceptable parenteral vehicle. Examples of such vehicles are water,saline, Ringer's solution, dextrose solution, and about 1-10% humanserum albumin. Liposomes and nonaqueous vehicles, such as fixed oils,can also be used. The vehicle or lyophilized powder can containadditives that maintain isotonicity (e.g., sodium chloride, mannitol)and chemical stability (e.g., buffers and preservatives). Theformulation is sterilized by known or suitable techniques.

Suitable pharmaceutical carriers are described in the most recentedition of Remington's Pharmaceutical Sciences, A. Osol, a standardreference text in this field.

Alternative Administration

Many known and developed modes can be used according to the presentinvention for administering pharmaceutically effective amounts of atleast one anti-IL-23p19 antibody according to the present invention.While pulmonary administration is used in the following description,other modes of administration can be used according to the presentinvention with suitable results. IL-23p19 antibodies of the presentinvention can be delivered in a carrier, as a solution, emulsion,colloid, or suspension, or as a dry powder, using any of a variety ofdevices and methods suitable for administration by inhalation or othermodes described here within or known in the art.

Parenteral Formulations and Administration

Formulations for parenteral administration can contain as commonexcipients sterile water or saline, polyalkylene glycols, such aspolyethylene glycol, oils of vegetable origin, hydrogenated naphthalenesand the like. Aqueous or oily suspensions for injection can be preparedby using an appropriate emulsifier or humidifier and a suspending agent,according to known methods. Agents for injection can be a non-toxic,non-orally administrable diluting agent, such as aqueous solution, asterile injectable solution or suspension in a solvent. As the usablevehicle or solvent, water, Ringer's solution, isotonic saline, etc. areallowed; as an ordinary solvent or suspending solvent, sterileinvolatile oil can be used. For these purposes, any kind of involatileoil and fatty acid can be used, including natural or synthetic orsemisynthetic fatty oils or fatty acids; natural or synthetic orsemisynthtetic mono- or di- or tri-glycerides. Parental administrationis known in the art and includes, but is not limited to, conventionalmeans of injections, a gas pressured needle-less injection device asdescribed in U.S. Pat. No. 5,851,198, and a laser perforator device asdescribed in U.S. Pat. No. 5,839,446 entirely incorporated herein byreference.

Alternative Delivery

The invention further relates to the administration of at least oneanti-IL-23p19 antibody by parenteral, subcutaneous, intramuscular,intravenous, intrarticular, intrabronchial, intraabdominal,intracapsular, intracartilaginous, intracavitary, intracelial,intracerebellar, intracerebroventricular, intracolic, intracervical,intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic,intrapericardiac, intraperitoneal, intrapleural, intraprostatic,intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal,intrasynovial, intrathoracic, intrauterine, intravesical, intralesional,bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermalmeans. At least one anti-IL-23p19 antibody composition can be preparedfor use for parenteral (subcutaneous, intramuscular or intravenous) orany other administration particularly in the form of liquid solutions orsuspensions; for use in vaginal or rectal administration particularly insemisolid forms, such as, but not limited to, creams and suppositories;for buccal, or sublingual administration, such as, but not limited to,in the form of tablets or capsules; or intranasally, such as, but notlimited to, the form of powders, nasal drops or aerosols or certainagents; or transdermally, such as not limited to a gel, ointment,lotion, suspension or patch delivery system with chemical enhancers suchas dimethyl sulfoxide to either modify the skin structure or to increasethe drug concentration in the transdermal patch (Junginger, et al. In“Drug Permeation Enhancement;” Hsieh, D. S., Eds., pp. 59-90 (MarcelDekker, Inc. New York 1994, entirely incorporated herein by reference),or with oxidizing agents that enable the application of formulationscontaining proteins and peptides onto the skin (WO 98/53847), orapplications of electric fields to create transient transport pathways,such as electroporation, or to increase the mobility of charged drugsthrough the skin, such as iontophoresis, or application of ultrasound,such as sonophoresis (U.S. Pat. Nos. 4,309,989 and 4,767,402) (the abovepublications and patents being entirely incorporated herein byreference).

Pulmonary/Nasal Administration

For pulmonary administration, preferably, at least one anti-IL-23p19antibody composition is delivered in a particle size effective forreaching the lower airways of the lung or sinuses. According to theinvention, at least one anti-IL-23p19 antibody can be delivered by anyof a variety of inhalation or nasal devices known in the art foradministration of a therapeutic agent by inhalation. These devicescapable of depositing aerosolized formulations in the sinus cavity oralveoli of a patient include metered dose inhalers, nebulizers, drypowder generators, sprayers, and the like. Other devices suitable fordirecting the pulmonary or nasal administration of antibodies are alsoknown in the art. All such devices can use formulations suitable for theadministration for the dispensing of antibody in an aerosol. Suchaerosols can be comprised of either solutions (both aqueous and nonaqueous) or solid particles.

Metered dose inhalers like the Ventolin metered dose inhaler, typicallyuse a propellent gas and require actuation during inspiration (See,e.g., WO 94/16970, WO 98/35888). Dry powder inhalers like Turbuhaler™(Astra), Rotahaler® (Glaxo), Diskus® (Glaxo), Spiros™ inhaler (Dura),devices marketed by Inhale Therapeutics, and the Spinhaler® powderinhaler (Fisons), use breath-actuation of a mixed powder (U.S. Pat. No.4,668,218 Astra, EP 237507 Astra, WO 97/25086 Glaxo, WO 94/08552 Dura,U.S. Pat. No. 5,458,135 Inhale, WO 94/06498 Fisons, entirelyincorporated herein by reference). Nebulizers like AERx™ Aradigm, theUltravent® nebulizer (Mallinckrodt), and the Acorn II® nebulizer(Marquest Medical Products) (U.S. Pat. No. 5,404,871 Aradigm, WO97/22376), the above references entirely incorporated herein byreference, produce aerosols from solutions, while metered dose inhalers,dry powder inhalers, etc. generate small particle aerosols. Thesespecific examples of commercially available inhalation devices areintended to be a representative of specific devices suitable for thepractice of this invention, and are not intended as limiting the scopeof the invention.

Preferably, a composition comprising at least one anti-IL-23p19 antibodyis delivered by a dry powder inhaler or a sprayer. There are severaldesirable features of an inhalation device for administering at leastone antibody of the present invention. For example, delivery by theinhalation device is advantageously reliable, reproducible, andaccurate. The inhalation device can optionally deliver small dryparticles, e.g., less than about 10 μm, preferably about 1-5 μm, forgood respirability.

Administration of IL-23p19 Antibody Compositions as a Spray

A spray including IL-23p19 antibody composition can be produced byforcing a suspension or solution of at least one anti-IL-23p19 antibodythrough a nozzle under pressure. The nozzle size and configuration, theapplied pressure, and the liquid feed rate can be chosen to achieve thedesired output and particle size. An electrospray can be produced, forexample, by an electric field in connection with a capillary or nozzlefeed. Advantageously, particles of at least one anti-IL-23p19 antibodycomposition delivered by a sprayer have a particle size less than about10 μm, preferably, in the range of about 1 μm to about 5 μm, and, mostpreferably, about 2 μm to about 3 μm.

Formulations of at least one anti-IL-23p19 antibody composition suitablefor use with a sprayer typically include antibody composition in anaqueous solution at a concentration of about 0.1 mg to about 100 mg ofat least one anti-IL-23p19 antibody composition per ml of solution ormg/gm, or any range, value, or fraction therein. The formulation caninclude agents, such as an excipient, a buffer, an isotonicity agent, apreservative, a surfactant, and, preferably, zinc. The formulation canalso include an excipient or agent for stabilization of the antibodycomposition, such as a buffer, a reducing agent, a bulk protein, or acarbohydrate. Bulk proteins useful in formulating antibody compositionsinclude albumin, protamine, or the like. Typical carbohydrates useful informulating antibody compositions include sucrose, mannitol, lactose,trehalose, glucose, or the like. The antibody composition formulationcan also include a surfactant, which can reduce or preventsurface-induced aggregation of the antibody composition caused byatomization of the solution in forming an aerosol. Various conventionalsurfactants can be employed, such as polyoxyethylene fatty acid estersand alcohols, and polyoxyethylene sorbitol fatty acid esters. Amountswill generally range between 0.001 and 14% by weight of the formulation.Especially preferred surfactants for purposes of this invention arepolyoxyethylene sorbitan monooleate, polysorbate 80, polysorbate 20, orthe like. Additional agents known in the art for formulation of aprotein, such as IL-23p19 antibodies, or specified portions or variants,can also be included in the formulation.

Administration of IL-23p19 Antibody Compositions by a Nebulizer

Antibody compositions of the invention can be administered by anebulizer, such as jet nebulizer or an ultrasonic nebulizer. Typically,in a jet nebulizer, a compressed air source is used to create ahigh-velocity air jet through an orifice. As the gas expands beyond thenozzle, a low-pressure region is created, which draws a solution ofantibody composition through a capillary tube connected to a liquidreservoir. The liquid stream from the capillary tube is sheared intounstable filaments and droplets as it exits the tube, creating theaerosol. A range of configurations, flow rates, and baffle types can beemployed to achieve the desired performance characteristics from a givenjet nebulizer. In an ultrasonic nebulizer, high-frequency electricalenergy is used to create vibrational, mechanical energy, typicallyemploying a piezoelectric transducer. This energy is transmitted to theformulation of antibody composition either directly or through acoupling fluid, creating an aerosol including the antibody composition.Advantageously, particles of antibody composition delivered by anebulizer have a particle size less than about 10 μm, preferably, in therange of about 1 gm to about 5 μm, and, most preferably, about 2 μm toabout 3 μm.

Formulations of at least one anti-IL-23p19 antibody suitable for usewith a nebulizer, either jet or ultrasonic, typically include aconcentration of about 0.1 mg to about 100 mg of at least oneanti-IL-23p19 antibody protein per ml of solution. The formulation caninclude agents, such as an excipient, a buffer, an isotonicity agent, apreservative, a surfactant, and, preferably, zinc. The formulation canalso include an excipient or agent for stabilization of the at least oneanti-IL-23p19 antibody composition, such as a buffer, a reducing agent,a bulk protein, or a carbohydrate. Bulk proteins useful in formulatingat least one anti-IL-23p19 antibody compositions include albumin,protamine, or the like. Typical carbohydrates useful in formulating atleast one anti-IL-23p19 antibody include sucrose, mannitol, lactose,trehalose, glucose, or the like. The at least one anti-IL-23p19 antibodyformulation can also include a surfactant, which can reduce or preventsurface-induced aggregation of the at least one anti-IL-23p19 antibodycaused by atomization of the solution in forming an aerosol. Variousconventional surfactants can be employed, such as polyoxyethylene fattyacid esters and alcohols, and polyoxyethylene sorbital fatty acidesters. Amounts will generally range between about 0.001 and 4% byweight of the formulation. Especially preferred surfactants for purposesof this invention are polyoxyethylene sorbitan mono-oleate, polysorbate80, polysorbate 20, or the like. Additional agents known in the art forformulation of a protein, such as antibody protein, can also be includedin the formulation.

Administration of IL-23p19 Antibody Compositions by a Metered DoseInhaler

In a metered dose inhaler (MDI), a propellant, at least oneanti-IL-23p19 antibody, and any excipients or other additives arecontained in a canister as a mixture including a liquefied compressedgas. Actuation of the metering valve releases the mixture as an aerosol,preferably containing particles in the size range of less than about 10μm, preferably, about 1 gm to about 5 gm, and, most preferably, about 2gm to about 3 μm. The desired aerosol particle size can be obtained byemploying a formulation of antibody composition produced by variousmethods known to those of skill in the art, including jet-milling, spraydrying, critical point condensation, or the like. Preferred metered doseinhalers include those manufactured by 3M or Glaxo and employing ahydrofluorocarbon propellant. Formulations of at least one anti-IL-23p19antibody for use with a metered-dose inhaler device will generallyinclude a finely divided powder containing at least one anti-IL-23p19antibody as a suspension in a non-aqueous medium, for example, suspendedin a propellant with the aid of a surfactant. The propellant can be anyconventional material employed for this purpose, such aschlorofluorocarbon, a hydrochlorofluorocarbon, a hydrofluorocarbon, or ahydrocarbon, including trichlorofluoromethane, dichlorodifluoromethane,dichlorotetrafluoroethanol and 1,1,1,2-tetrafluoro ethane, HFA-134a(hydrofluoroalkane-134a), HFA-227 (hydrofluoroalkane-227), or the like.Preferably, the propellant is a hydrofluorocarbon. The surfactant can bechosen to stabilize the at least one anti-IL-23p19 antibody as asuspension in the propellant, to protect the active agent againstchemical degradation, and the like. Suitable surfactants includesorbitan trioleate, soya lecithin, oleic acid, or the like. In somecases, solution aerosols are preferred using solvents, such as ethanol.Additional agents known in the art for formulation of a protein can alsobe included in the formulation. One of ordinary skill in the art willrecognize that the methods of the current invention can be achieved bypulmonary administration of at least one anti-IL-23p19 antibodycomposition via devices not described herein.

Oral Formulations and Administration

Formulations for oral administration rely on the co-administration ofadjuvants (e.g., resorcinols and nonionic surfactants, such aspolyoxyethylene oleyl ether and n-hexadecylpolyethylene ether) toincrease artificially the permeability of the intestinal walls, as wellas the co-administration of enzymatic inhibitors (e.g., pancreatictrypsin inhibitors, diisopropylfluorophosphate (DFF) and trasylol) toinhibit enzymatic degradation. Formulations for delivery of hydrophilicagents including proteins and antibodies and a combination of at leasttwo surfactants intended for oral, buccal, mucosal, nasal, pulmonary,vaginal transmembrane, or rectal administration are taught in U.S. Pat.No. 6,309,663. The active constituent compound of the solid-type dosageform for oral administration can be mixed with at least one additive,including sucrose, lactose, cellulose, mannitol, trehalose, raffinose,maltitol, dextran, starches, agar, arginates, chitins, chitosans,pectins, gum tragacanth, gum arabic, gelatin, collagen, casein, albumin,synthetic or semisynthetic polymer, and glyceride. These dosage formscan also contain other type(s) of additives, e.g., inactive dilutingagent, lubricant, such as magnesium stearate, paraben, preserving agent,such as sorbic acid, ascorbic acid, .alpha.-tocopherol, antioxidant suchas cysteine, disintegrator, binder, thickener, buffering agent,sweetening agent, flavoring agent, perfuming agent, etc. Tablets andpills can be further processed into enteric-coated preparations. Theliquid preparations for oral administration include emulsion, syrup,elixir, suspension and solution preparations allowable for medical use.These preparations can contain inactive diluting agents ordinarily usedin said field, e.g., water. Liposomes have also been described as drugdelivery systems for insulin and heparin (U.S. Pat. No. 4,239,754). Morerecently, microspheres of artificial polymers of mixed amino acids(proteinoids) have been used to deliver pharmaceuticals (U.S. Pat. No.4,925,673). Furthermore, carrier compounds described in U.S. Pat. No.5,879,681 and U.S. Pat. No. 5,5,871,753 and used to deliver biologicallyactive agents orally are known in the art.

Mucosal Formulations and Administration

A formulation for orally administering a bioactive agent encapsulated inone or more biocompatible polymer or copolymer excipients, preferably, abiodegradable polymer or copolymer, affording microcapsules which due tothe proper size of the resultant microcapsules results in the agentreaching and being taken up by the folliculi lymphatic aggregati,otherwise known as the “Peyer's patch,” or “GALT” of the animal withoutloss of effectiveness due to the agent having passed through thegastrointestinal tract. Similar folliculi lymphatic aggregati can befound in the bronchei tubes (BALT) and the large intestine. Theabove-described tissues are referred to in general as mucosallyassociated lymphoreticular tissues (MALT). For absorption throughmucosal surfaces, compositions and methods of administering at least oneanti-IL-23p19 antibody include an emulsion comprising a plurality ofsubmicron particles, a mucoadhesive macromolecule, a bioactive peptide,and an aqueous continuous phase, which promotes absorption throughmucosal surfaces by achieving mucoadhesion of the emulsion particles(U.S. Pat. No. 5,514,670). Mucous surfaces suitable for application ofthe emulsions of the present invention can include corneal,conjunctival, buccal, sublingual, nasal, vaginal, pulmonary, stomachic,intestinal, and rectal routes of administration. Formulations forvaginal or rectal administration, e.g., suppositories, can contain asexcipients, for example, polyalkyleneglycols, vaseline, cocoa butter,and the like. Formulations for intranasal administration can be solidand contain as excipients, for example, lactose or can be aqueous oroily solutions of nasal drops. For buccal administration, excipientsinclude sugars, calcium stearate, magnesium stearate, pregelinatinedstarch, and the like (U.S. Pat. No. 5,849,695).

Transdermal Formulations and Administration

For transdermal administration, the at least one anti-IL-23p19 antibodyis encapsulated in a delivery device, such as a liposome or polymericnanoparticles, microparticle, microcapsule, or microspheres (referred tocollectively as microparticles unless otherwise stated). A number ofsuitable devices are known, including microparticles made of syntheticpolymers, such as polyhydroxy acids, such as polylactic acid,polyglycolic acid and copolymers thereof, polyorthoesters,polyanhydrides, and polyphosphazenes, and natural polymers, such ascollagen, polyamino acids, albumin and other proteins, alginate andother polysaccharides, and combinations thereof (U.S. Pat. No.5,814,599).

Prolonged Administration and Formulations

It can be desirable to deliver the compounds of the present invention tothe subject over prolonged periods of time, for example, for periods ofone week to one year from a single administration. Various slow release,depot or implant dosage forms can be utilized. For example, a dosageform can contain a pharmaceutically acceptable non-toxic salt of thecompounds that has a low degree of solubility in body fluids, forexample, (a) an acid addition salt with a polybasic acid, such asphosphoric acid, sulfuric acid, citric acid, tartaric acid, tannic acid,pamoic acid, alginic acid, polyglutamic acid, naphthalene mono- ordi-sulfonic acids, polygalacturonic acid, and the like; (b) a salt witha polyvalent metal cation, such as zinc, calcium, bismuth, barium,magnesium, aluminum, copper, cobalt, nickel, cadmium and the like, orwith an organic cation formed from e.g., N,N′-dibenzyl-ethylenediamineor ethylenediamine; or (c) combinations of (a) and (b), e.g., a zinctannate salt. Additionally, the compounds of the present invention or,preferably, a relatively insoluble salt, such as those just described,can be formulated in a gel, for example, an aluminum monostearate gelwith, e.g., sesame oil, suitable for injection. Particularly preferredsalts are zinc salts, zinc tannate salts, pamoate salts, and the like.Another type of slow release depot formulation for injection wouldcontain the compound or salt dispersed for encapsulation in a slowdegrading, non-toxic, non-antigenic polymer, such as a polylacticacid/polyglycolic acid polymer for example as described in U.S. Pat. No.3,773,919. The compounds or, preferably, relatively insoluble salts,such as those described above, can also be formulated in cholesterolmatrix silastic pellets, particularly for use in animals. Additionalslow release, depot or implant formulations, e.g., gas or liquidliposomes, are known in the literature (U.S. Pat. No. 5,770,222 and“Sustained and Controlled Release Drug Delivery Systems”, J. R. Robinsoned., Marcel Dekker, Inc., N.Y., 1978).

Having generally described the invention, the same will be more readilyunderstood by reference to the following examples, which are provided byway of illustration and are not intended as limiting.

EXAMPLES Example 1 Isolation of Human Anti-Human IL-23 SpecificAntibodies by Phage Display

General methods have been described for selection of antigen-specificantibodies from the HuCAL™ libaries prepared at MorphoSys (Knappik etal., 2000; Krebs et al., 2001; Rauchenberger et al, 2003). Vh regionspecific sub-pools of the HuCAL Gold™ Fab library (Kretzschmar & vonRuden, 2002) were used for the selection of antibodies againstrecombinant human IL-23 (hrIL-23). Several different selectionstrategies were used and include:

1. Selection against recombinant hIL-23 protein that was immobilizeddirectly on plastic, with or without preadsorption of the library onrecombinant human IL-12 protein (hrIL-12) also adsorbed directly onplastic. The recombinant hIL-23 and hIL-12 proteins were produced atCentocor.

2. Selection with recombinant human IL-23 protein in solution, followedby recovery of the bound phage by capture of the hIL-23 protein on animmobilized hrIL-12p40 mAb. Selections were carried with or withoutpreadsorption of the library on recombinant hrIL-12 protein capturedwith the same mAb.

3. Selection with chemically biotinylated hrIL-23 protein in solution,followed by capture of the bound phage with SA-coated magnetic beads.Selections were carried out with or without hrIL-12 protein in molarexcess as a competitor.

Recovered phagemid DNA was converted en masse into a Fab expressionvector and individual clones following transformation were screened forbinding to hrIL-23 and not to hrIL-12. Sequencing of the positive clonesidentified 76 unique Fabs.

Example 2 Characterization of Fabs

Positive Fabs were produced and purified as previously described(Knappik et al., 2000; Krebs et al., 2001; Rauchenberger et al, 2003)and confirmed for binding specificity to hrIL-23 but not to hrIL-12 orto the p40 subunit of hrIL-12 (hrp40) in assays similar to thosedescribed in Example 3 below. Confirmed Fabs were tested for (1)inhibition of hrIL-23 binding to human IL-23 receptor (hIL-23R) or tohuman IL-12 receptor β1 (hIL-12Rβ1), (2) lack of inhibition of hrIL-12binding to IL-12RILβ1, (3) inhibition of hrIL-23 binding to TALL-104cells naturally expressing IL-23R and IL-12Rβ1, and (4) binding affinityto hrIL-23, hrIL-12 and hrp40 subunit. The binding specificity andaffinity are summarized in Table 1 and the inhibition of hrIL-23 bindingto hIL-23R is listed in Table 2. Fab12A in Table 1 is a referencestandard that is derived from an IL-12p40 specific mAb. IL-23R-Fc inTable 2 is a reference standard corresponding to the extracellulardomain of human IL-23R fused to a human Fc.

In general, the receptor inhibition assays were similar to thosedescribed below in Example 4 for the mAb derivatives of these Fabs. Oneadditional assay was to measure the inhibition of rhIL-23 binding toTALL 104 cells. These cells express both the human IL-23 and IL-12 Rbeta 1 receptors. 10 of the 13 candidate Fabs had the desired activityprofile of no reactivity with human IL-12 or p40 proteins in any assayand at least partial inhibition of hrIL-23 binding to the IL-23receptor. The CDR sequences of six of the Fabs (4083, 4190, 4205, 4217,4649, and 4658) are shown in Table 4 (bold font). The full V-regionsequences for these Fabs are shown in Table 8.

Production of Fabs in a human IgG1 format

Candidate Fabs were cloned into human IgG1/kappa or lambda mAb formatvectors and produced by transient transfection in HEK293 cells forfurther analysis as mAbs. Overall, eleven of the 13 active Fabs show adesired profile as mAbs. They are specific for IL-23 and at leastpartially inhibited human IL-23 binding to the human IL-23R-Fc fusionprotein (Table 3). The assays and results are cited in the Examples thatfollow.

Example 3 Subunit Specificity of hIL-23p19 mAbs Derived from AntibodyPhage Display

Purified mouse anti-hIL-23 mAbs were evaluated in cytokine capture ELISAto determine their antigen subunit specificity. Briefly, IL-23 mAbs werecoated onto plates and incubated with 100 ng/ml) hrIL-23, hrIL-12, andhrp40, respectively. Following incubation with biotinylated anti-p40mAb, the binding was detected using HRP-conjugated streptavidin. Ananti-p40 mAb and an anti-IL-12 mAb (20C2, Catalog No. 555065, BDPharmingen, San Diego, lif.) with known specificity were used ascontrols.

FIGS. 1A and 1B demonstrate the binding specificity for two of thesemAbs, MOR04083 (same as 4083) and MOR04190 (same as 4190). FIG. 1A showsthat the mAbs bind specifically hrIL-23 and not hrIL-12 or hrp40monomer. Because the IL-23p19 subunit must covalently associate with p40to be secreted from mammalian cells, IL-23 mAbs that do not recognizep40 monomer must bind either the IL-23p19 subunit alone or a jointepitope of the p19-p40 heterodimer. Therefore, these IL-23 mAbs arereferred to as IL-23p19 mAbs. In comparison, all 3 proteins (hrIL-23,hrIL-12 and hrp40) bind to mAb 12A, a neutralizing anti-human p40specific antibody. FIG. 1B shows that the same mAbs do not bind tomurine IL-23 or to murine p40. In a reverse format, the immobilized mAbshave similar binding curves to hrIL-23 in solution (FIG. 2), consistentwith their comparable binding affinity as Fabs (Table 1). The bindingspecificity of these and the other candidate mAbs is summarized in Table3.

Example 4 Inhibition of IL-23 Receptor Binding by IL-23p19 mAbs

To demonstrate that the IL-23p19 mAbs are neutralizing antibodiesagainst the p19 subunit, the mAbs were tested for their inhibition ofIL-23 and IL-23R binding. In this experiment, a human IL-23R-Fc fusionprotein was immobilized on a plate. This fusion protein consists of theextracellular domain of human IL-23 receptor fused to a human Fcsegment. Biotinylated hrIL-23 was added to the plate either alone orafter preincubation with individual IL-23p19 mAbs. Soluble IL-23R(IL-23R-Fc) was used as a positive control. IL-23 binding was detectedwith HRP-conjugated streptavidin. As shown in FIG. 3A, the mAbs MOR04083and MOR04190 prevent IL-23/IL-23R binding with a potency about 3-foldweaker than soluble IL-23R-Fc. There was no inhibition by B21M, a mAbwith unrelated specificity. In contrast, when IL-12Rβ1 was immobilizedon a plate, these mAbs did not inhibit IL-23/IL-12Rβ1 binding (FIG. 3B).IL-23 binding was inhibited by the p40 neutralizing mAb CNTO 1275 (sameas mAb 12A), as expected. Similarly, these mAbs do not blockIL-12/IL-12Rβ1 binding (FIG. 3C). CNTO 1275 again served as a positivecontrol. The selective inhibition of IL-23/IL-23R binding and the lackof interference with IL-12 or IL-23 binding to IL-12Rβ1 furtherdemonstrates that these IL-23p19 mAbs do not bind the p40 subunit andthus are neutralizing anti-human IL-23p19 antibodies. The receptorinhibition studies with these mAbs are summarized in Table 3.

Example 5 Neutralization of IL-23 Biological Function by IL-23p19 mAbs

IL-23 is known to induce intracellular STAT3 phosphorylation and IL-17production by T cells. Therefore, the IL-23p19 mAbs were tested fortheir ability to inhibit these biological functions of human IL-23.

In one experiment, natural killer (NKL) cells were stimulated withhrIL-23 either alone or after preincubation with the MOR04083 andMOR0190 mAbs at 20 ug/ml and 10 ug/ml, respectively. MAb 12A (1 ug/ml)was the positive control and C8.3 (10 ug/ml), a non-neutralizinganti-human p40 mAb, was the negative control. Treated cells were stainedwith fluorochrome-conjugated anti-phospho-STAT3 antibodies and analyzedby intracellular flow cytometry (FIG. 4). These mAbs completely inhibitSTAT3 phosphorylation, albeit with lower potency than the neutralizinganti-p40 mAb 12A. The lower potency of the IL-23p19 mAbs likely reflectstheir relatively weak affinity.

In another experiment, freshly isolated murine splenocytes were treatedwith hrIL-23 preincubated with titrated IL-23p19 mAbs or control mAbs.hrIL-23 with no antibody preincubation was used as the positive control.After 3 days in culture, cell supernatants were collected and assayed byELISA using an IL-17 ELISA duo set (R&D Systems). As shown in FIG. 5A,IL-23p19 mAbs MOR04083 and MOR04190 inhibited hrIL-23 mediated IL-17production. These mAbs also inhibited IL-17 production induced by nativeIL-23 produced by human (FIG. 5B) and cynomologous monkey (FIG. 5C)PBMCs.

In comparison, IL-23p19 mAbs were tested for their ability to inhibithrIL-12 induced IFNγ production. Briefly, NK92MI cells were treated withIL-12 preincubated with titrated IL-23p19 mAbs or control mAbs (FIG. 6).IL-12 with no antibody preincubation was used as the negative controland CNTO 1275 as the positive control. ELISA analysis performed 24 hourspost-stimulation showed no effect of IL-23p19 mAbs MOR04083 and 4190 onIL-12 induced IFNγ production demonstrating that the antibodies do notbind and neutralize the p40 subunit shared by IL-12 and IL-23. Theresults of these assays are summarized in Table 3.

Example 6 Epitope Identification of IL-23p19 mAbs

Competition binding analysis was performed to determine if theneutralizing IL-23p19 mAbs bind to similar or different IL-23p19epitopes. The results for mAbs, MOR04083, MOR04190 and MOR04217, areshown in FIG. 7. IL-23 mAbs were individually coated on ELISA plates.Competing mAbs were added, followed by the addition of biotinylatedhrIL-23. For positive control, the same mAb for coating was used as thecompeting mAb (“self-competition”). IL-23 binding was detected usingstreptavidin. All three mAbs show cross-competition to varying extents,indicating binding to spatially related sites.

Example 7 Affinity Maturation of Candidate Neutralizing Fabs

Fabs MOR04083, 04190, 04649 and 04658 were selected for independentaffinity maturation based on the above characterization in both Fab andmAb formats. Utilizing the cassette feature of the HuCal™ system(Knappik et al., 2000), two variant phage libraries were constructed foreach Fab, one for CDR3 of the light chain variable region (VL) and theother for CDR2 of the heavy chain variable region (VH). These librarieswere selected against biotinylated hrIL-23 in solution under varyingstringencies of wash and antigen concentration. 35 unique Fabs wererecovered, each showing improved binding activity relative to thestarting parental Fab. Subsequently, three additional Fabs (5267, 5268,and 5269; all VL-CDR3 variants of 4083) were selected in a second roundof screening. The CDR sequences of the parental Fabs, the maturedderivatives from the VL-CDR3 or VH-CDR2 libraries, and variants of thosesequences are shown in Tables 4A and B. The complete V-region sequencesare shown in Table 8.

Example 8 Production and Characterization of Affinity Matured Fabs

The 38 selected Fabs were produced, purified and characterizedessentially as described in Examples 2-4 above. Ten of the Fabs gavepoor yields and/or showed heterogeneous patterns in size exclusionchromatography and were excluded from further analysis. The remaining 28Fabs were analyzed for specificity of binding, affinity, and inhibitionof receptor binding. All of the Fabs were specific for IL-23p19 and had10-500 fold higher affinities for hrIL-23 than the correspondingparental Fab (Tables 5 and 6). All showed improved IC50 values forinhibition of hrIL-23 binding to the IL-23R Fc fusion protein and, likethe parental Fabs, did not inhibit either IL-23 or IL-12 binding toIL-12Rb1 receptor Fc fusion protein (Tables 5 and 6). As expected fromthese results, none of the Fabs inhibited hrIL-23 binding to TALL-104cells as measured by flow cyotometry, consistent with the similar lackof inhibition by the parental Fabs.

Example 9 Production and Characterization of the Affinity Matured Abs ina mAb Format

34 of the 35 selected Fabs were cloned into human IgG1/kappa or lambdamAb format vectors and produced as mAbs by transient transfection inHEK293 cells for further analysis. All the antibodies were evaluated forinhibition of IL-17 production as described in Example 5, above (Table7). In most cases, each of the matured derivatives was more potent thanits corresponding parent, with improvements in IC50 up to 200 fold. Thebiochemical properties of the 34 mAbs were evaluated by SDS-PAGE andsize exclusion chromatography for indications of aggregation, chainheterogeneity, and incomplete disulfide bond formation between the heavyand light chains and in the hinge region.

From the combined activity and biochemical analysis, 7 mAbs wereselected for more detailed analysis, at least one from each originalparental antibody. Antibodies MOR05058 and 05059, derived from the VLCDR3 diversity libraries of MOR04649, were excluded from this set (seeExamples 10 and 11). All selected candidates inhibited IL-17 productioninduced by native IL-23 from human (FIG. 8) and cynomologous monkeyPBMCs (not shown). As expected, all inhibited hrIL-23 binding tohrIL-23R Fc fusion protein with a potency greater than that of thecontrol mAb IL-23A (FIG. 9). With the possible exception of MOR05053,these selected mAbs did not inhibit native IL-12 bioactivity (notshown), consistent with the lack of binding of those available as Fabsto hrIL-12 protein.

Example 10 Production and Characterization of Cross-Chain CombinationmAbs

The parent Fabs MOR04190, 04649, and 4658 gave rise to improved Fabsfrom both the VH CDR2 and VL CDR3 diversity libraries. The Fabs derivedfrom MOR04649 were of particular interest due to their relatively potentactivity from both types of libraries. However, the parental MOR04649Fabcontains a predicted, but potentially unfavorable, N-linkedglycosylation site in VH CDR2 that is not present in any of the 6improved Fabs derived from the VH CDR2 library. To eliminate thisglycosylation site and test for potential improved activity, the heavychains of MOR05042 and 05045 were expressed with the light chains ofMOR05058 and 5059 in HEK293 cells (Table 4C—mAbs 42-58, 42-59, 45-58,and 45-59). None of the combinations were more potent antagonists (IL-17production and inhibition IL-23 binding to IL-23R) than the respectivedonor chain mAbs and each showed a greater tendency towards aggregationby size exclusion chromatography (not shown).

Example 11 Substitution Mutagenesis of Selected Matured mAbs and TheirCharacterization

Amino acid substitutions were introduced into selected mAbs to eliminatethe predicted N-linked glycosylation site and/or conform the aminotermini of variable regions with their closest predicted human germlineV-region sequence. The predicted N-linked glycosylation site in the Vhof 5058 and 5059 (“NYS” in CDR2, same as in the parent Vh of MOR04649)was eliminated by substitution of arginine (4649r) or aspartic acid(4649d) for asparagine at position 59 (direct numbering). The CDRsequences of these VH regions are shown in Table 4A and the fullV-region sequences are given in Table 8. These variants were produced bytransient expression in HEK 293 cells and purified by Protein A affinitychromatography. These mAbs showed improved potency relative to theparental antibodies in their inhibition of IL-17 production. Thearginine substitution in MOR05059 had the best profile based on activityand biochemical characterization and was named mAb 3759 Table 4C).

MAbs5040 and 3759 were selected as the top leads based on theiractivities and biochemical characterization. Amino acid substitutionswere introduced for conformity with human germline antibody sequence anda single amino acid substitution was made in the =5040 VL region torevert a framework mutation back to germline, substituting a valine forthreonine at position 86.

The amino acid sequences changed from the original mAb format were asfollows:

Antibody VH VL 5040 E(3) to Q D(1) to E, T(86) to V 3759 Q(1)E(3) to EQD(1)I(2) to QS

The E3 to Q change in VH of both antibodies is reversion of an Esubstitution introduced upon cloning of the Fab into the mAb formatvector. Q was present at this position in the original Fabs and can beused as a variant to the E substitution in various mAbs.

These variants are designated 5040^(Q/EV) and 3759^(EQ/QS). Thecomponent V-regions of 5040^(Q/EV) are 5040 VH and 4190^(EV) VL (Table4C). The component V-regions of 3759^(EQ/QS) are 4649r^(E) VH and5059^(QS) VL (Table 4C). The sequences of the CDRs and full V-regions ofthe component chains of both antibodies are shown in Tables 4 and 8,respectively. Similar substitutions can be identified for any of thecandidates by comparison to their predicted human germline sequences.

The mAbs 5040^(Q/EV) and 3759^(EQ/QS) were produced by transientexpression in HEK 293 cells and purified by Protein A affinitychromatography. These mAbs retain complete specificity for human IL-23relative to IL-12 and p40, as shown in FIG. 10. These mAbs inhibit thebinding of recombinant human IL-23 to IL-23R-Fc and are more potent thanthe reference, mAb23A (FIG. 11A). As expected from their specificityprofile, they do not inhibit IL-23 (FIG. 11B) or IL-12 (FIG. 11C)binding to IL-12Rβ1. Consistent with this pattern of receptorinhibition, these mAbs do not inhibit IL-12 induced IFNγ production fromNK92M1 cells (FIG. 12), but do inhibit both recombinant (FIG. 13) andnative (FIG. 14) IL-23 induced production of IL-17 from murinesplenocytes. These mAbs also show very strong inhibition of IL-17induction by native IL-23 from cynomologous monkey (FIG. 15),demonstrating a high degree of cross-reactivity with IL-23 fromcynomologous monkey. These mAbs also inhibited STAT3 phosphorylationinduced in human NK cells by recombinant human IL-23 (not shown).

The mAbs 5040^(Q/EV) and 3759^(EQ/QS) recognize closely positionedepitopes on IL-23 as demonstrated by their inhibition of mAB23A binding(FIG. 16A) and their reciprocal competition with each other (FIGS. 16Band 16C). The epitope of mAb23A has been mapped on human p19 in theregion around 193-G105:

I₉₃HQGLIFYEKLLG₁₀₅(SEQ ID NO:148).

The competition results show that epitopes for mAbs 5040^(Q/EV) and3759^(EQ/QS) lie in the same region.

Example 12 Coding Sequence Variants of mAbs 5040^(Q/EV) and 3759^(EQ/QS)and their Characterization

The coding sequence of the variable regions of the antibodies wereengineered into three different coding sequence variants to evaluate theimpact on expression of these proteins. The first variant used thecodons as obtained from the original library , with a few nucleotidesubstitutions to remove consensus mRNA splice sites. The second variant,germline codon exchange (GCE), was designed by aligning the variableregion amino acid sequences to germline genes, identifying the closestmatching germline gene and replacing the codons in the original codingsequence with the synonomous codons that are used in the germline gene.At positions where the amino acid residue did not have a match togermline genes, the codon that is used at the highest frequency inhighly expressed human proteins was substituted for the original codon.The third codon variant was designed by replacing the starting antibodycodons with the codon that is used at the highest frequency in highlyexpressed human proteins. Each codon variant did express as measured bytransient transfection in HEK 293 cells and CHO cells. This result showsthat stable cell line tranfectants can be established in these, andlikely other host cells and the highest expressing variant can be usedfor development of a production cell line. The mAbs are evaluated asdescribed in Example 11, in addition to other functional and biochemicaland biophysical properties analyses. Table 9 shows the variable heavyand light chain nucleotide sequences for the 5040^(Q/EV) and3759^(EQ/QS) mAb variants.

For the purposes of this invention, 70-100% amino acid or nucleotidesequence identity (i.e., 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 orany range or value therein) is determined using a suitable computeralgorithm, as known in the art.

It will be clear that the invention can be practiced otherwise than asparticularly described in the foregoing description and examples.Numerous modifications and variations of the present invention arepossible in light of the above teachings and, therefore, are within thescope of the appended claims.

TABLE 1 Binding Specificity of Candidate Fabs Biacore (Fab SpecificityELISA: Antigens in capture mode) solution to immobilized Fabs K_(D)[nM]IL-23 IL-23 IL-12 IL-12 p40 IL-23 IL-12 MOR0# CNTO R&D CNTO R&D R&D CNTOCNTO 4083 + nd − nd nd 16 no binding 4086 + nd − nd nd 36 no binding; n:3 4185 + nd − nd nd 79 no binding 4190 + nd − nd nd 11 no binding4205 + + − − − 140 slight binding* 4217 + − − − 41 slight binding*4235 + − − − 65 slight binding* 4491 + − − − 190 no binding 4647 + − − −12 4649 + + − − − 7 4651 + + − − 160 no binding 4655 + 66 no binding4658 + + − − − 11 no binding Fab12A + + + + + 1.1 0.6

TABLE 2 IC50 of Candidate Fabs in hrIL-23/hIL-23R Assay MOR0# IC50 [nM]4083 4.6 +/− 3.9 4086 no complete inhibition 4185 280 4190 4.8 +/− 2  4205 38 4217 16 4235 190 4491 10 ~50% inhibition 4647 2.1 4649 0.2 +/−0.2 4651 36 4655 286 4658 0.7 IL-23R-Fc 1.8 +/− 1.8

TABLE 3 Characterization of the Parental Antibodies in a mAb Format.pSTAT3 IL-12 Biochemical receptor Assay bioassay in IL-23 induced IL-17production assay IL-23 binding binding assays Results at NK92MI Nativehuman Native cyno mAb hrIL-23 subunit IL-12/ IL-23/ IL-23/ noted IFNg inhrIL-17 IL-23 IL-23 MOR# specificity IL-12Rb1 IL-12Rb1 IL-23Rconcentration NK92MI cells neutralization neutralization neutralization4083 (κ) p19 − − + +/− at 10 − + + + + at 20 4190 (κ) p19 − − + + at 10− + + + 4649 (λ) p19 − − + +/− at 1 − + + + + at 10 4658 (λ) p19 − − +/−−/+ at 10 − −/+ + + 4205 p19 − − −/+ + at 10 N/d − N/d N/d 4217 p19 − −−/+ − at 10 N/d −/+ N/d N/d 4185 p19 − − −/+ − at 7 N/d − N/d N/d 4235p19 − − −/+ − at 10 N/d − N/d N/d 4090 p19 − − −  N/d N/d − N/d N/d 4647p19 − − +/− − at 10 − − N/d N/d 4491 p19 − − +/− − at 10 − − N/d N/d4651 p19 − − +/− − at 10 − − N/d N/d 4085  p19* − − − − at 3 − − N/d N/d4086  p19* − − − − at 5 N/d   +*** N/d N/d 4655  p19* − − − − at 10 −  +*** N/d N/d 4193 IL-12/IL-23p40 − − −/+ − at 6 + + N/d N/d 4201IL-12/IL-23p40 −  +, −/+  N/d + + N/d N/d no titration 4704IL-12/IL-23p40  −/+** −/+ −/+ + at 10 + + N/d N/d Symbol Description −No inhibition −/+ Slight Inhibiiton +/− Weak, incomplete inhibition +Inhibition * Did not bind to linked rhIL-23 with no His-tag (from R&DSystems) ** Better inhibits R&D IL-12, than CNTO IL-12 *** Caused celldeath at high concentration N/d Not done

TABLE 4A Hc V-region CDR sequences of candidate antibodies H-CDR1 H-CDR3Clone # VH (SEQ ID NO:) H-CDR2 (SEQ ID NO:) (SEQ ID NO:) Comments 40831A NYAIS (1) GIIPMFGYANYAQKFQG DIYAGMD Primary hit (7) V (40) 5028GIIPVFGFTHYAQKFQG Affinity (8) maturation 4190 1A SNYIS (2)GIIPIFGHANYAQKFQG SKKGMYG Primary hit (9) GWTYPLM MFDL (41) 5033IIIPPIGNAWYAQKFQG Affinity (10) maturation 5034 LIDPNFGGAYYAQKFQGAffinity (11) maturation 5036 LIDPVFGGAYYAQKFQG Affinity (12) maturation5037 LIDPMFGGAYYAQKFQG Affinity (13) maturation 5038 -INAHLGGTWYAQKFQGAffinity (14) maturation 5040 ISPGTGINAYYAQKFQG Affinity (15) maturation4190x Z₁Z₂Z₃Z₄Z₅Z₆Z₇Z₈Z₉Z₁₀YAQK Predicted FQG!! (16) 4205 5 NYWIS (3)WIRPGDSDTRYSPSFEG HYYGMDY Primary hit (17) (42) 4217 3 1.1.1.1.1 sVSYISSSGSSTYYADSVKG GTFWSFG Primary hit  ywit (18) NYFAN (4) (43) 4649 5NYWIG (5) IIDPSNSYTNYSPSFQG WYYKPFD Primary hit (19) V (44) 4649rIIDPSNSYTRYSPSFQG Δ (20) glycosylation site 4649r^(E) IIDPSNSYTRYSPSFQGPlus E1 substitutions 4649d IIDPSNSYTDYSPSFQG Δ (21) glycosylation site5041 IISPTGSVTWYSPSFQG Affinity (22) maturation 5042 IISPTGSSTWYSPSFQGAffinity (23) maturation 5043 FISPDGSHTWYSPSFQG Affinity (24 maturation5044 IISPSGSTTWYSPSFQG Affinity (25) maturation 5045 IISPTGSATWYSPSFQGAffinity (26) maturation 5046 IIDPVSSWTKYSPSFQG Affinity (27) maturation4649x IIX₁PX₂X₃SX₄TX₅YSPSFQG** predicted (28) 4658 3 SFGMS (6)NISSSGSS--TYYADSVKG YWGTPYL Primary hit (29) MQFDN (45) 5039NIEHKYLNYATYYAASVKG Affinity (30) maturation 5047 NIEHKYLGYATSYAASVKGAffinity (146) maturation 5048 NIEHKFMGYTTYYAAGVKG Affinity (31)maturation 5049 GIEHKYLSYTTHYAASVKG Affinity (32) maturation 5050SIEHKYTGYTTYYAAPVKG Affinity (33) maturation 5051 QIEHKYLSYTTLYAASVKGAffinity (34) maturation 5052 SIEHKYLSYTTFYAASVKG Affinity (35)maturation 5053 NIEGKYTSYTTYYAASVKG Affinity (36) maturation 5054GIEHKYLSYATLYAASVKG Affinity (37) maturation 5055 NIEHKYLGYATVYAASVKGAffinity (38) maturation 5056 SIEHKYLSYATYYAAGVKG Affinity (39)maturation All antibodies expressed as Fabs have Q at residue 3 in Vh,whereas when expressed as mAbs, most had E at residue 3. **X₁ is D or S;X₂ is S, V, D, or T; X₃ is N, S, or G; X₄ is Y, W, T, H, V, S, or A; X₅is N, D, R, K, or W !!Z₁ is G, I, or L; Z₂ is I or S; Z₃ is I, P, N, orD; Z₄ is P, G, or A; Z₅ is I, M, P, T, H, N, or V; Z₆ is F, I, G, or L;Z₇ G or I; Z₈ is H, Y, N, or G; Z₉ is A or T; Z₁₀ is N, W, or Y ++a₁ isS or A; a₂ is T or G; a₃ is P or L; a₄ is S or N; a₅ is S, M, or L; a₆is I or V ##b₁ is T, F, D, or S; b₂ is S, I, A, T, R, or L; b₃ is N, T,L, S, or G; b₄ is T, Y, S, or I; b₅ is P or L; b₆ is F or P

TABLE 4B Lc V-region CDR sequences of candidate antibodies L-CDR1 L-CDR2 L-CDR3 Clone # VL (SEQ ID NO:) (SEQ ID NO:) (SEQ ID NO:) Comments4083 κ3 RASQSVLGNY GASSRAT HQYGSISTT (58) Primary hit LA (46) (52) 5267QQYSHLLIT (59) Affinity maturation 5268 QQYSHISLT (60)  Affinitymaturation 5269 QQFAHILLT (61) Affinity maturation 4190 κ3 RASQSVSSNYYASRRAT QQTSNTPFT (62) Primary hit LA (47) (53) 4190^(EV) QQTSNTPFTPlus E1 & V86 substitutions 5029 QQFITYLPT (63) Affinity maturation 5030QQDALSPFT (64) Affinity maturation 5031 QQDRGTPFT (65) Affinitymaturation 5032 QQSLNIPFT (66) Affinity maturation 5057 QQDTSSPFT (67)Affinity maturation 4190x QQb₁b₂b₃b₄b₅b₆FT## Predicted (68) 4205 λ1SGSSSNIGSY GNTHRPS QTYASLGPGEV (69) Primary Hit YVN (48) (54) 4217 κ1RASQSIFYNL GASNRAT QQYSSEPVT (70) Primary Hit A (49) (55) 4649 λ1TGSSSNIGSG GNSKRPS SSWT--PSSVV (71) Primary hit YDVH (50) (56) 5058SSWTDTPNMIV Affinity (72) maturation 5059 ASWTDGLSLVV Affinity (73)maturation 5059^(QS) ASWTDGLSLVV Plus Q1, S2 substitutions 4649xa₁SWTDa₂a₃a₄a₅a₆V++ Predicted (74) 4658 λ2 TGTSSDVGGY SVSSRPSSSYDTNKPLVV (75) Primary hit NSVS (51) (57) 5060 GSYDVYGRFYV (76)Affinity maturation 5061 SSYYFYLQRIV (77) Affinity maturation 5062QTYYFSYSGPV (78) Affinity maturation 5063 GSWDPIFSYEV (79) Affinitymaturation

TABLE 4C Antibodies produced, purified and evaluated Ab Name VH VLFab*^(#) MAb* Comments 4083 4083 4083 x x 5028 5028 4083 x x 5267** 40835267 x (in progress) 5268** 4083 5268 x (in progress) 5269** 4083 5269 x(in progress) 4190 4190 4190 x x 5033 5033 4190 x 5034 5034 4190 x x5036 5036 4190 x x 5037 5037 4190 x 5038 5038 4190 x x 5040 5040 4190 x5040^(Q/EV) 5040 4190^(EV) x Vh-Q3 back substitution in mAb 5029** 41905029 x 5030** 4190 5030 x 5031** 4190 5031 x 5032** 4190 5032 x 5057**4190 5057 x 4205 4205 4205 x x 4217 4217 4217 x x 4649 4649 4649 x x5041 5041 4649 x x 5042 5042 4649 x x 42-58 5042 5058 x Pair 5058 VLwith VH lacking CDR2 glycosylation site 42-59 5042 5059 x Pair 5059 VLwith VH lacking CDR2 glycosylation site 5043 5043 4649 x x 5044 50444649 x x 5045 5045 4649 x x 45-58 5045 5058 x Pair 5058 VL with VHlacking CDR2 glycosylation site 45-59 5045 5059 x Pair 5059 VL with VHlacking CDR2 glycosylation site 5046 5046 4649 x x 5058 4649 5058 x x5059 4649 5058 x x 3758 4649r 5058 x 3759 4649r 5059 x 3759^(EQ/QS)4649r^(E) 5059^(QS) x Vh-Q3 substitution in mAb 3658 4649d 5058 x 36594649d 5059 x 4658 4658 4658 x x 5039 5039 4658 x x 5047 5047 4658 x x5048 5048 4658 x x 5049 5049 4658 x x 5050 5050 4658 x x 5051 5051 4658x 5052 5052 4658 x x 5053 5053 4658 x x 5054 5054 4658 x 5055 5055 4658x x 5056 5056 4658 x x 5060 4658 5060 x x 5061 4658 5061 x x 5062 46585062 x x 5063 4658 5063 x x *Except as indicated in the “comments” box,position 3 in the heavy chain was Q in the Fabs and E in the mAbs. **Theaffinity matured kappa light chains of 4083 and 4190 contain a T to Vsubstitution relative to the parents in FW3 (FAVYYC). V is a germlineresidue at this position. ^(#)Several Fabs listed as “affinity matured”showed some aggregation during purification and thus were not evaluated.They were previously evaluated as hits as crude samples.

TABLE 5 Characterization of Affinity-Matured Fabs: specificity, receptorneutralization, and affinity. IL-23/ IL-23R IL-12 K_(D) [pM] IC₅₀ [nM]IL-23/ (R&D)/ Specificity FACS MOR0# Library SET (n: 1) (n: 1 −4) IL-12R^(b)1 IL-12R ^(b)1 ELISA (TALL −104) 4083 — 1600 7.1 ± 8.3 O.K. O.K.O.K. — 5028 H-CDR2 133 0.43 ± 0.58 O.K. O.K. O.K. — 5267 L-CDR3 2000 0.14 O.K. O.K. n.d. n.d. 5268 660  0.15 O.K. O.K. n.d. n.d. 5269 9600.2 O.K. O.K. n.d. n.d. 4190 — 4400 1.3 ± 1.5 O.K. O.K. O.K. — 5034H-CDR2 126  0.4 ± 0.15 O.K. O.K. O.K. — 5036 32 0.32 ± 0.02 O.K. O.K.O.K. — 5038 38 0.17 ± 0.05 O.K. O.K. O.K. — 4649 — 1100 1.2 O.K. O.K.O.K. — 5041 H-CDR2 41 0.07 ± 0.04 O.K. O.K. O.K. — 5042 4 0.06 ± 0.03O.K. O.K. O.K. — 5043 18 0.05 ± 0.03 O.K. O.K. O.K. — 5044 43 0.05 ±0.04 O.K. O.K. O.K. — 5045 9 0.05 ± 0.02 O.K. O.K. O.K. — 5046 23 0.08 ±0.01 O.K. O.K. O.K. — 5058 L-CDR3 33 0.11 ± 0.08 O.K. O.K. O.K. — 505993 0.69 ± 0.72 O.K. O.K. O.K. —

TABLE 6 Characterization of Affinity-Matured Fabs: specificity, receptorneutralization, and affinity. IL-23/ IL-23R IL-12 K_(D) [pM] IC₅₀ [nM]IL-23/ (R&D)/ Specificity FACS MOR0# Library SET (n: 1) (n: 1 −4) IL-12R^(b)1 IL-12R ^(b)1 ELISA (TALL −104) 4658 — 4300 14 O.K. O.K. O.K. —5039 H-CDR2 27  0.1 ± 0.09 O.K. O.K. O.K. — 5047 36 0.13 ± 0.1  O.K.O.K. O.K. — 5048 20 0.1 ± 0.1 O.K. O.K. O.K. — 5049 7 0.39 ± 0.62 O.K.O.K. O.K. — 5050 23 0.89 ± 1.15 O.K. O.K. O.K. — 5052 10 0.58 ± 0.74O.K. O.K. O.K. — 5053 27 0.98 ± 1.3  O.K. O.K. O.K. — 5055 29 0.79 ±1.0  O.K. O.K. O.K. — 5056 65 0.52 ± 0.68 O.K. O.K. O.K. — 5060 L-CDR3142  1.0 ± 1.14 O.K. O.K. O.K. — 5061 58 1.25 ± 1.49 O.K. O.K. O.K. —5062 98 1.34 ± 1.5  O.K. O.K. O.K. — 5063 69 0.32 ± 0.25 O.K. O.K. O.K.—

TABLE 7 Characterization of Affinity-Matured Antibodies in mAb Format:Inhibition of IL-17 production. Inhibition of hrIL-23 binding toimmobilized IL-23R-Fc fusion protein. IC₅₀ values from titration curves.The mAbs (see Table 4C) are listed in order of decreasing potency. Thematured antibodies are grouped according to their respective parents:pink (5028 is from 4083); (5040, 5038, 5029, 5030, 5057, 5036, 5032,5034, 5033, and 5037 are with 4190); (5042, 5045, 5058, 5041, 5059,5044, 5043, 5046, and 4083 are with 4649); (5054, 5053, 5049, 5048,5052, 5047, 5050, 5051, 5055, 5056, 5039, 5063, 5062, and 5061 are with4658). MAb 23A is a reference murine anti-human IL-23 mAb mAb IC50,ug/ml 5042 0.00127 5045 0.001396 5040 0.002641 5058 0.002847 50410.003007 5054 0.003227 5053 0.00493 5059 0.01062 5044 0.01414 50430.01439 5049 0.01616 5048 0.01624 5052 0.0178 5047 0.02342 5050 0.027665038 0.02815 5046 0.04281 5029 0.04907 mAb23A 0.05415 5030 0.06458 50510.0663 5055 0.09155 5056 0.09198 5028 0.1039 5057 0.1103 5039 0.16065036 0.1702 5032 0.1716 5034 0.1854 5063 0.1981 5062 0.1989 5031 0.21494190 0.218 4649 0.2758 5033 0.2834 5061 0.3087 5037 0.3364 4083 1.3954658 1.956

TABLE 8Sequences of initial IL-23p19 mAbs and their matured and engineered derivatives.MOR04083 Family              (SEQ ID NOS: 80 & 81)             1                                                                   1174083 Vh  (1)         QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYAISWVRQAPGQGLEWMGGIIPMFGYANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDIYAGMDVWGQGTLVTVSS 5028 Vh  (1)         QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYAISWVRQAPGQGLEWMGGIIPvFGfthYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDIYAGMDVWGQGTLVTVSS              (SEQ ID NOS: 82-85)             1                                                                   1084083 Vk  (1)          DIVLTQSPATLSLSPGERATLSCRASQSVLGNYLAWYQQKPGQAPRLLIYGASSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYGSISTTFGQGTKVEIK 5268 Vk  (1)         DIVLTQSPATLSLSPGERATLSCRASQSVLGNYLAWYQQKPGQAPRLLIYGASSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCqQYshISLTFGQGTKVEIK 5267 Vk  (1)         DIVLTQSPATLSLSPGERATLSCRASQSVLGNYLAWYQQKPGQAPRLLIYGASSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCqQYshliITFGQGTKVEIK 5269 Vk  (1)         DIVLTQSPATLSLSPGERATLSCRASQSVLGNYLAWYQQKPGQAPRLLIYGASSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCqQfahIllTFGQGTKVEIK MOR04190 Family             (SEQ ID NOS: 86-92)             1                                                                     1274190 Vh  (1)         QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSNYISWVRQAPGQGLEWMGGIIPIFGHANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSKKGMYGGWTYPLMMFDLWGQGTLVTVSS 5033 Vh  (1)         QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSNYISWVRQAPGQGLEWMGiIIPpiGnAwYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSKKGMYGGWTYPLMMFDLWGQGTLVTVSS 5040 Vh  (1)         QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSNYISWVRQAPGQGLEWMGispgtginAyYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSKKGMYGGWTYPLMMFDLWGQGTLVTVSS 5038 Vh  (1)          QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSNYISWVRQAPGQGLEWMG-InahlGgtwYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSKKGMYGGWTYPLMMFDLWGQGTLVTVSS5034 Vh  (1)         QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSNYISWVRQAPGQGLEWMGlIdPnFGgAyYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSKKGMYGGWTYPLMMFDLWGQGTLVTVSS 5036 Vh  (1)         QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSNYISWVRQAPGQGLEWMGlIdPvFGgAyYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSKKGMYGGWTYPLMMFDLWGQGTLVTVSS 5037 Vh  (1)         QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSNYISWVRQAPGQGLEWMGlIdPmFGgAyYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSKKGMYGGWTYPLMMFDLWGQGTLVTVSS           (SEQ ID NOS: 93-98)             1                                                             1084190 Vk  (1)         DIVLTQSPATLSTSPGERATLSCRASQSVSSNYLAWYQQKPGQAPRLLIYYASRRATGVPARFSGSGSGTDFTLTISSLEPEDFATYYCQQTSNTPFTFGQGTKVEIK 4190^(EV)Vk (1)         EIVLTQSPATLSTSPGERATLSCRASQSVSSNYLAWYQQKPGQAPRLLIYYASRRATGVPARFSGSGSGTDFTLTISSLEPEDFAvYYCQQTSNTPFTFGQGTKVEIK 5029 Vk  (1)         DIVLTQSPATLSLSPGERATLSCRASQSVSSNYLAWYQQKPGQAPRLLIYYASRRATGVPARFSGSGSGTDFTLTISSLEPEDFAvYYCQQfitylpTFGQGTKVEIK 5030 Vk  (1)         DIVLTQSPATLSLSPGERATLSCRASQSVSSNYLAWYQQKPGQAPRLLIYYASRRATGVPARFSGSGSGTDFTLTISSLEPEDFAvYYCQQdalsPFTFGQGTKVEIK 5031 Vk  (1)         DIVLTQSPATLSLSPGERATLSCRASQSVSSNYLAWYQQKPGQAPRLLIYYASRRATGVPARFSGSGSGTDFTLTISSLEPEDFAvYYCQQdrgTPFTFGQGTKVEIK 5032 Vk  (1)         DIVLTQSPATLSTSPGERATLSCRASQSVSSNYLAWYQQKPGQAPRLLIYYASRRATGVPARFSGSGSGTDFTLTISSLEPEDFAvYYCQQslNiPFTFGQGTKVEIK MOR04205              (SEQ ID NO: 99)             1                                                              1164205 Vh  (1)         QVQLVQSGAEVKKPGESLKISCKGSGYSFTNYWISWVRQAPGKGLEWMGWIRPGDSDTRYSPSFEGQVTISADKSISTAYLQWSSLKASDTAMYYCARHYYGMDYWGQGTLVTVSS              (SEQ ID NO: 100)             1                                                               1104205 V1  (1)         DIVLTQPPSVSGAPGQRVTISCSGSSSNIGSYYVNWYQQLPGTAPKLLIYGNTHRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCQTYASLGPGEVFGGGTKLTVL MOR04217              (SEQ ID NO: 101)             1                                                                1214217 Vh  (1)         QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWITWVRQAPGKGLEWVSYISSSGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGTFWSFGNYFANWGQGTLVTVSS              (SEQ ID NO: 102)             1                                                                 1074217 Vk  (1)         DIVLTQSPATLSLSPGERATLSCRASQSIFYNLAWYQQKPGQAPRLLIYGASNRATGVPARFSGSGSGTDFTLTISSLEPEDFATYYCQQYSSEPVTFGQGTKVEIK MOR04649 Family             (SEQ ID NOS: 103-112)             1                                                         *       1174649 Vh  (1)         QVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRQMPGKGLEWMGIIDPSNSYTNYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARWYYKPFDVWGQGTLVTVSS 4649d Vh (1)         QVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRQMPGKGLEWMGIIDPSNSYTdYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARWYYKPFDVWGQGTLVTVSS 4649r Vh (1)         QVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRQMPGKGLEWMGIIDPSNSYTrYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARWYYKPFDVWGQGTLVTVSS 4649r^(E) Vh (1)         eVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRQMPGKGLEWMGIIDPSNSYTrYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARWYYKPFDVWGQGTLVTVSS 5046 Vh  (1)         QVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRQMPGKGLEWMGIIDPvsSwTkYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARWYYKPFDVWGQGTLVTVSS 5044 Vh  (1)         QVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRQMPGKGLEWMGIIsPSgStTwYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARWYYKPFDVWGQGTLVTVSS 5043 Vh  (1)         QVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRQMPGKGLEWMGfIsPdgShTwYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARWYYKPFDVWGQGTLVTVSS 5041 Vh  (1)         QVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRQMPGKGLEWMGIIsPtgSvTwYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARWYYKPFDVWGQGTLVTVSS 5042 Vh  (1)         QVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRQMPGKGLEWMGIIsPtgSsTwYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARWYYKPFDVWGQGTLVTVSS 5045 Vh  (1)         QVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRQMPGKGLEWMGIIsPtgSaTwYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARWYYKPFDVWGQGTLVTVSS             (SEQ ID NOS: 113-116)             1                                                                 1114649 VL  (1)         DIVLTQPPSVSGAPGQRVTISCTGSSSNIGSGYDVHWYQQLPGTAPKLLIYGNSKRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCSSWT--PSSVVFGGGTKLTVL 5058 VL  (1)         DIVLTQPPSVSGAPGQRVTISCTGSSSNIGSGYDVHWYQQLPGTAPKLLIYGNSKRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCSSWTdtPnmiVFGGGTKLTVL 5059 VL  (1)         DIVLTQPPSVSGAPGQRVTISCTGSSSNIGSGYDVHWYQQLPGTAPKLLIYGNSKRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCaSWTdglSlVVFGGGTKLTVL 5059^(QS)VL  (1)         qsVLTQPPSVSGAPGQRVTISCTGSSSNIGSGYDVHWYQQLPGTAPKLLIYGNSKRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCaSWTdglSlVVFGGGTKLTVL MOR04658 Family             (SEQ ID NOS: 117-127)             1                                                              1234658 Vh (1)  QVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSNISSS--GSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYWGTPYLMQFDNWGQGTLVTVSS5048 Vh  (1)         QVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSNIehkfmGytTYYAagVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYWGTPYLMQFDNWGQGTLVTVSS 5050 Vh  (1)         QVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSsIehkytGytTYYAapVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYWGTPYLMQFDNWGQGTLVTVSS 5053 Vh  (1)         QVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSNIehkytsytTYYAaSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYWGTPYLMQFDNWGQGTLVTVSS 5039 Vh  (1)         QVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSNIehkylnyaTYYAaSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYWGTPYLMQFDNWGQGTLVTVSS 5055 Vh  (1)         QVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSNIehkylGyaTvYAaSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYWGTPYLMQFDNWGQGTLVTVSS 5056 Vh  (1)         QVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSsIehkylsyaTYYAagVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYWGTPYLMQFDNWGQGTLVTVSS 5052 Vh  (1)         QVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSsIehkylsytTfYAaSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYWGTPYLMQFDNWGQGTLVTVSS 5049 Vh  (1)         QVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSgIehkylsytThYAaSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYWGTPYLMQFDNWGQGTLVTVSS 5051 Vh (1)         QVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSqIehkylsytTlYAaSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYWGTPYLMQFDNWGQGTLVTVSS 5054 Vh  (1)         QVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSgIehkylsyaTlYAaSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYWGTPYLMQFDNWGQGTLVTVSS            (SEQ ID NO: 147) 5047 Vh   (1)QVQLVESGGGLVQPGGSLRLSCAASGFTFSSFGMSWVRQAPGKGLEWVSNIehkylGyaTsYAaSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYWGTPYLMQFDNWGQGTLVTVSS             (SEQ ID NOS: 128-132)             1                                                           1114658 VL  (1)         DIALTQPASVSGSPGQSITISCTGTSSDVGGYNSVSWYQQHPGKAPKLMIYSVSSRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYDTNKPLVVFGGGTKLTVL 5061 VL  (1)         DIALTQPASVSGSPGQSITISCTGTSSDVGGYNSVSWYQQHPGKAPKLMIYSVSSRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYyfylqriVEGGGIKLTVL 5062 VL  (1)         DIALTQPASVSGSPGQSITISCTGTSSDVGGYNSVSWYQQHPGKAPKLMIYSVSSRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCqtYyfsysgpVFGGGTKLTVL 5060 VL  (1)         DIALTQPASVSGSPGQSITISCTGTSSDVGGYNSVSWYQQHPGKAPKLMIYSVSSRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCgSYDvygrfyVFGGGTKLTVL 5063 VL  (1)         DIALTQPASVSGSPGQSITISCTGTSSDVGGYNSVSWYQQHPGKAPKLMIYSVSSRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCgSwDpifsyeVFGGGTKLTVL *Consensus N-linked glycosylation sitein 4649 Vh

TABLE 9 Nucleotide Sequences IL-23 p19 5040^(Q/EV)  VH-GCE (SEQ ID NO: 133): (VH amino acid sequence is 5040Vh) Q  V   Q L   V  Q  S   G  A  E   V  K  K  P   G  S  S •   1CAGGTGCAGC TGGTGCAGTC TGGGGCTGAG GTGAAGAAGC CTGGGTCCTCGTCCACGTCG ACCACGTCAG ACCCCGACTC CACTTCTTCG GACCCAGGAG                                                  CDR1                                            ~~~~~~~~~~~ •V  K  V   S  C  K  A   S  G  G   T  F  S   S  N  Y  I •  51GGTGAAGGTC TCCTGCAAGG CTTCTGGAGG CACCTTCAGC AGCAACTACACCACTTCCAG AGGACGTTCC GAAGACCTCC GTGGAAGTCG TCGTTGATGT ~~~~~                                             ~~~ • S  W  V   R  Q  A   P  G  Q  G   L  E  W   M  G  I 101TCAGCTGGGT GCGACAGGCC CCTGGACAAG GGCTTGAGTG GATGGGGATCAGTCGACCCA CGCTGTCCGG GGACCTGTTC CCGAACTCAC CTACCCCTAG                   CDR2~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ S  P  G  T   G  I  N   A  Y  Y   A  Q  K  F   Q  G  R • 151AGCCCTGGCA CCGGTATCAA CGCATACTAC GCACAGAAGT TCCAGGGCAGTCGGGACCGT GGCCATAGTT GCGTATGATG CGTGTCTTCA AGGTCCCGTC •V  T  I   T  A  D  E   S  T  S   T  A  Y   M  E  L  S • 201AGTCACGATT ACCGCGGACG AATCCACGAG CACAGCCTAC ATGGAGCTGATCAGTGCTAA TGGCGCCTGC TTAGGTGCTC GTGTCGGATG TACCTCGACT                                                 CDR3                                                ~~~~~~ • S  L  R   S  E  D   T  A  V  Y   Y  C  A   R  S  K 251GCAGCCTGAG ATCTGAGGAC ACGGCCGTGT ATTACTGTGC GAGAAGCAAGCGTCGGACTC TAGACTCCTG TGCCGGCACA TAATGACACG CTCTTCGTTC                      CDR3~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ K  G  M  Y   G  G  W   T  Y  P   L  M  M  F   D  L  W • 301AAGGGCATGT ACGGCGGCTG GACCTACCCC CTGATGATGT TCGACCTGTGTTCCCGTACA TGCCGCCGAC CTGGATGGGG GACTACTACA AGCTGGACAC •G  Q  G   T  L  V  T   V  S  S 351 GGGCCAGGGC ACCCTGGTGA CCGTGAGCAG CCCCGGTCCCG TGGGACCACT GGCACTCGTC G IL-23 p19 5040^(Q/EV)  VH-HCO (SEQ ID NO: 134): (VH amino acid sequence is 5040Vh) Q  V  Q  L   V  Q  S   G  A  E   V  K  K  P   G  S  S •   1CAGGTGCAGC TGGTGCAGAG CGGCGCCGAG GTGAAGAAGC CCGGCAGCAGGTCCACGTCG ACCACGTCTC GCCGCGGCTC CACTTCTTCG GGCCGTCGTC                                                CDR1                                              ~~~~~~~~~~~ •V  K  V   S  C  K  A   S  G  G   T  F  S   S  N  Y  I •  51CGTGAAGGTG AGCTGCAAGG CCAGCGGCGG CACCTTCAGC AGCAACTACAGCACTTCCAC TCGACGTTCC GGTCGCCGCC GTGGAAGTCG TCGTTGATGT ~~~~~                                             ~~~ • S  W  V   R  Q  A   P  G  Q  G   L  E  W   M  G  I 101TCAGCTGGGT GCGCCAGGCC CCCGGCCAGG GCCTGGAGTG GATGGGCATCAGTCGACCCA CGCGGTCCGG GGGCCGGTCC CGGACCTCAC CTACCCGTAG              CDR2~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ S  P  G  T   G  I  N   A  Y  Y   A  Q  K  F   Q  G  R • 151AGCCCCGGCA CCGGCATCAA CGCCTACTAC GCCCAGAAGT TCCAGGGCCGTCGGGGCCGT GGCCGTAGTT GCGGATGATG CGGGTCTTCA AGGTCCCGGC •V  T  I   T  A  D  E   S  T  S   T  A  Y   M  E  L  S • 201CGTGACCATC ACCGCCGACG AGAGCACCAG CACCGCCTAC ATGGAGCTGAGCACTGGTAG TGGCGGCTGC TCTCGTGGTC GTGGCGGATG TACCTCGACT                                                ~~~~~~ • S  L  R   S  E  D   T  A  V  Y   Y  C  A   R  S  K 251GCAGCCTGCG CAGCGAGGAC ACCGCCGTGT ACTACTGCGC CCGCAGCAAGCGTCGGACGC GTCGCTCCTG TGGCGGCACA TGATGACGCG GGCGTCGTTC                      CDR3~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ K  G  M  Y   G  G  W   T  Y  P   L  M  M  F   D  L  W • 301AAGGGCATGT ACGGCGGCTG GACCTACCCC CTGATGATGT TCGACCTGTGTTCCCGTACA TGCCGCCGAC CTGGATGGGG GACTACTACA AGCTGGACAC •G  Q  G   T  L  V  T   V  S  S 351 GGGCCAGGGC ACCCTGGTGA CCGTGAGCAG CCCCGGTCCCG TGGGACCACT GGCACTCGTC G IL-23 p19 5040^(Q/EV)   VH-MOR (SEQ ID NO: 135): (VH amino acid sequence is 5040Vh) Q  V  Q  L   V  Q  S   G  A  E   V  K  K  P   G  S  S •   1CAGGTGCAAT TGGTTCAGTC TGGCGCGGAA GTGAAAAAAC CGGGCAGCAGGTCCACGTTA ACCAAGTCAG ACCGCGCCTT CACTTTTTTG GCCCGTCGTC                                                CDR1                                              ~~~~~~~~~~~ •V  K  V   S  C  K  A   S   G G   T  F  S   S  N  Y  I •  51CGTGAAAGTG AGCTGCAAAG CCTCCGGAGG CACTTTTTCT TCTAATTATAGCACTTTCAC TCGACGTTTC GGAGGCCTCC GTGAAAAAGA AGATTAATAT ~~~~~                                             ~~~ • S  W  V   R  Q  A   P  G  Q  G   L  E  W   M  G  I 101TTTCTTGGGT GCGCCAAGCC CCTGGGCAGG GTCTCGAGTG GATGGGCATTAAAGAACCCA CGCGGTTCGG GGACCCGTCC CAGAGCTCAC CTACCCGTAA              CDR2~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ S  P  G  T   G  I  N   A  Y  Y   A  Q  K  F   Q  G  R • 151TCTCCTGGTA CTGGTATTAA TGCTTATTAT GCTCAGAAGT TTCAGGGTCGAGAGGACCAT GACCATAATT ACGAATAATA CGAGTCTTCA AAGTCCCAGC •V  T  I   T  A  D  E   S  T  S   T  A  Y   M  E  L  S • 201GGTGACCATT ACCGCGGATG AAAGCACCAG CACCGCGTAT ATGGAACTGACCACTGGTAA TGGCGCCTAC TTTCGTGGTC GTGGCGCATA TACCTTGACT                                                ~~~~~~ • S  L  R   S  E  D   T  A  V  Y   Y  C  A   R  S  K 251GCAGCCTGCG TAGCGAAGAT ACGGCCGTGT ATTATTGCGC GCGTTCTAAGCGTCGGACGC ATCGCTTCTA TGCCGGCACA TAATAACGCG CGCAAGATTC                      CDR3~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ K  G  M  Y   G  G  W   T  Y  P   L  M  M  F   D  L  W • 301AAGGGTATGT ATGGTGGTTG GACTTATCCT CTTATGATGT TTGATCTTTGTTCCCATACA TACCACCAAC CTGAATAGGA GAATACTACA AACTAGAAAC •G  Q  G   T  L  V  T   V  S  S 351 GGGCCAAGGC ACCCTGGTGA CGGTTAGCTC ACCCGGTTCCG TGGGACCACT GCCAATCGAG T IL-23 p19 5040^(Q/EV)  VK-HCO (SEQ ID NO: 136): (VK amino acid sequence is 4190^(EV)) E  I  V  L   T  Q  S   P  A  T   L  S  L  S   P  G  E •   1GAGATCGTGC TGACCCAGAG CCCCGCCACC CTGAGCCTGA GCCCCGGCGACTCTAGCACG ACTGGGTCTC GGGGCGGTGG GACTCGGACT CGGGGCCGCT                                 CDR1                    ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ •R  A  T   L  S  C  R   A  S  Q   S  V  S   S  N  Y  L •  51GCGCGCCACC CTGAGCTGCC GCGCCAGCCA GAGCGTGAGC AGCAACTACCCGCGCGGTGG GACTCGACGG CGCGGTCGGT CTCGCACTCG TCGTTGATGG ~~~~~ • A  W  Y   Q  Q  K   P  G  Q  A   P  R  L   L  I  Y 101TGGCCTGGTA CCAGCAGAAG CCCGGCCAGG CCCCCCGCCT GCTGATCTACACCGGACCAT GGTCGTCTTC GGGCCGGTCC GGGGGGCGGA CGACTAGATG         CDR2~~~~~~~~~~~~~~~~~~~~~~~ Y  A  S  R   R  A  T   G  V  P   A  R  F  S   G  S  G • 151TACGCCAGCC GCCGCGCCAC CGGCGTGCCC GCCCGCTTCA GCGGCAGCGGATGCGGTCGG CGGCGCGGTG GCCGCACGGG CGGGCGAAGT CGCCGTCGCC •S  G  T   D  F  T  L   T  I  S   S  L  E   P  E  D  F • 201CAGCGGCACC GACTTCACCC TGACCATCAG CAGCCTGGAG CCCGAGGACTGTCGCCGTGG CTGAAGTGGG ACTGGTAGTC GTCGGACCTC GGGCTCCTGA                             CDR3                  ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ • A  V  Y   Y  C  Q   Q  T  S  N   T  P  F   T  F  G 251TCGCCGTGTA CTACTGCCAG CAGACCAGCA ACACCCCCTT CACCTTCGGCAGCGGCACAT GATGACGGTC GTCTGGTCGT TGTGGGGGAA GTGGAAGCCG Q  G  T  K   V  E  I   K 301 CAGGGCACCA AGGTGGAGAT CAAGGTCCCGTGGT TCCACCTCTA GTTC IL-23 p19 5040^(Q/EV)  VK-HCO (SEQ ID NO: 137): (VK amino acid sequence is 4190^(EV)) E  I  V  L   T  Q  S   P  A  T   L  S  L  S   P  G  E •   1GAAATTGTGT TGACACAGTC TCCAGCCACC CTGTCTTTGT CTCCAGGGGACTTTAACACA ACTGTGTCAG AGGTCGGTGG GACAGAAACA GAGGTCCCCT                                 CDR1                    ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ •R  A  T   L  S  C  R   A  S  Q   S  V  S   S  N  Y  L •  51AAGAGCCACC CTCTCCTGCA GGGCCAGTCA GAGTGTTAGC AGCAACTACTTTCTCGGTGG GAGAGGACGT CCCGGTCAGT CTCACAATCG TCGTTGATGA ~~~~~ • A  W  Y   Q  Q  K   P  G  Q  A   P  R  L   L  I  Y 101TAGCCTGGTA CCAACAGAAA CCTGGCCAGG CTCCCAGGCT CCTCATCTATATCGGACCAT GGTTGTCTTT GGACCGGTCC GAGGGTCCGA GGAGTAGATA         CDR2~~~~~~~~~~~~~~~~~~~~~~~ Y  A  S  R   R  A  T   G  V  P   A  R  F  S   G  S  G • 151TACGCATCCC GCAGGGCCAC TGGCGTGCCA GCCAGGTTCA GTGGCAGTGGATGCGTAGGG CGTCCCGGTG ACCGCACGGT CGGTCCAAGT CACCGTCACC •S  G  T   D  F  T  L   T  I  S   S  L  E   P  E  D  F • 201GTCTGGGACA GACTTCACTC TCACCATCAG CAGCCTAGAG CCTGAAGATTCAGACCCTGT CTGAAGTGAG AGTGGTAGTC GTCGGATCTC GGACTTCTAA                             CDR3                  ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ • A  V  Y   Y  C  Q   Q  T  S  N   T  P  F   T  F  G 251TTGCAGTTTA TTACTGTCAG CAGACTTCTA ATACTCCTTT TACCTTTGGCAACGTCAAAT AATGACAGTC GTCTGAAGAT TATGAGGAAA ATGGAAACCG Q  G  T  K   V  E  I   K 301 CAGGGTACGA AAGTTGAAAT TAAAGTCCCATGCT TTCAACTTTA ATTT IL-23 p19 5040^(Q/EV)  VK-HCO (SEQ ID NO: 138): (VK amino acid sequence is 4190^(EV)) E  I  V  L   T  Q  S   P  A  T   L  S  L  S   P  G  E •   1GAGATCGTGC TGACCCAGAG CCCGGCGACC CTGAGCCTGT CTCCGGGCGACTCTAGCACG ACTGGGTCTC GGGCCGCTGG GACTCGGACA GAGGCCCGCT                                 CDR1                    ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ •R  A  T   L  S  C  R   A  S  Q   S  V  S   S  N  Y  L •  51ACGTGCGACC CTGAGCTGCA GAGCGAGCCA GTCTGTTTCT TCTAATTATCTGCACGCTGG GACTCGACGT CTCGCTCGGT CAGACAAAGA AGATTAATAG ~~~~~ • A  W  Y   Q  Q  K   P  G  Q  A   P  R  L   L  I  Y 101TGGCTTGGTA CCAGCAGAAA CCAGGTCAAG CACCGCGTCT ATTAATTTATACCGAACCAT GGTCGTCTTT GGTCCAGTTC GTGGCGCAGA TAATTAAATA         CDR2~~~~~~~~~~~~~~~~~~~~~~~ Y  A  S  R   R  A  T   G  V  P   A  R  F  S   G  S  G • 151TATGCTTCTC GTCGTGCAAC TGGGGTCCCG GCGCGTTTTA GCGGCTCTGGATACGAAGAG CAGCACGTTG ACCCCAGGGC CGCGCAAAAT CGCCGAGACC •S  G  T   D  F  T  L   T  I  S   S  L  E   P  E  D  F • 201ATCCGGCACG GATTTTACCC TGACCATTAG CAGCCTGGAA CCTGAAGACTTAGGCCGTGC CTAAAATGGG ACTGGTAATC GTCGGACCTT GGACTTCTGA                             CDR3                  ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ • A  V  Y   Y  C  Q   Q  T  S  N   T  P  F   T  F  G 251TTGCGGTGTA TTATTGCCAG CAGACTTCTA ATACTCCTTT TACCTTTGGCAACGCCACAT AATAACGGTC GTCTGAAGAT TATGAGGAAA ATGGAAACCG Q  G  T  K   V  E  I   K 301 CAGGGTACGA AAGTTGAAAT TAAAGTCCCATGCT TTCAACTTTA ATTT IL-23 p19 3759^(EQ/QS)  VH-GCE (SEQ ID NO: 139): (VH amino acid sequence is 4649r^(E)) E  V  Q  L   V  Q  S   G  A  E   V  K  K  P   G  E  S •   1GAGGTGCAGC TGGTGCAGTC TGGAGCAGAG GTGAAAAAGC CCGGGGAGTCCTCCACGTCG ACCACGTCAG ACCTCGTCTC CACTTTTTCG GGCCCCTCAG                                                  CDR1                                            ~~~~~~~~~~~ •L  K  I   S  C  K  G   S  G  Y   S  F  S   N  Y  W  I •  51TCTGAAGATC TCCTGTAAGG GTTCTGGATA CAGCTTTAGC AACTACTGGAAGACTTCTAG AGGACATTCC CAAGACCTAT GTCGAAATCG TTGATGACCT ~~~~~                                             ~~~ • G  W  V   R  Q  M   P  G  K  G   L  E  W   M  G  I 101TCGGCTGGGT GCGCCAGATG CCCGGGAAAG GCCTGGAGTG GATGGGGATCAGCCGACCCA CGCGGTCTAC GGGCCCTTTC CGGACCTCAC CTACCCCTAG                      CDR2~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ I  D  P  S   N  S  Y   T  R  Y   S  P  S  F   Q  G  Q • 151ATCGACCCTA GCAACTCTTA CACCAGATAC AGCCCGTCCT TCCAAGGCCATAGCTGGGAT CGTTGAGAAT GTGGTCTATG TCGGGCAGGA AGGTTCCGGT •V  T  I   S  A  D  K   S  I  S   T  A  Y   L  Q  W  S • 201GGTCACCATC TCAGCCGACA AGTCCATCAG CACCGCCTAC CTGCAGTGGACCAGTGGTAG AGTCGGCTGT TCAGGTAGTC GTGGCGGATG GACGTCACCT                                                ~~~~~~ • S  L  K   A  S  D   T  A  M  Y   Y  C  A   R  W  Y 251GCAGCCTGAA GGCCTCGGAC ACCGCCATGT ATTACTGTGC GAGATGGTACCGTCGGACTT CCGGAGCCTG TGGCGGTACA TAATGACACG CTCTACCATG        CDR3~~~~~~~~~~~~~~~~~~~ Y  K  P  F   D  V  W   G  Q  G   T  L  V  T   V  S  S • 301TACAAGCCCT TCGACGTGTG GGGCCAGGGC ACCCTGGTGA CCGTGAGCAGATGTTCGGGA AGCTGCACAC CCCGGTCCCG TGGGACCACT GGCACTCGTC • S 351 C GIL-23 p19 3759^(EQ/QS)  VH-HCO (SEQ ID NO: 140): (VH amino acid sequence is 4649r^(E)) E  V  Q  L   V  Q  S   G  A  E   V  K  K  P   G  E  S •   1GAGGTGCAGC TGGTGCAGAG CGGCGCCGAG GTGAAGAAGC CCGGCGAGAGCTCCACGTCG ACCACGTCTC GCCGCGGCTC CACTTCTTCG GGCCGCTCTC                                                  CDR1                                            ~~~~~~~~~~~ •L  K  I   S  C  K  G   S  G  Y   S  F  S   N  Y  W  I •  51CCTGAAGATC AGCTGCAAGG GCAGCGGCTA CAGCTTCAGC AACTACTGGAGGACTTCTAG TCGACGTTCC CGTCGCCGAT GTCGAAGTCG TTGATGACCT ~~~~~                                             ~~~ • G  W  V   R  Q  M   P  G  K  G   L  E  W   M  G  I 101TCGGCTGGGT GCGCCAGATG CCCGGCAAGG GCCTGGAGTG GATGGGCATCAGCCGACCCA CGCGGTCTAC GGGCCGTTCC CGGACCTCAC CTACCCGTAG                      CDR2~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ I  D  P  S   N  S  Y   T  R  Y   S  P  S  F   Q  G  Q • 151ATCGACCCCA GCAACAGCTA CACCCGCTAC AGCCCCAGCT TCCAGGGCCATAGCTGGGGT CGTTGTCGAT GTGGGCGATG TCGGGGTCGA AGGTCCCGGT •V  T  I   S  A  D  K   S  I  S   T  A  Y   L  Q  W  S • 201GGTGACCATC AGCGCCGACA AGAGCATCAG CACCGCCTAC CTGCAGTGGACCACTGGTAG TCGCGGCTGT TCTCGTAGTC GTGGCGGATG GACGTCACCT                                                ~~~~~~ • S  L  K   A  S  D   T  A  M  Y   Y  C  A   R  W  Y 251GCAGCCTGAA GGCCAGCGAC ACCGCCATGT ACTACTGCGC CCGCTGGTACCGTCGGACTT CCGGTCGCTG TGGCGGTACA TGATGACGCG GGCGACCATG        CDR3~~~~~~~~~~~~~~~~~~~ Y  K  P  F   D  V  W   G  Q  G   T  L  V  T   V  S  S • 301TACAAGCCCT TCGACGTGTG GGGCCAGGGC ACCCTGGTGA CCGTGAGCAGATGTTCGGGA AGCTGCACAC CCCGGTCCCG TGGGACCACT GGCACTCGTC • S 351 C GIL-23 p19 3759^(EQ/QS)  VH-MOR (SEQ ID NO: 141): (VH amino acid sequence is 4649r^(E)) E  V  Q  L   V  Q  S   G  A  E   V  K  K  P   G  E  S •   1GAGGTGCAAT TGGTTCAGAG CGGCGCGGAA GTGAAAAAAC CGGGCGAAAGCTCCACGTTA ACCAAGTCTC GCCGCGCCTT CACTTTTTTG GCCCGCTTTC                                                CDR1                                            ~~~~~~~~~~~ •L  K  I   S  C  K  G   S  G  Y   S  F  S   N  Y  W  I •  51CCTGAAAATT AGCTGCAAAG GTTCCGGATA TTCCTTTTCT AATTATTGGAGGACTTTTAA TCGACGTTTC CAAGGCCTAT AAGGAAAAGA TTAATAACCT ~~~~~                                             ~~~ • G  W  V   R  Q  M   P  G  K  G   L  E  W   M  G  I 101TTGGTTGGGT GCGCCAGATG CCTGGGAAGG GTCTCGAGTG GATGGGCATTAACCAACCCA CGCGGTCTAC GGACCCTTCC CAGAGCTCAC CTACCCGTAA            CDR2~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ I  D  P  S   N  S  Y   T  R  Y   S  P  S  F   Q  G  Q • 151ATCGATCCGT CTAATAGCTA TACCCGCTAT TCTCCGAGCT TTCAGGGCCATAGCTAGGCA GATTATCGAT ATGGGCGATA AGAGGCTCGA AAGTCCCGGT •V  T  I   S  A  D  K   S  I  S   T  A  Y   L  Q  W  S • 201GGTGACCATT AGCGCGGATA AAAGCATTAG CACCGCGTAT CTTCAATGGACCACTGGTAA TCGCGCCTAT TTTCGTAATC GTGGCGCATA GAAGTTACCT                                                ~~~~~~ • S  L  K   A  S  D   T  A  M  Y   Y  C  A   R  W  Y 251GCAGCCTGAA AGCGAGCGAT ACGGCCATGT ATTATTGCGC GCGTTGGTATCGTCGGACTT TCGCTCGCTA TGCCGGTACA TAATAACGCG CGCAACCATA        CDR3~~~~~~~~~~~~~~~~~~~ Y  K  P  F   D  V  W   G  Q  G   T  L  V  T   V  S  S • 301TATAAGCCTT TTGATGTTTG GGGCCAAGGC ACCCTGGTGA CGGTTAGCTCATATTCGGAA AACTACAAAC CCCGGTTCCG TGGGACCACT GCCAATCGAG • S 351 A TIL-23 p19 3759^(EQ/QS)  VL-GCE (SEQ ID NO: 142): (VL amino acid sequence is 5059^(QS)) Q  S  V  L   T  Q  P   P  S  V   S  G  A  P   G  Q  R •   1CAGTCTGTGC TGACGCAGCC GCCCTCAGTG TCTGGGGCCC CAGGGCAGAGGTCAGACACG ACTGCGTCGG CGGGAGTCAC AGACCCCGGG GTCCCGTCTC                                   CDR1                 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ •V  T  I   S  C  T  G   S  S  S   N  I  G   S  G  Y  D •  51GGTCACCATC TCCTGCACTG GGAGCAGCTC CAACATCGGG AGCGGTTATGCCAGTGGTAG AGGACGTGAC CCTCGTCGAG GTTGTAGCCC TCGCCAATAC ~~~~~~~~ • V  H  W   Y  Q  Q   L  P  G  T   A  P  K   L  L  I 101ATGTACACTG GTACCAGCAG CTTCCAGGAA CAGCCCCCAA ACTCCTCATCTACATGTGAC CATGGTCGTC GAAGGTCCTT GTCGGGGGTT TGAGGAGTAG              CDR2   ~~~~~~~~~~~~~~~~~~~~~~~ Y  G  N  S   K  R  P   S  G  V   P  D  R  F   S  G  S • 151TATGGTAACA GCAAGCGGCC CTCAGGGGTC CCTGACCGAT TCTCTGGCTCATACCATTGT CGTTCGCCGG GAGTCCCCAG GGACTGGCTA AGAGACCGAG •K  S  G   T  S  A  S   L  A  I   T  G  L   Q  S  E  D • 201CAAGTCTGGC ACCTCAGCCT CCCTGGCCAT CACTGGGCTC CAGAGCGAGGGTTCAGACCG TGGAGTCGGA GGGACCGGTA GTGACCCGAG GTCTCGCTCC                                       CDR3                      ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ • E  A  D   Y  Y  C   A  S  W  T   D  G  L   S  L  V 251ATGAGGCTGA TTATTACTGC GCCAGCTGGA CCGACGGCCT GAGCCTGGTGTACTCCGACT AATAATGACG CGGTCGACCT GGCTGCCGGA CTCGGACCAC ~~~ V  F  G  G   G  T  K   L  T  V   L  G 301GTGTTCGGCG GCGGCACCAA GCTGACCGTG CTGGGCCACAAGCCGC CGCCGTGGTT CGACTGGCAC GACCCG IL-23 p19 3759^(EQ/QS)  VL-HCO (SEQ ID NO: 143): (VL amino acid sequence is 5059^(QS)) Q  S  V  L   T  Q  P   P  S  V   S  G  A  P   G  Q  R •   1CAGAGCGTGC TGACCCAGCC CCCCAGCGTG AGCGGCGCCC CCGGCCAGCGGTCTCGCACG ACTGGGTCGG GGGGTCGCAC TCGCCGCGGG GGCCGGTCGC                                    CDR1               ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ •V  T  I   S  C  T  G   S  S  S   N  I  G   S  G  Y  D •  51CGTGACCATC AGCTGCACCG GCAGCAGCAG CAACATCGGC AGCGGCTACGGCACTGGTAG TCGACGTGGC CGTCGTCGTC GTTGTAGCCG TCGCCGATGC ~~~~~~~~ • V  H  W   Y  Q  Q   L  P  G  T   A  P  K   L  L  I 101ACGTGCACTG GTACCAGCAG CTGCCCGGCA CCGCCCCCAA GCTGCTGATCTGCACGTGAC CATGGTCGTC GACGGGCCGT GGCGGGGGTT CGACGACTAG             CDR2   ~~~~~~~~~~~~~~~~~~~~~~~ Y  G  N  S   K  R  P   S  G  V   P  D  R  F   S  G  S • 151TACGGCAACA GCAAGCGCCC CAGCGGCGTG CCCGACCGCT TCAGCGGCAGATGCCGTTGT CGTTCGCGGG GTCGCCGCAC GGGCTGGCGA AGTCGCCGTC •K  S  G   T  S  A  S   L  A  I   T  G  L   Q  S  E  D • 201CAAGAGCGGC ACCAGCGCCA GCCTGGCCAT CACCGGCCTC CAGAGCGAGGGTTCTCGCCG TGGTCGCGGT CGGACCGGTA GTGGCCGGAG GTCTCGCTCC                                       CDR3                      ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ • E  A  D   Y  Y  C   A  S  W  T   D  G  L   S  L  V 251ACGAGGCCGA CTACTACTGT GCCAGCTGGA CCGACGGCCT GAGCCTGGTGTGCTCCGGCT GATGATGACA CGGTCGACCT GGCTGCCGGA CTCGGACCAC ~~~ V  F  G  G   G  T  K   L  T  V   L  G 301GTGTTCGGCG GCGGCACCAA GCTGACCGTG CTGGGCCACAAGCCGC CGCCGTGGTT CGACTGGCAC GACCCG IL-23 p19 3759^(EQ/QS)   VL-MOR (SEQ ID NO: 144): (VL amino acid sequence is 5059^(QS)) Q  S  V  L   T  Q  P   P  S  V   S  G  A  P   G  Q  R •   1CAGAGCGTGC TGACCCAGCC GCCTTCAGTG AGTGGCGCAC CAGGTCAGCGGTCTCGCACG ACTGGGTCGG CGGAAGTCAC TCACCGCGTG GTCCAGTCGC                                    CDR1                 ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ •V  T  I   S  C  T  G   S  S  S   N  I  G   S  G  Y  D •  51TGTGACCATC TCGTGTACGG GCAGCAGCAG CAACATTGGT TCTGGTTATGACACTGGTAG AGCACATGCC CGTCGTCGTC GTTGTAACCA AGACCAATAC ~~~~~~~~ • V  H  W   Y  Q  Q   L  P  G  T   A  P  K   L  L  I 101ATGTGCATTG GTACCAGCAG TTGCCCGGGA CGGCGCCGAA ACTTCTGATTTACACGTAAC CATGGTCGTC AACGGGCCCT GCCGCGGCTT TGAAGACTAA              CDR2   ~~~~~~~~~~~~~~~~~~~~~~~ Y  G  N  S   K  R  P   S  G  V   P  D  R  F   S  G  S • 151TATGGTAATT CTAAGCGTCC CTCAGGCGTG CCGGATCGTT TTAGCGGATCATACCATTAA GATTCGCAGG GAGTCCGCAC GGCCTAGCAA AATCGCCTAG •K  S  G   T  S  A  S   L  A  I   T  G  L   Q  S  E  D • 201CAAAAGCGGC ACCAGCGCGA GCCTTGCGAT TACGGGCCTG CAAAGCGAAGGTTTTCGCCG TGGTCGCGCT CGGAACGCTA ATGCCCGGAC GTTTCGCTTC                                      CDR3                      ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ • E  A  D   Y  Y  C   A  S  W  T   D  G  L   S  L  V 251ACGAAGCGGA TTATTATTGC GCTTCTTGGA CTGATGGTCT TTCTCTTGTTTGCTTCGCCT AATAATAACG CGAAGAACCT GACTACCAGA AAGAGAACAA ~~~ V  F  G  G   G  T  K   L  T  V   L  G 301GTGTTTGGCG GCGGCACGAA GTTAACCGTT CTTGGCCACAAACCGC CGCCGTGCTT CAATTGGCAA GAACCG

TABLE 10 SEQ ID NO: 145 (human IL-23p19 subunit)Met Leu Gly Ser Arg Ala Val Met Leu Leu Leu Leu Leu Pro Trp Thr1               5                  10                  15Ala Gln Gly Arg Ala Val Pro Gly Gly Ser Ser Pro Ala Trp Thr Gln            20                  25                  30Cys Gln Gln Leu Ser Gln Lys Leu Cys Thr Leu Ala Trp Ser Ala His        35                  40                  45Pro Leu Val Gly His Met Asp Leu Arg Glu Glu Gly Asp Glu Glu Thr    50                  55                  60Thr Asn Asp Val Pro His Ile Gln Cys Gly Asp Gly Cys Asp Pro Gln65                  70                  75                  80Gly Leu Arg Asp Asn Ser Gln Phe Cys Leu Gln Arg Ile His Gln Gly                85                  90                  95Leu Ile Phe Tyr Glu Lys Leu Leu Gly Ser Asp Ile Phe Thr Gly Glu            100                 105                 110Pro Ser Leu Leu Pro Asp Ser Pro Val Ala Gln Leu His Ala Ser Leu        115                 120                 125Leu Gly Leu Ser Gln Leu Leu Gln Pro Glu Gly His His Trp Glu Thr    130                 135                 140Gln Gln Ile Pro Ser Leu Ser Pro Ser Gln Pro Trp Gln Arg Leu Leu145                 150                 155                 160Leu Arg Phe Lys Ile Leu Arg Ser Leu Gln Ala Phe Val Ala Val Ala                165                 170                 175Ala Arg Val Phe Ala His Gly Ala Ala Thr Leu Ser Pro            180                 185

1. An isolated nucleic acid molecule encoding an IL-23p19 antibody,comprising a light chain variable region nucleotide sequence and a heavychain variable region nucleotide sequence, said light chain variableregion nucleotide sequence encoding: a complementarity determiningregion light chain 1 (CDRL1) amino acid sequence of SEQ ID NO:50; aCDRL2 amino acid sequence of SEQ ID NO:56; and a CDRL3 amino acidsequence of SEQ ID NO:73, said heavy chain variable region nucleotidesequence encoding: a complementarity determining region heavy chain(CDRH1) amino acid sequence of SEQ ID NO:5; a CDRH2 amino acid sequenceof SEQ ID NO:20; and a CDRH3 amino acid sequence of SEQ ID NO:44.
 2. Anisolated nucleic acid vector comprising the nucleic acid moleculeaccording to claim
 1. 3. An isolated host cell comprising the isolatednucleic acid molecule according to claim 1, wherein the host cell isprokaryotic or eukaryotic.
 4. The host cell according to claim 3,wherein said host cell is at least one selected from COS-1, COS-7,HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, P3X63Ag8.653,and SP2/0-Ag14, myeloma, and lymphoma cells.
 5. A method for producingan IL-23p19 antibody, comprising culturing the isolated host cell ofclaim 3 under conditions such that the IL-23p19 antibody is expressedand recovered.
 6. An isolated nucleic acid molecule encoding an IL-23p19antibody, comprising a light chain variable region nucleotide sequenceand a heavy chain variable region nucleotide sequence, said light chainvariable region nucleotide sequence encoding a light chain variableregion amino acid sequence of SEQ ID NO:116 and said heavy chainvariable region nucleotide sequence encoding a heavy chain variableregion amino acid sequence of SEQ ID NO:106.
 7. An isolated nucleic acidvector comprising one or both of (i) a variable region nucleotidesequence encoding a light chain variable region amino acid sequence ofSEQ ID NO:116 and (ii) a variable region nucleotide sequence encoding aheavy chain variable region amino acid sequence of SEQ ID NO:106.
 8. Anisolated host cell comprising the isolated nucleic acid moleculeaccording to claim 6, wherein the host cell is prokaryotic oreukaryotic.
 9. The host cell according to claim 8, wherein said hostcell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO,BSC-1, Hep G2, 653, SP2/0, 293, HeLa, P3X63Ag8.653, SP2/0-Ag14, myeloma,and lymphoma cells.
 10. A method for producing an IL-23p19 antibody,comprising culturing the isolated host cell of claim 8 under conditionssuch that the IL-23p19 antibody is expressed and recovered.
 11. Anisolated nucleic acid molecule encoding an IL-23p19 antibody, comprisinga light chain variable region nucleotide sequence selected from thegroup consisting of SEQ ID NOS: 142-144 and a heavy chain variableregion nucleotide sequence selected from the group consisting of SEQ IDNOS: 139-141.
 12. An isolated nucleic acid vector comprising one or bothof (i) a light chain variable region nucleotide sequence selected fromthe group consisting of SEQ ID NOS: 142-144 and (ii) a heavy chainvariable region nucleotide sequence selected from the group consistingof SEQ ID NOS: 139-141.
 13. An isolated host cell comprising theisolated nucleic acid molecule according to claim 11, wherein the hostcell is prokaryotic or eukaryotic.
 14. The host cell according to claim13, wherein said host cell is at least one selected from COS-1, COS-7,HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, P3X63Ag8.653,SP2/0-Ag14, myeloma, and lymphoma cells.
 15. A method for producing anIL-23p19 antibody, comprising culturing the isolated host cell of claim13 under conditions such that the IL-23p19 antibody is expressed andrecovered.
 16. An isolated nucleic acid vector composition comprising afirst isolated vector comprising a nucleotide sequence encoding: acomplementarity determining region light chain 1 (CDRL1) amino acidsequence of SEQ ID NO:50; a CDRL2 amino acid sequence of SEQ ID NO:56;and a CDRL3 amino acid sequence of SEQ ID NO:73, and a second isolatedvector comprising a nucleotide sequence encoding: a complementaritydetermining region heavy chain (CDRH1) amino acid sequence of SEQ IDNO:5; a CDRH2 amino acid sequence of SEQ ID NO:20; and a CDRH3 aminoacid sequence of SEQ ID NO:44.